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Abstract 
 
E-selectin is a member of a family of cell-adhesion proteins, which plays a crucial 
role in many physiological processes and diseases [1], and in particular, in the 
early phases of the inflammatory response. Its role is to promote the tethering 
and the rolling of leukocytes along the endothelial surface [2]. These steps are 
then followed by integrin-mediated firm adhesion and final transendothelial 
migration. Therefore, control of the leukocyte-endothelial cell adhesion process 
may be useful in cases, where excessive recruitment of leukocytes can 
contribute to acute or chronic diseases such as stroke, reperfusion injury, 
psoriasis or rheumatoid arthritis [3].  
In this work, efforts to develop in silico-based protocols to study the interaction 
between E-selectin and its ligands, are presented. Hence, different protocols had 
to be developed and validated. In particular, a new procedure for the analysis of 
the conformational preferences of E-selectin antagonists was established and the 
results compared to those obtained with the MC(JBW)/SD approach, which had 
already demonstrated its validity in the past [161,168]. Thus, the comparison 
between the two protocols permitted to recognize a different conformational 
preference of the two methods for the orientation of the sialic acid moiety of sLex 
(3) (torsions Φ3 and Ψ3, Figure A), which reflects the contrasting opinions existing 
for the conformation adopted by sLex (3) in solution [150–168]. A more detailed 
analysis revealed that probably both approaches deliver only a partially correct 
view and that in reality, in solution, sLex (3) exists as a mixture of low energy 
conformers and not as supposed to date [150–154,161–163] as a population of a 
single conformer.  
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Figure A: sLex (3) and the Φ, Ψ convention for the definition of the glycosidic torsions. 
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 1 
A. General introduction 
 
Selectins form a family of cell-adhesion proteins. They can be found mainly on the 
surface of vascular endothelial cells (E- & P-selectin), platelets (P-selectin) and 
leukocytes (L-selectin). They play a crucial role in many physiological processes, among 
them inflammation [1]. 
 
Inflammation is a key biological process for the defense of the organism. Its regulation is 
therefore very important, as any malfunction can lead to deleterious effects. In a healthy 
person, tissue injury, or invasion by pathogens usually triggers the release of 
inflammatory mediators like chemokines or platelet-activating factors [2,3], initiating a 
complex cascade of reactions that finally lead to the migration of leukocytes to the 
inflammatory stimulus, and thereby to the healing of injuries or the elimination of 
pathogens. In case of excessive leukocyte extravasation, massive cell-death and various 
disease conditions [4,5], like arthritis or myocardial ischemia-reperfusion injury can take 
place. 
 
In more recent studies, it has also been suggested [6-8] that certain cancer cells 
travelling in the blood stream exploit the E-selectin-mediated adhesion process to 
metastasize, using the same route leukocytes use to cross the endothelial membrane. 
 
The development of drugs mediating the adhesion of leukocytes would therefore be of 
great interest for controlling inflammatory processes, as well as for cancer therapies. 
 2 
A.I. Selectins and the mediation of leukocyte adhesion 
 
A.I.1. The selectin family 
 
Lectins are carbohydrate-recognizing proteins that are divided in four families [9], 
namely : 
 - C-type lectins (calcium), which binding site contains one or more calcium ions. 
 - S-type lectins (sulfur) also called galectins, which contain free thiol groups. 
 - P-type lectins (phosphor), which specifically recognize phosphorylated 
mannose residues. 
 - Other lectins, not fitting in the three previous categories. 
It is to note that enzymes modifying carbohydrate residues are not called lectins, which 
only recognize and bind to them.  
 
Selectins are membrane bound proteins belonging to the class of the C-lectins, as they 
all contain a calcium ion in their binding site. Three different selectins have been 
described so far : E-, P- and L-selectin, the first letter corresponding to the location 
where they were first identified [10] : E-selectin can be found on the surface of 
endothelial cells, as well as P-selectin. P-selectin originally was identified in α-granules 
of platelets [11,12], while L-selectin was identified on most types of leukocytes. E-
selectin in particular was first described in the late 1980’s [13] as an antigen of two cell-
adhesion mouse monoclonal antibodies, namely H 18/7 and H 4/18. Cloning and 
characterization [14] in 1989 revealed a C-type lectin, consisting of 589 amino acids, 
with a molecular weight of 64 kDa in its mature state. 
 
The structures of all three selectins show a high similarity and consist (see figure 1) of 
five different domains [15,16]. The extracellular part contains a carbohydrate recognition 
domain (CRD, also called lectin domain, Lec) at the N-terminus, which is stabilized by a 
calcium ion. It is 120-130 amino acids long (depending on the selectin type) and is 
followed by a 35-40 amino acids domain called epidermal growth factor-like (or EGF) 
domain. Although carbohydrate ligands bind specifically to the CRD, it has been shown 
that the EGF domain is also mandatory for binding, probably stabilizing the conformation 
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of the CRD [17,18]. The active part of the protein (CRD-EGF or Lec-EGF domain) is 
separated from the cellular membrane by several repetitive units, called complement 
regulatory-like or consensus repeat (CR) domains, each about 60 amino acids long. L-
selectin contains two CRs, while E-selectin contains six, and in P-selectin the number 
varies from four to nine. It was found in case of P-selectin [19], that although those 
elements are not required for the binding of selectins to their ligands, they play a role in 
the leukocyte rolling efficiency. This suggests that the CR domains may act as spacers, 
keeping the CRD at a distance far enough from the cell surface for optimal action. 
Finally, the transmembrane domain is followed by a short (17-34 amino acids) 
cytoplasmic C-terminal tail, supposedly involved in signal transduction [20]. 
 
 
Figure 1 : Schematic representation of the three members of the selectin family. 
 
L-selectin 
E-selectin 
P-selectin 
Lectin domain 
(N-terminal CR domain 
Cytoplasmic tail 
(C-terminal) 
EGF domain Transmembrane 
domain Plasma membrane 
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A.I.2. The inflammatory cascade 
 
In a healthy organism, pathogen invasion or tissue injury usually triggers the release of 
inflammatory mediators like chemokines or platelet-activating factors [2,3]. These 
mediators act as a signals initiating and directing the migration of leukocytes through the 
endothelial membrane of blood or lymphatic vessels to the site of damage. This 
leukocyte migration is a complex action that can be divided into a series of steps, 
referred to as the inflammatory cascade [21,22] (see figure 2). 
 
 
Figure 2 : The inflammatory cascade. 
 
Upon release of the inflammatory mediators (e.g. histamine, thrombin, TNF-α, IL-1 or 
LPS), the stimulated endothelial cells present E- and P-selectin at their surface. P-
selectin, already present in the Waibel-Palade bodies of the cells is rapidly transported 
to the cell surface, and expressed within seconds to minutes after stimulation by 
thrombin or histamin [23,24] and exposed for 30-60 minutes before subsequent 
internalization. E-selectin, in contrast, has to be de novo synthesized, and its production 
is induced by TNF-α, IL-1 or LPS [13,25]. Its highest expression level is thus detected 
after three to four hours. It is then internalized again. Once one or both P- and E-selectin 
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are present, they can interact with the leukocytes travelling into the lymph or blood flow, 
initiating the inflammatory cascade. 
 
First step : Tethering and rolling. 
Natural ligands of E- and P-selectin (ESL-1, PSGL-1, etc. see part A.I.3) are present at 
the surface of the leukocytes. Their interaction with the selectins is characterized by fast 
association and dissociation processes [26-28], that aim to slow down the leukocyte 
flow. Once interacting with the endothelial monolayer (tethering), leukocytes roll on the 
surface of the blood vessels (see figure 3). 
L-selectin also plays an important role in this first step. Indeed, it is expressed by 
leukocytes and able to interact in particular with E-selectin [29], but also with PSGL-1 
ligands present on the already tethered leukocytes, increasing the number of leukocytes 
attracted to the inflammation site. 
 
 
Figure 3 : Leukocytes rolling on the surface of a vessel [30]. 
 
Second step : Integrin activation. 
The close interaction of leukocytes with the endothelial surface leads to a contact with 
cytokines released by the inflammation process. This triggers the activation of 
leukocytes integrins [26,31]. Integrins are important players in the adhesion process and 
therefore also play an essential role in the inflammatory cascade. 
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Third step : Firm adhesion. 
Activated integrins on the surface of leukocytes can now play their role. They interact 
with their endothelial ligands (namely the immunoglobulines VCAM-1 and ICAM-1, and 
others like MAdCAM-1 [26,31], cf. figure 6) stronger than selectin mediated interactions, 
thus stopping the leukocytes’ rolling. 
 
Fourth step : Extravasation or transendothelial migration. 
When leukocytes finally firmly adhere to the endothelial membrane, they can cross it, to 
the site of inflammation (figure 4). This process in itself is complex and not completely 
understood. It has already been shown that leukocytes may use both the paracellular 
and transcellular routes [32]. Transmigration is probably facilitated by extracellular 
proteases, such as matrix metalloproteinases (MMPs) as well as by some junctional 
adhesion molecules (JAM-A, -B or -C) [33]. 
 
 
Figure 4 : A leukocyte transmigrating to the site of an inflammation [30]. 
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A.I.3. The natural ligands of the selectins 
 
As selectins are carbohydrate binding proteins, their natural ligands are glycolipids or 
glycoproteins. More precisely, it is generally accepted that ligands containing the 
trisaccharides Lewisx (Lex, 1), Lewisa (Lea, 3) or the sialylated tetrasaccharides sialyl 
Lewisx (sLex, 2) and sialyl Lewisa (sLea, 4) shown in figure 5 would bind the selectins [34-
36]. 
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Figure 5 : The natural selectin ligands carbohydrate epitopes. 
 
Soluble recombinant forms of the selectins as well as selectin-IgG fusion proteins have 
been used as affinity probes to isolate and identify some of their natural glycoprotein 
ligands : 
 - L-selectin is binding to five endothelial glycoproteins called MAdCAM-1 [37,38], 
Gly-CAM-1 [39], CD34 [40], Spg200 [41] and the podocalyxin-like protein [42]. 
The sialomucin Gly-CAM-1 is of particular interest in this case, as its 
posttranslational modifications have been intensively studied, showing that 
sialylation, fucosylation and sulfation are essential to the binding to L-selectin 
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[39,43,44]. 
 - The natural ligand to P-selectin is PSGL-1, a homodimeric protein linked by two 
disulfide bridges [45], which is also a sialomucin. Further studies showed that 
sialylation and fucosylation were required for the binding [46-50] of this 
glycoprotein, as well as sulfation of two of the three N-terminal tyrosines it 
contains (Tyr46 and one between Tyr48 and Tyr51). This makes it a potential 
ligand for L-selectin as well [51-54]. 
 - Screening for E-selectin ligands revealed a glycoprotein, subsequently named 
ESL-1. In contrast to the ligands presented above, ESL-1 requires N-linked 
glycan modifications for binding E-selectin. It is also noticeable that ESL-1 only 
binds E-selectin, and not P-selectin [55]. Three other glycans were also 
identified as E-Selectin ligands [56], each containing a sialyl di-Lex motif. In 
addition, E-selectin recognizes PSGL-1, but with the difference to P-selectin 
that the sulfation of the tyrosine residues is not mandatory [48,57]. 
 
Interactions between the three selectins and some of their ligands are summarized in 
figure 6 below. In the following we will focus more on E-selectin. 
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Figure 6 : Selectins, integrins and their binding partners. The depicted selectin ligands have been 
identified by affinity isolation with the respective selectins as affinity probes [2]. 
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A.II. Structural determination of the selectins 
 
A good knowledge of selectins’ biology requires a comprehensive understanding of the 
3D-structure of these proteins, of their carbohydrate ligands, and complexes thereof. In 
the case of E-selectin, the ligand of reference is sLex (2, figure 5). For the purpose of 
uncovering the structural specificities of E-selectin, and in particular of its binding site, 
different methods have been used : (i) Structure-activity relationship (SAR) studies, 
measuring the affinity to E-selectin of sLex and derivatives thereof in order to determine 
the pharmacophores. (ii) NMR studies (e.g. using nOe, STD or multidimensional 
methods) performed with sLex (2) in solution alone (determining solution conformation) 
or in combination with the protein (giving hints about the bioactive conformation). (iii) 
Theoretical binding models have been developed with help of molecular modeling. (iv) 
X-ray crystal structure of selectins co-crystallized with sLex. 
 
A.II.1. SAR studies to the determination of the pharmacophore 
 
The first chemical synthesis of sLex (2) has been reported in 1991 [58]. However, 
despite the availability of very efficient glycosylation methods, the chemical syntheses of 
polysaccharides requires selectively protected sugars, greatly increasing the number of 
steps and hence the length and cost of production, especially in large scale. In order to 
simplify the synthesis, chemo-enzymatic [59] approaches have been developped. 
 
In extensive studies, all functional groups of sLex have been chemically modified in a 
systematic process to identify the groups being crucial for binding to E-selectin. Those 
groups are named pharmacophores. 
 - The role of the different hydroxyl groups of fucose (Fuc) was determined by 
Gaeta et al. [60], and Hasegawa et al. [61]. They replaced them individually or 
collectively by hydrogen atoms, obtaining deoxy-derivatives that were found to 
be completely inactive against E-selectin. In analogy to the mannose-binding 
protein (MBP-A), which CRD domain shows 80% sequence homology to the 
one of E-selectin [62], it was assumed that the fucose hydroxyl groups are 
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binding to the calcium ion of the protein. It is, however, noticeable that only the 
Fuc-3 hydroxyl was found to be critical for binding to P-selectin. 
 - Gaeta et al. [60] also tried to substitute the fucose moiety by an arabinose 
(formally replacing the 5-methyl group by a hydrogen) in order to check the 
influence of the methyl. The compound obtained was found to be five-fold less 
active than the original one. This shows that the methyl is important for activity, 
although not crucial. 
 - The role of the galactose (Gal) hydroxyl groups was first determined by Kunz et 
al. [63], who produced deoxy- and fluoro-derivatives of sLex (2). Thanks to 
systematic replacements at each position, they noted that the affinity of the 
molecule was significantly reduced in the absence of the Gal-4 hydroxyl and 
disappeared when the Gal-6 one was replaced, stressing the importance of 
these groups for binding. 
 - The contribution of the various functional groups of the N-acetyl-neuraminic 
acid (NeuNAc, or sialic acid) moiety, has also been examined in details 
[61,64,65]. Among them (glycerol side chain, amide, 3-OH, carboxylic acid), 
only the carboxylic acid was found of particular importance for the binding. 
 - Finally, several studies were directed at the N-acetyl-glucosamine (GlcNAc) 
moiety [66-68]. No direct contribution to the binding was detected. It was 
therefore suggested that this part of the molecule acted mostly as a spacer, 
maintaining the critical functional groups of both sides of the molecule in the 
required spatial orientation. 
 
All these informations allow for the representation of the pharmacophore, based on the 
structure of sLex (2, figure 7). 
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Figure 7 : Pharmacophore elements of the sLex (2) molecule. 
 
A.II.2. Solution conformation and bioactive conformation of sLex 
determined by NMR 
 
Early work towards the structural determination of selectins was devoted to the study of 
the conformation of sLex (2) in solution. The method of choice for these studies was 
NMR, using labeled or unlabeled molecules. 
 
Initially, three different studies [69] agreed in finding only one single stable conformation 
of the molecule in water. ROESY and NOESY NMR spectroscopy [70] revealed 
significant interglycosidic nuclear Overhauser effect (nOe) between the following sLex 
protons (illustrated in figure 8) : 
 - H-3 of GlcNAc and H-1 of Fuc ; 
 - H-4 of GlcNAc and H-1 of Gal ; 
 - H-2 of Gal and H-5 and methyl of Fuc ; 
 - H-3 of Gal and H-3(axial) of NeuNAc. 
 



 

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Figure 8 : nOe recorded between various protons of sLex (2) in solution. 
 
Further ROESY experiments combined with molecular modeling [71] led to distinctive 
values for the various dihedral angles Φ and Ψ (as defined in figure 9), at least for the 
ones between Fuc-GlcNAc and GlcNAc-Gal. Subsequent studies, however, focusing on 
the Gal-NeuNAc linkage [71-74] showed much higher flexibility of this part of the 
molecule and the energy minima evaluated by the different teams are not in agreement, 
suggesting that sLex (2) in solution may exist as an ensemble of conformations, although 
the Lex (1) core of the molecule may be relatively rigid. Some of the angles values are 
listed in table 1. 
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Figure 9 : Interglycosidic dihedral angles as they are defined for sLex (2). 
Φ
Φ
Ψ
Ψ
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The bioactive conformation was first investigated by Peters et al. [75-77] and Cooke et 
al. by transfer-nOe (trNOE) spectroscopy [74]. Significant changes were observed in the 
bound state in comparison to the free (in solution) state. Indeed, the significant nOe 
between H-3 of Gal and H-3(axial) of NeuNAc completely disappeared in the bound 
state, whereas a new interaction appeared between H-3 of Gal and H-8 of NeuNAc. New 
dihedral angles were then deduced, corresponding to the bioactive conformation [76,77]. 
They were comparable to the angles found in one of the solution conformations 
suggested by Breg et al. [73] (see table 1 for the values). 
 
Combining these findings suggests that sLex (2) in solution easily flips between three to 
four different minimal energy conformations, one of them being very close to the 
expected bioactive (bound to E-selectin) conformation. The results also show the pre-
organization in solution of the Lex (1) core close to the bioactive conformation. One 
decisive element of this pre-organization, as shown in the model from Peters et al. 
[75,78], is the stacking of the Gal and Fuc moieties above one another, with GlcNac 
playing the role of a spacer. This spatial arrangement is stabilized by an interaction of 
the hydrophobic faces of the two monosaccharide units. This also explains the loss of 
activity observed after replacing the methyl group of fucose by other substituents with a 
different size or polarity. Noteworthy is also the position of the pharmacophore. In the 
bioactive conformation, all of its parts would be in line along one side of the 
tetrasaccharide (figure 7). 
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NeuNAc-Gal Gal-GlcNAc GlcNAc-Fuc  
Ref. 
Φ Ψ Φ Ψ Φ Ψ 
163° -57° 
-170° -8° 
-79° 7° 
[69,70] 
68° -20° 
48° 15° 22° 30° 
-95° -45° 
-70° 5° [72,73] 
-160° -20° 
50° 15° 48° 22° 
48° 24° 
[72] n.e. n.e. 46° 18° 
-23° 15° 
-95° -60° 
-70° 0° 
Solution 
conformations 
[79] 
-160° -25° 
65° 15° 65° 40° 
[72] -58° -20° 25° 33° 70° 14° 
[79] -70° 8° 52° 22° 20° 34° 
[75,76] -76° 6° 39° 12° 38° 26° 
[80] -65° -12° 34° 16° 41° 22° 
Bioactive 
conformations 
[81] -43° -12° 45° 19° 29° 41° 
Table 1 : Interglycosidic dihedral angles values, as evaluated by different groups. 
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A.II.3. Binding models design with help of modeling and X-ray 
structural information 
 
The E-selectin binding site has also been studied more closely by mutagenesis [16], 
revealing that a relatively small and shallow patch of the lectin domain (CRD) was 
responsible for the direct binding to sLex, involving the amino acids Arg97, Lys111, Lys113, 
Ser47 and Tyr48. Based on these results, and those about the bioactive conformation of 
sLex, different models were suggested for the binding mode of the tetrasaccharide. Many 
different models have been developed, that all showed partial agreement with the finally 
published crystal structure of sLex co-crystallized with Lec-EGF [82]. Three of them are 
discussed below. 
 
 - The first relevant model was developed by Graves et al. [83] who solved the X-
ray structure of the Lec-EGF domain (no ligand). More details about the binding 
mode of sLex (2) were uncovered at the same time after co-crystallization of the 
tetrasaccharide with a selectin-like mutant of MBP-A [83] (mannose-binding 
protein, see part A.II.1). The model confirmed the binding of Fuc-2 and Fuc-3 
hydroxyl groups with the calcium ion. Unexpectedly however, the carboxylic 
acid of NeuNAc was not shown to interact with the protein despite the findings 
of earlier SAR studies (see part A.II.1). 
 - Kogan et al. [84] as well as Ernst et al. [78] independently proposed models 
based on molecular modeling docking studies. Both agree in the principal 
interactions important for binding, namely the interaction of Fuc-2 and Fuc-3 
hydroxyls with the calcium ion embedded in the protein, the binding of Gal-6 
hydroxyl to the Tyr94 residue in the CRD, and the contact of the carboxylic acid 
of NeuNAc with Arg97. Slight differences are also noticeable, like the contact of 
the Gal-4 hydroxyl with Asn105, not predicted by Kogan et al., the coordination of 
the calcium ion by the protein and the fucose hydroxyl assumed to bind to 
Asn82. Both models are illustrated on figure 10 and figure 11. 
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Figure 10 : Binding mode of sLex, as suggested by Kogan et al. [84]. 
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Figure 11 : Binding mode of sLex, as suggested by Ernst et al. [78]. Differences with the previous 
model (figure 10) are highlighted in blue. 
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Definitive answers were finally found after the publication by Somers et al. [82] of the 
crystal structure of sLex bound to the Lec-EGF domains of both E- and P-selectin. They 
devised a new binding model (figure 12) that provided some surprises. In particular, the 
selectin-bound calcium ion appeared to be complexed by the Fuc-3 and the Fuc-4 
hydroxyl groups instead of the previously suggested Fuc-2 and Fuc-3, the Fuc-4 
hydroxyl being also involved in hydrogen bonds with Asn82 and Glu80, and the Fuc-3 
hydroxyl with Asn105. Fuc-2 hydroxyl further interacts with Asn83 and Glu107 through 
water-mediated hydrogen bonds. On behalf of the Gal moiety, contacts between Gal-4 
hydroxyl with Tyr94 and Gal-6 hydroxyl with Glu92 were detected. Finally the carboxylic 
acid of NeuNAc interacts with the amino acid residues Arg97 and Tyr48. It occurs that the 
conformation of sLex (2) deduced from this crystal structure is very similar to the 
bioactive conformation suggested by Peters et al. Based on NMR measurements 
[76,77]. 
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Figure 12 : Binding mode of sLex, as proposed by Somers et al. [82], based on the crystal 
structure. 
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A.III. Early developments in the design of E-selectin 
antagonists 
 
Since it has been demonstrated that selectins play a key role in the regulation of the 
inflammatory cascade, they have become targets of choice for the development of new 
anti-inflammatory agents. Due to the extensive studies that were carried out towards the 
structure and binding mode of sLex (2), the molecule was consequently used as a lead. 
 
Mimics thereof were therefore designed and synthesized [85], mainly following two 
goals : 
 - Simplification of the structure : Smaller molecules, ideally bearing the 
minimal pharmacophoric groups in the correct spatial orientation and easier to 
synthesize. They will also be more suited to library design. 
 - Overcoming pharmacokinetic and pharmacodynamic hurdles : sLex is a 
carbohydrate molecule with all of its disadvantages, namely hydrolytical 
instability, high polarity leading to low bioavailability and fast renal excretion. 
 
In order to present the different contributions in a comprehensive way, they will be sorted 
after the numbers of sugar units that have been replaced in comparison with the 
structure of sLex (2). Moreover, as affinity values are evaluated in different assay formats 
in the various research teams publishing on the subject, all IC50 values in the following 
will be given relative to sLex, which IC50 has been normalized to 1.0 mM (rIC50 = 1). 
 
A.III.1. Replacement of one sugar unit 
 
A.III.1.1 Replacement of NeuNAc 
 
On the N-acetyl-neuraminic acid (NeuNAc) unit, it has been shown that only the 
carboxylic acid had significant importance for the binding affinity [61,64,65]. In addition, 
NeuNAc is the most expensive building block in the synthesis of sLex, and its 
replacement by a negatively charged group at the 3-position of the galactose thus 
presents many advantages. 
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Substitution of NeuNAc by sulfate groups led to the known natural ligands sulfo-Lex and 
sulfo-Lea or related derivatives [61,86,87]. Affinities reported were similar to the one of 
sLex. Phosphate groups were also used for the same purpose [61,88,89], with similar 
results (figure 13). 
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Figure 13 : sLex mimics containing a sulfo or phospho group replacing NeuNAc. rIC50 values are 
shown in brackets. 
 
The most common structural simplification is the simple alkylation of the Gal-3 hydroxyl, 
introducing a carboxymethyl group. The product obtained (7) showed similar activity to 
sLex [90]. In order to gain more knowledge into the binding conditions, Duthaler et al. 
[91] also fixed the carboxymethyl group by embedding it into a cyclic six-membered 
acetal (8). The compound, however, showed no activity against E-selectin as the 
carboxylic acid conformation obtained was different from the bioactive one (figure 14). 
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Figure 14 : Mimics containing a carboxymethyl group replacing NeuNAc. rIC50 values are shown 
in brackets. 
 
The most successful replacement of NeuNAc was obtained using L(-)-cyclohexyllactic 
acid ((2S)-3-cyclohexyl-2-hydroxy-propionic acid). However, as will be discussed later, it 
was only studied in combination with other replacements. 
 
A.III.1.2 Replacement of GlcNAc 
 
The second sugar unit which was replaced is the GlcNAc moiety. Indeed, it has been 
shown that its role is to act as a spacer, maintaining ideal stacking between the fucose 
and galactose units [66-69,92,93], and the crystal structure confirmed that it has no 
interaction with the protein [82]. The synthesized compounds therefore aim to keep the 
core conformation as close as possible to the one of sLex, but using less synthetically 
demanding building blocks. One compound (9, figure 15) replacing GlcNAc with an 
indolizidinone type heterocycle proved unactive against E-selectin, but showed the same 
activity to P-selectin than sLex [94]. Compound 10 however, with a quinic acid derivative 
was equally active as sLex in an E-selectin assay [95]. One of the best spacers to date is 
a (1R,2R)-cyclohexan-1,2-diol unit and has been introduced by Töpfer et al. [96]. It not 
only dramatically simplifies the synthesis conditions, but compound 11 also showed a 3-
fold better activity against E-selectin than the lead. 
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Figure 15 : Mimics containing different spacers in replacement to GlcNAc. rIC50 values are shown 
in brackets. 
 
Up to now, no mimics replacing only the galactose or the fucose units were disclosed. 
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A.III.2. Replacement of two sugar units 
 
A.III.2.1 Replacement of NeuNAc and GlcNAc together 
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Figure 16 : Mimics used for the testing of GlcNAc replacing spacers in the presence of a 
carboxymethyl group as NeuNAc replacement. rIC50 values are disclosed in brackets. 
 
The next step in the simplification process of sLex was to combine the effects of NeuNAc 
and GlcNAc replacements. Starting from the common mimic 7, which has equal activity 
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than sLex, a variety of spacers have been tested, with the goal to improve the 
pharmacokinetic properties without loosing activity (figure 16). 
 
Of particular interest is the substitution of the GlcNAc unit with (1R,2R)-cyclohexan-1,2-
diol. Wong et al. [97] first suggested that this replacement, in parallel with the 
substitution of NeuNAc with a carboxymethyl group should be energetically neutral, 
based on sLex. Molecules containing this spacer (19) and many others (12-18) have 
been synthesized and tested [98-102] by different teams. Not surprisingly, too flexible 
spacers (13-15) led to a loss of activity of the resulting molecules. This may be explained 
by entropic penalties, as the molecules are flexible, and therefore are not pre-organized 
into the bioactive conformation. It is noticeable too, that compounds containing 
indolizidinone (20) or quinic acid (21) proved inactive. Among this series of compounds 
the only surprise came from the ethyleneglycol spacer (12), which affinity towards E-
selectin was found equivalent to the one of sLex, despite the relative flexibility of this 
linker. Since similar molecules (e.g. 27, figure 18) tested in other laboratories showed no 
activity [103], the activity of 12 should not be over-interpreted. 
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Figure 17 : Mimics developed at Novartis AG, Basel [78,104] : Replacement of the NeuNAc unit 
in the presence of a cyclohexanediol unit replacing GlcNAc. 
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With these results in mind, Ernst et al. [103] designed new mimics replacing the 
carboxymethyl group at Gal-3 with the more sterically constraining (2S)-cyclohexyl- or 
(2S)-phenyl-lactic acid (figure 17). In their approach to develop pre-organized mimics 
adopting a solution conformation as close as possible to the bioactive conformation, they 
developed a modeling tool [104,105] that is quickly presented in part B.III.1. Using this 
new tool, they could show that the introduction of sterically demanding groups next to 
the acid function replacing the NeuNAc moiety should force the carboxylate to adopt the 
bioactive conformation observed in sLex. They also confirmed the suitability of 
cyclohexanediol in replacement to the GlcNAc unit and suggested further modifications 
of this unit that fulfilled the conformational requirement even better (molecules 26-32, 
figure 18). Compound 22 (figure 17), also called CGP69669 in the following, is of 
particular interest to this thesis as it will be our main reference compound after sLex (2). 
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Figure 18 : Mimics developped at Novartis AG, Basel [103]: Further improvements of the diol 
unit. rIC50 values are displayed in brackets. 
 
In additional attempts to improve affinity, various modifications at the Gal-6 position of 
mimic 22 were investigated, that led, however, to inactive compounds [106]. Increased 
rigidification of compound 22 was also reached by building macrocyclic mimic 33 [107] 
(figure 20), that unfortunately turned out to be even less active than sLex. Finally, further 
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results published by Thoma et al. [108] indicated that the presence of a benzoic group at 
Gal-2 position (resulting from incomplete deprotection) gave compounds (33-35, figure 
19) that were up to three times more active than their Gal-2 deprotected counterparts 
(25 and 27, figure 18). This result will be developed further as part of the present thesis 
work (see part B.III). It is also noteworthy that molecule 34 is probably the best E-
selectin inhibitor published to date. 
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Figure 19 : Mimics developed at Novartis AG, Basel [107,108] : Additional attempts towards 
better activities. rIC50 values are displayed in brackets. 
 
A.III.2.2 Replacement of both GlcNAc and Gal 
 
Another explored approach is the replacement of the central N-acetyl-lactosamine part 
of sLex, consisting of Gal and GlcNAc. NeuNAc and Fuc units are kept untouched. In the 
first approach [96], disappointing affinities were found, pointing to two prerequisites of 
the linker that have to be fulfilled : (i) The linker should bear groups mimicking the Gal-4 
and Gal-6 hyroxyls, which have been proved mandatory for binding [63] ; (ii) Poor 
activity is expected by the introduction of a too flexible linker, because of high entropic 
costs upon binding (37-39, figure 20). 
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Figure 20 : Mimics containing different spacers in replacement to Gal-GlcNAc [96]. rIC50 values 
are shown in brackets. 
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Figure 21 : Mimics containing different spacers in replacement to Gal-GlcNAc [109-111]. 
Inhibition ratios are shown in brackets. 
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Additional, more rigid linkers linkers, were therefore tried, that unfortunately did not lead 
to better results (40-42, figure 21). 
 
A.III.3. Replacement of three sugar units 
 
The L-fucose unit of sLex (2) binds to the calcium ion embedded in the CRD of the 
selectins and contain three of the six pharmacophores of the molecule. It is probably the 
most difficult residue to substitute. Therefore, the largest and most drug-like group of 
selectin antagonists is based on structures containing only this sugar unit, with the 
exception of some cases, where it is replaced by D-mannose or L-galactose. The sugar 
unit is then substituted by additional groups that aim to mimick the other 
pharmacophores of the reference ligand (Gal-4 and Gal-6 hydroxyls, NeuNAc carboxylic 
acid). 
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43
(inactive) [56]
49 : R = H (inactive)
50 : R = Bn (0.87)
[121]
 
Figure 22 : Monosaccharide mimics of sLex : Use of an aryl spacer. rIC50 values are shown in 
brackets. 
 
 29 
Some approaches used the substituents that already proved efficient in former mimics, 
like the cyclohexanediol replacing GlcNAc, and the cyclohexyllactic acid replacing 
NeuNAc. Most common linkers (replacing galactose) were polyaryl (e.g. biphenyl) [112-
114], or polyamides (e.g. glycopeptides) [115-120] and met various success. 
Single aryl groups (differently substituted) were studied independently by Ernst et al. [56] 
(compounds 43-48) and Liu et al. [121] (compounds 49-50). Among the molecules that 
were synthesized (see figure 22), few showed a faint activity (at best equivalent to the 
one of sLex). 
 
Mimics using malonic acid [122] or piperidine carboxylic acid [123] derivatives in 
replacement to NeuNAc were not more potent (examples are disclosed in figure 23, 
compounds 51-55). 
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(5) [123]
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Figure 23 : Monosaccharide mimics of sLex : Use of malonic or piperidine carboxylic acids as 
NeuNAc-Gal replacement. rIC50 values are shown in brackets. 
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The first breakthrough among the class of monosaccharidic selectin antagonists was 
published by Kogan et al. [112-114], who developed a library containing as much as 45 
different structures based on derivatized biphenyl residues linked to the anomeric 
position of mannose (replacing fucose). With the exception of three of them (compounds 
56-58, figure 24), all were less active against E-selectin than sLex. However, many 
showed increased activity against P-selectin, namely two to twenty times better than 
sLex. Noteworthy is also the dimeric structure of compound 58, mimicking the extended 
sialyl di-Lex structure of the natural ligands isolated from human neutrophils [56] (see 
also part A.I). The synthetic dimer 58 was found to be six times more active than sLex. 
Consequently, the molecule is now in phase II clinical trials, carried out by Texas 
Biotechnology, Houston, TX, USA, for the treatment of asthma, reperfusion injury and 
psoriasis [115]. 
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Figure 24 : Monosaccharide mimics of sLex [112-114]: Use of biphenyl spacers. rIC50 values are 
shown in brackets. 
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Large efforts have been invested by Wong et al. [97,115-120] in the creation of libraries 
of fucose- mannose- or galactose-based glycopeptides. For that purpose, he pointed at 
two key elements that influence the inhibitor’s potency, namely turns, mimicking the 
GlcNAc unit, and hydroxyls, that should replace the galactose pharmacophores. Figure 
25 gives examples of both, and a selection of the most potent inhibitors discovered by 
this approach (59-62) is shown in figure 26. In general, activity improvement was much 
better against P-selectin than E-selectin. 
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Figure 25 : sLex mimics library design, from Wong et al. [97]. 
 
Another approach, based on combinatorial synthesis, has been studied by Armstrong et 
al. [122] and Wong et al. [123]. They used two- and four-component Ugi reactions using 
an aldehyde, a primary amine, an isonitrile and a carboxylic acid, thereby producing a 
variety of small glycopeptide structures. Here again, affinity was mainly gained against 
P-selectin, and little against E-selectin. 
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Figure 26 : sLex mimics library of Wong et al. [97], examples. rIC50 values are shown in brackets. 
 
A.III.4. Non-carbohydrate sLex mimics 
 
The group of Kondo et al. [124] was the first to introduce a non-carbohydrate sLex mimic 
(64, figure 27). Using their own models, they carried out a pharmacophore search, that 
identified the possible inhibitory molecule 63. The compound was then optimized using 
conformational analysis and medicinal chemistry methods, resulting in compound 64. 
However, the high molecular weight of this compound is a drawback to its possible 
development as a drug. In addition, 64 probably forms micelles because of its long 
lipophilic tail, leading to a polyvalent interaction towards target proteins. 
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Figure 27 : Non-glycosidic high molecular weight sLex mimics [124]. rIC50 is shown in brackets. 
 
More recently, two groups, using crystallography experiments and molecular modeling, 
independently came across the possibility to replace the fucose moiety with quinic acid 
derivatives [125-126]. They both developed small-molecular weight E- or P-selectin 
inhibitors, some examples of which are disclosed in figure 28. Kaila et al. [125] focused 
on molecule libraries where the 2-hydroxy group of quinic acid is substituted 
(compounds 65-66), whereas Girard et al. [126] preferred amide formation at the 
carboxylic acid site (compounds 67-68). However, although the activities are acceptable 
for P-selectin inhibition, good E-selectin non-glycosidic inhibitors remain elusive. 
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Figure 28 : Non-glycosidic sLex mimics based on quinic acid. rIC50 (against P-selectin) is shown 
in brackets. 
 
A.III.5. Addressing secondary binding sites 
 
Many of the rational design approaches used in the examples described so far aimed at 
the improvement of the binding affinity by minimizing entropic costs. This resulted in the 
development of inhibitors in which the pharmacophores were pre-organized as close as 
possible to the bioactive conformation of sLex, thus avoiding energetically costly 
conformational changes prior to binding. Another possibility to improve affinity is the 
enhancement of the enthalpic contribution by additional protein-ligand interactions. It 
was therefore suggested that the introduction of lipophilic groups could lead to new 
interactions with hydrophilic patches on the surface of the protein, close to the binding 
site. 
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Hayashi et al. [127,128] published the structure of sLex derivatives functionalized with 
hydrophobic groups, either at the reducing end, or at the N-acetyl of GlcNAc position on 
sLex. Some of the products showed increased binding affinity (figure 29). 
 
 
 
OO
OH
NH
OO
O
O
HO
HO
HOOH
OH
O
HOOC
OH
NHAcHO
HOHO
OH
OR1
R2O
 
 
 
 
Figure 29 : Mimics of sLex adressing secondary binding pockets [127,128]. 
 
Ernst et al. [78] further investigated the effect of aliphatic, aromatic and heteroaromatic 
acyl substituents at the GlcNAc nitrogen atom, resulting in a substantial increase of the 
binding affinities (figure 30). 
 
1.6 Me C12H25 71 
1.0 C4H9 Et 70 
2.0 C4H9 C12H25 69 
0.1 Napht Et 74 
0.1 Napht C12H25 73 
1.5 Me Et 72 
IC50 
(mM) 
R2 R1  
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Figure 30 : Mimics of sLex adressing secondary binding pockets [78]. 
 
All the examples presented in this chapter allow us to draw some important features 
about the conception of potent selectins (E-selectin in particular) inhibitors. 
 
A.III.6. Conclusions 
 
 - It has been proven really difficult to devise a good inhibitor without keeping the 
fucose and galactose units untouched. 
 - Studies where GlcNAc was replaced by a spacer have shown that pre-
organization of the ligand in solution is required for good binding. 
 - It has also been found that further steric constraints (added on GlcNAc or 
NeuNAc mimics) play an important role for pre-organization. 
 - Finally, recent results have shown that additional interactions with lipophilic 
pockets close to the binding site of the protein may significantly improve 
ligands’ affinities. 
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A.IV. Bioassays evaluating ligands affinity to E-selectin 
 
Different bioassays have been devised by the various teams working in the selectin field. 
Some are based on ELISA, Biacore or NMR. In the case of the present work, bioassays 
were carried out at GlycoMimetics Inc., Gaithersburg, MD, USA. The company 
developed two assays as standards for the evaluation of ligands’ activity towards E-
selectin [129,130]. One of them is a static polymer-based cell-free assay based on 
ELISA techniques, whereas the second one is a cell-based flow assay. Both are 
described hereafter. 
 
A.IV.1. Static cell-free bioassay 
 
Thoma et al. [129,130] prepared a glycopolymer based on a polylysine backbone, which 
side-chains are substituted with sLea (4, 20%), glycerol (75%) and biotin (5%) (figure 
31). The glycopolymer is used as a competitive ligand in a binding assay. 
 
The assay uses an E-selectin/hIg construct [129], which is coated on a microtiter plate. 
The bound protein is then incubated first with the glycopolymer, different concentrations 
of the ligand to test. and labeled streptavidin. After washing, fluorescence intensity is 
measured allowing to calculate the affinity of the tested ligand. 
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Figure 31 : Structure of the sLea polymer used in the static cell-free bioassay [129]. 
 
A.IV.2. Cell-based flow assay 
 
Considering that the IC50 values determined in a static assay may not reflect correctly 
the conditions occurring in vivo, the same team devised a second bioassay [130], based 
on flowing cells. For that purpose, a parallel plate flow chamber coated with human 
umbilical vein endothelial cells (HUVECs) was used to study the rolling of polymorphous 
neutrophils (PMNs) in contact with selectins in a hydrodynamic flow, therefore mimicking 
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the non-equilibrium conditions found in vivo. Digital image acquisition was used to 
determine the number of interacting cells in the presence or absence of any potential E-
selectin inhibitor [131] (figure 32). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32 : Set-up of the cell-based flow assay [130]. 
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B. Results and discussion 
 
B.I. Thesis 
 
In the present work, we focused on two axes of research : 
 
 - The first one is the targeting of lipophilic patches of the protein localized near 
the sLex binding site, that could be reached by substituting the galactose unit at 
position 2, thereby gaining binding affinity from enthalpic contributions. A library 
of mimics is thus planned, taking advantage of the properties of Huisgen 1,3-
dipolar cycloaddition of alkynes to an azide [132].  
 
 - Our second research axis is to force our ligands into a solution conformation 
expected to be as close as possible to the bioactive conformation, thereby 
minimizing entropic costs upon binding. 
 
B.II. First hypothesis : New interactions in non-specific 
binding pockets 
 
B.II.1. Introduction 
 
B.II.1.1 Crystal structure and modeling studies 
 
Our first hypothesis is based on the published crystal structure of the Lec-EGF construct 
co-crystallized with sLex [82] and molecular modeling studies derived thereof. 
Based on the crystal structure, a computer model of the Lec-EGF domain of E-selectin 
has been developed at our Institute by Dr. Michele Porro [133]. The model was then 
used for the virtual docking of several structures to the binding site of the protein, 
beginning with sialyl Lewisx (sLex, 2), which is assumed to be one of the natural ligands 
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(cf. part A.I.3). A second compound of great importance is our reference compound, 
CGP69669 (22), one of the best ligands known at the time and therefore a suitable lead 
compound. Our main expectation from these docking studies was to find areas close to 
the binding site that could be reached easily by new substituents, hopefully leading to 
supplementary interactions, thereby resulting in an increase of the affinity. 
 
OO
OH
OR
NHAc
OO
O
O
HO
OH
HOOH
OH
O
HOOC
OH
NHAcHO
HOHO
OH OOO
O
O
HO
OH
HOOH
OH
OH
COONa
sLex (2) CGP69669 (22) [103]
 
Figure 33 : Formulas of sLex (2) and CGP69669 (22) [134]. 
 
The docking results are illustrated in the following figures (figure 34 and figure 35), 
where the pharmacophore is highlighted. In a summarized way (for more details, see 
part A.II.1), the 3-OH and 4-OH of the fucose moiety (green circles) are expected to bind 
the calcium ion embedded in the protein, whereas the carboxylic acid, the 4-OH and 6-
OH of the galactose moiety, and even the 2-OH of the fucose (yellow circles) interact 
with several amino acids of the protein. Our interest was focused on the region 1 of the 
protein, which does not belong to the generally accepted binding site. It is, however, 
close to the core of the ligand, and possibly a good opportunity to gain further interaction 
with the protein and hence better affinity. 
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Figure 34 : sLex (2) docked in Lec-EGF. 
 
It is interesting to note that the complexity of the sLex molecule is not required for good 
binding. Indeed, the simpler molecule 22 has an experimental relative IC50 (rIC50) of 
0.08, whereas rIC50 of sLex has been normalized to 1 (12 times less). 
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Figure 35 : Compound 22 docked in Lec-EGF. 
 
B.II.1.2 Adressing the lipophilic pocket facing Gal-2 
 
Modification in region 1, which can be reached by modifying the position 2 of the 
galactose unit is the subject that will be addressed in the following. The idea arose from 
molecular modeling studies, themselves based on the published crystal structure [82]. 
They showed that the position 2 of the galactose was facing a lipophilic patch on the 
surface of E-selectin. It was therefore assumed that aromatic groups at this position 
would trigger an increase in the affinity. 
 
As it is discussed later (see B.II.2.2), 1,3-dipolar cycloaddition of various alkynes to an 
azide was considered as a valuable reaction for modifying the position 2 of the galactose 
with a broad range of chemical entities. Further considering that aromatic (substituted or 
unsubstituted) groups seemed promising in modeling studies, we used the following 
commercially available alkynes (80a-k, figure 36). 
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In the following, the synthesis of the protected 2-azido-2-deoxy-galactoside precursor 
will first be discussed in details, focusing on the key coupling steps. Considerations 
about click chemistry and the very last steps (final deprotection) will follow. 
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Figure 36 : Alkynes for the planned triazole library. 
 
B.II.2. Synthesis 
 
The target molecule is the protected precursor 96 having an azido group at the position 
2 of the galactose moiety (figure 37). 
 
The retrosynthetic study shows the linear coupling sequence of specifically made 
building blocks. The sequence starts with the suitably protected thioethyl fucoside 81 
[135], which was first coupled with the optically pure (1R,2R)-cyclohexane-1,2-diol 83. 
The molecule obtained (84) was further coupled with the 2-azido-2-deoxy-galactoside 
unit 90, and after deprotection the cyclohexyllatic acid moiety 99 was added. 
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Once the target precursor has been obtained, two routes are possible : Either the 1,3-
dipolar cycloaddition could be carried out directly on the protected molecule 96 (before 
final catalytic hydrogenation), or the molecule could first be deprotected, 1,3-dipolar 
cycloaddition remaining the last step. 
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Figure 37 : Target molecule 96, and retrosynthetic pathway to it. 
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In the next pages, the synthesis will be developed step by step, focusing on the different 
coupling reactions. 
 
B.II.2.1 Coupling steps 
 
Coupling (glycosidation) steps are key steps in carbohydrate chemistry, and therefore, 
the different protecting groups have to be conscientiously chosen for their stability 
towards coupling conditions and their “orthogonal” character. This means that a part of 
them will have to be cleaved selectively in the presence of the other protecting groups. 
 
One of the main properties of a coupling reaction in carbohydrate chemistry is its 
reliability in respect to regio- and/or stereoselectivity [136-145]. In our synthesis, three 
key coupling steps are used. The first one should lead to the α-fucoside anomer, the 
second one has to build the β-galactoside, and the last one should lead specifically to 
the attachment of cyclohexyllactic acid at the position 3 of the galactose moiety. Other 
coupling orders were envisioned too, for example with an enzymatic fucosylation as the 
last step. 
 
Fucose protection and coupling to (1R,2R)-cyclohexane-1,2-diol : 
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Scheme 1 : Synthesis of the fucose-diol building block 84 [134,96,146]: a) Br2, DCM, 0°C to r.t., 
1h (quant.) ; b) TEAB, DMF. r.t., 3h (70%). 
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Before carrying out the coupling, the fucose had to be suitably protected. Our starting 
material was D-fucose. 
 
The protection pattern is partly dictated by the coupling reaction which should yield the 
α-anomer. Therefore, in the 2-position, protective groups with so-called “neighboring 
group participation” [147-150] properties should be avoided. 
 
Participating groups, for example, are esters and amides, and trigger the formation of 
trans-glycosides (β-anomer in the case of fucose) via the mechanism presented in figure 
38. The bromide is removed with a promoter (e.g. silver salt) leading to the 
corresponding oxonium ion which reacts intramolecularly to form an intermediate 
dioxolenium ion. The access of the alcohol to the α position is now blocked. Therefore, 
the alcohol attacks from the β direction, selectively forming the β-anomer of the product. 
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Figure 38 : Glycosidation mechanism with a participating group [149]. 
 
Since we planned to synthesize an α-fucoside (cis product), which is thermodynamically 
favorable, a non-participating group at position 2 of the fucose is needed. Ethers are 
perfectly suited for that role. Among them, benzyl and silyl ethers are the most 
preferable, as they are relatively easy to cleave (moreover selectively) afterwards. 
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In the course of the synthesis, the last coupling step is mediated by dibutyltin oxide (see 
below) and cesium fluoride. As silyl ethers can be cleaved by fluoride ions, their use is 
thus not recommended in this synthesis. Benzyl ethers can selectively be removed by 
hydrogenation. They are stable under basic and acidic conditions, and therefore suited 
for our purpose. There are different types of benzyl ethers. The most used among them 
are simple benzyl and para-methoxybenzyl ethers [151-155]. In our case, simple benzyl 
ethers were chosen. The issue is further discussed in part C.III.3. 
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Scheme 2 : Protection of the fucose [135] : a) Ac2O, pyridine, 0°C to r.t., 17h (quant.) ; b) EtSH, 
SnCl4, DCE, 0°C, 4h (78%) ; c) K2CO3, aq. MeOH, 19h (86%) ; d) BnBr, NaH, DMF, 0°C to r.t., 
16h (80%). 
 
Several methods are described in the literature for the synthesis of anomeric thioethers 
[156-159], using various Lewis acid promoters. After some trials using boron trifluoride 
diethyl etherate [156,158] that were not completely satisfying, tin tetrachloride [157] was 
chosen for allowing a cleaner reaction, also with a higher yield. 
 
Once the suitably protected fucose (81, scheme 2) was obtained, coupling using the in 
situ anomerization procedure [160] was executed. In a first step, 81 is reacted with 
bromine to form an anomeric mixture of the corresponding fucosyl bromides. With TEAB 
the α-anomer was then anomerized into the more reactive β-anomer which was then 
coupled with the (1R,2R)-cyclohexane-1,2-diol (83) to give (1R,2R)-2-(2,3,4-tri-O-benzyl-
L-fucosyl)cyclohexane-1,2-diol (84). As expected, the α-anomer was the main product. 
But the minor β-anomer was still present in a 10%-20% amount, and proved difficult to 
separate on classical column chromatography. 
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Preparation and coupling of the galactose mimic : 
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Scheme 3 : Synthesis of 93 : a) NaN3, CAN, MeCN, -20°C, 18h, 53% ; b) LiBr, MeCN, r.t., 15h 
(94%) ; c) silica gel supported Ag2SiO3, DCM, r.t., 185h (54%) ; d) K2CO3, MeOH / H2O 1:1, 41h 
(76%). 
 
The main feature of this galactose mimic is the presence of an azide at position 2, 
instead of a hydroxy group. The azide could be introduced easily, starting from 
peracetylated D-galactal (89). Azidonitration [161-163] was achieved with sodium azide 
and cerium ammonium nitrate (CAN) in acetonitrile (the mechanism [162,164] of the 
reaction being presented in figure 39). 
 
Cerium(IV) from CAN first oxidizes an azide ion into an azide radical. In the absence of 
an acceptor, these radicals would decompose into three molecules of nitrogen. 
However, in a suitable solvent like acetonitrile [164], an olefin would be competitively 
azidated, resulting in a carbenium ion after the radical intermediate is deactivated by a 
second cerium(IV) ion. The high stereoselectivity of the reaction (90% of the azide ends 
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up in equatorial – galactose – configuration and 10% in the axial – talose – 
configuration) is specific to the galactose series, as interactions with the axially 
positioned 4-O-acetyl group prevent the axial positioning of the azide. The obtained 
oxycarbenium ion can react in two different ways. Either (i, figure 39) it is attacked 
directly by the nitrate ion present predominantly forming the more stable α-anomer of the 
product, or (ii, figure 39) it forms an intermediate imine-carbenium ion with acetonitrile. 
SN2-substitution with a nitrate then yields the β-anomer. 
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Figure 39 : Azidonitration mechanism. 
 
From the mechanism, it looks that the α/β ratio of the product could be influenced by 
modifying the dilution. In our case a typical α/β ratio was from 1:1 to 2:1. However, as 
both anomers of 90 could be used in the next step, increased stereoselectivity was not 
required. As already mentioned above, the reaction also produced some 10% of the by-
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product having an axial azide (resulting in an α-talose derivative), which could not be 
properly separated. It was, however, easily separable after the coupling step. 
 
The nitro group is a very good leaving group and could readily be displaced with lithium 
bromide, to form quantitatively the α-galactosyl bromide (91, see Scheme 3) needed for 
the coupling with 84. 
 
It is to note that both the galactosyl nitrate and the galactosyl bromide are reactive 
species, and hence expected to undergo decomposition upon normal phase column 
chromatography. We therefore envisaged the use of both 90 and 91 without purification. 
In a recent paper, however, Liu et al. [163] showed that the azidonitration step might 
also produce N-acetyl-3,4,6-tri-O-acetyl-2-azido-2-deoxy-α-D-galactopyranosylamine 
(94, figure 40), mainly during work-up procedure. 94 is prone to binding alkali metal ions, 
and thus makes the subsequent formation of 91 using lithium bromide more difficult to 
run to completion. Consequently, chromatographic purification of 90 is mandatory, even 
if some of it is lost through decomposition, as it eliminates by-product 94. 
 
O
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Figure 40 : By-product 94. 
 
In the subsequent galactosylation of 84, no participating neighboring group is present. 
Therefore, glycosidation will lead to the more stable cis-anomer, which is α. From the 
work of Paulsen et al. [165-171], it is known that insoluble silver salts are very efficient in 
promoting the formation of β-galactosides. 
 
Coupling was thus performed with silica gel supported silver silicate, resulting in product 
92, which was then treated without purification with potassium carbonate to give the 
partially deprotected product 93. Unfortunately, yields over both steps never exceeded 
45%, whereas the literature [168,170,172] sometimes describes yields of 70% or over. 
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The issue is discussed longer in part C-II. However, it was always possible to recover 
most of the unreacted starting material 84. 
 
Preparation and coupling of the lactic acid derivative : 
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Scheme 4 : Synthesis of the target protected tetrasaccharide mimic 96 [78,104]: a) 93, Bu2SnO, 
MeOH, reflux, 18h ; 95, CsF, DME, r.t., 20h (71% over 2 steps). 
 
Our starting material was D(+)-phenylactic acid (97, (2R)-2-hydroxy-3-phenyl-propionic 
acid). The aromatic ring was first hydrogenated using 5% Rhodium on alumina. The 
benzyl ester was then formed, and the hydroxyl group was activated through triflation 
prior to coupling (see scheme 5 for details). 
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Scheme 5 : Synthesis of the lactic acid building block 95 [173,104] : a) Rh/Al2O3, H2 (4 bar), 
water/dioxane/AcOH 4:2:1, r.t., 72h (93%) ; b) Cs2CO3, MeOH/water 1:1, r.t., 1h ; BnBr, DMF, r.t., 
20h (58% over 2 steps) ; c) Tf2O, 2,6-di-tert-butylpyridine, DCM, -20°C to 0°C, 3h (70%). 
 
The alkylation step was mediated by the formation of a stannylene acetal [174-183] on 
the deprotected galactosyl moiety of the molecule 93. For thermodynamic reasons, even 
with a free hydroxyl group in position 6, the stannylene acetal mainly forms between 
position 3 and 4 favoring the building of a 5-member-ring over a 6-member ring. 
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In solution, the stannylene acetal can be found in two different forms [178], either dimers 
with 5-coordinate tin atoms, or even oligomers with 6-coordinate tin atoms. In figure 41, 
the mechanism focuses on the dimers. Due to the presence of the n-butyl groups, the 
covalently linked oxygens of the galactose are either in an equatorial (4-OH here) or an 
axial (3-OH) position, based on the tin atom. In that configuration, only axial oxygen 
atoms are activated, resulting in the regioselectivity of the reaction. 
 
Fluoride ions have a good affinity for tin, comparable to their affinity for silicon. When 
cesium fluoride is added, fluoride ions will strongly coordinate with the tin atom, thus 
weakening its bond with oxygen. The more nucleophilic oxygen then readily attacks the 
triflate activated carbon on the cyclohexyllactic acid resulting in a SN2 reaction. 
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Figure 41 : Mechanism of the stannylene acetal mediated coupling. 
 
96 is a key building block for the synthesis of a library of triazoles, by two different 
pathways. Either triazoles were built on protected molecule 96, as presented below 
(B.II.2.2) or deprotection could have been carried out first, library synthesis remaining 
the very last step of the synthesis (B.II.2.3). 
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B.II.2.2 Construction of a triazole library via click chemistry 
 
Introduction to Click Chemistry : 
The concept of “Click Chemistry” was first introduced by Sharpless et al. in 1999 [184]. 
Referring to chemical reactions taking place in Nature, it aims to find a set of powerful, 
reliable and selective reactions that could easily and rapidly couple small building blocks 
via heteroatom links. In addition, such reactions should meet a range of stringent criteria 
: 
“The reaction must be modular, wide in scope, give very high yields, generate only 
inoffensive byproducts that can be removed by nonchromatographic methods, and 
be stereospecific (but not necessarily enantioselective). The required process 
characteristics include simple reaction conditions (ideally, the process should be 
insensitive to oxygen and water), readily available starting materials and reagents, 
the use of no solvent or a solvent that is benign (such as water) or easily removed, 
and simple product isolation.”[185, p. 2008] 
 
In our case, the reaction chosen is the Huisgen 1,3-dipolar cycloaddition of alkynes to an 
azide, resulting in triazoles [132,186-188] (see figure 42). Until the last couple of years, 
this reaction did not obtain the deserved attention, probably because of concerns about 
the safety of working with azides. However, azides belong to the most convenient 
groups in synthetic chemistry. They are insensitive to acids, bases, or oxidants, which 
makes them very well suited for carbohydrate chemistry, and are consequently more 
and more often used as protecting groups for primary amines (see below B.II.2.3 for 
amine-azide interchange). On the other hand, a broad range of alkynes are 
commercially available. 
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Figure 42 : 1,3-dipolar cycloaddition of alkynes to azides. 
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As is shown in figure 42, a given alkyne might couple to the azide giving two different 
regioisomers, so-called 1,4- and 1,5-regioisomers (trans and cis respectively) [186]. 
Therefore, when a mixture of sterically unhindered azides and alkynes is heated, it is 
likely that a 1:1 mixture of both isomers is obtained. Efforts to control this selectivity have 
met varying success, until Rostovstev et al. [186] and Tornøe et al. [189] reported the 
use of copper(I) as a catalyst, yielding selectively the 1,4-trans-regioisomer at ambient 
temperature. Furthermore, Cu(I) can be prepared in situ, using copper(II) sulfate which is 
reduced with sodium ascorbate. Even metallic copper has been shown to catalyse the 
regioselective reaction [190]. 
 
Synthesis of the triazole library : 
The triazoles were synthesized mostly from the protected 96, containing an azido group 
at position 2 of the galactose unit. The standard method described by Rostovstev et al. 
[186] used catalytic amounts (~10% eq.) of copper(II) sulfate and excess sodium 
ascorbate, in a 1:1 mixture of water and tert-butanol. In our case, the acetylenes that 
were among the most promising substituents according to molecular modeling, contain a 
triple bond conjugated with an aromatic system, and are thus deactivated. In addition, 
the benzyl protected 96 is relatively lipophilic and did not dissolve well in the reported 
solvent mixture. Therefore, the reaction times were much longer than reported. They 
ranged from 3 days in the best case (benzylacetylene, or 3-phenyl-1-propyne, 80c) to no 
reaction at all (biphenylacetylene, or 4-ethynylbiphenyl, 80a). In order to increase the 
reaction rate, methanol was used as the only solvent, and copper(II) sulfate and sodium 
ascorbate added in stoichiometric amounts. With these conditions 4-ethynylbiphenyl 80a 
reacted to completion in two days. 
 
B.II.2.3. Final deprotection 
 
The idea behind : 
Libraries of compounds are often built by parallel synthesis. Basically, one common 
scaffold is synthesized in large amounts, and then separated into small batches that are 
elaborated into the different members of the library. 
In our case we planned the 1,3-cycloaddition to be carried out at the end of the 
synthesis, ideally as the last step. Moreover, we aimed to have as little as possible work-
up and purification steps of the end-products. In practice, it means that : 
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 - The library precursor should be fully deprotected ; 
 - The last reaction, building the library, should be clean and quantitative ; 
 - Few, ideally no purification steps should be necessary. 
 
We thus planned to perform the last step of the synthesis (copper(II) catalysed 1,3-
cycloaddition of alkynes to the azide) in a 96-well microtiter plate, where ideally the static 
bioassays could be performed without any more purification step. 
 
The chosen reaction looks perfectly suited for this approach, as it could be run in water 
with no organic co-solvent (or few enough to be acceptable for the assay). Moreover, the 
reactants (copper(II) sulfate, sodium ascorbate) should be used in catalytic quantities, 
and are not expected to poison the protein. And finally, a high yield of the reaction 
should lower the need for further purification. The prerequisite, therefore, is to deprotect 
the target compound 96 prior to triazole formation. 
 
Amine-azide interchange : 
The remaining protecting groups of 96 are three benzyl ethers on the fucose moiety and 
the benzyl ester protecting the lactic acid moiety. The most common method for the 
cleaving of benzyl groups is catalytic hydrogenation, using palladium on activated 
charcoal. Under these conditions, the azido group will be reduced to an amine. 
Fortunately, procedures have been described for the synthesis of an azide from a 
primary amine [191-196]. The reactant used is trifluoromethanesulfonyl azide (triflyl 
azide, TfN3), which is freshly prepared before use (scheme 6). The reaction was used as 
described in the cited literature [191,193], using both protected and unprotected 
galactosamine as test compound. The major drawback of the method is the use of 
dichloromethane as solvent for the TfN3 preparation, as it is known that azides (sodium 
azide in particular) may turn into explosives (CH2ClN3, CH2(N3)2) in chlorinated solvents. 
A. Titz from our Institute developed a new method, using toluene as solvent, which 
proved as efficient as dichloromethane [197]. 
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Scheme 6 : Amine to azide exchange applied to galactosamine [191,193] : a) DCM/water 2:1, 
0°C, 2h ; b) TfN3, K2CO3, cat. CuSO4, MeOH/water/DCM 6:3:1, 16h ; c) Ac2O, pyridine, r.t., 16h 
(58% over two steps. 
 
Final deprotection and library synthesis : 
With all the tools in hand, deprotection of 96 under reducing conditions was tried. The 
azido group was first reduced into a primary amine, which turned to be nucleophilic 
enough to react with the benzyl ester, thus forming a 6-membered ring lactam (as 
illustrated in figure 43). It turned out impossible to cleave with methods soft enough to 
keep the integrity of the entire molecule. 
 
Different methods (other hydrogenation conditions, DDQ oxidation, Lewis acid 
mediation) were tried for the cleavage of the benzyl groups, aiming to prevent the 
formation of the lactam (further discussed in part C.III). Up to now, none of them give the 
expected results. 
 
Therefore, the triazole library was formed from the protected 96, before the final 
deprotection by hydrogenolysis was carried out. This was carried out successfully with a 
small set of five triazoles, that were then tested in bioassays to test their E-selectin 
antagonist activity. 
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Figure 43 : Lactam formation during the hydrogenation of 96. 
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B.II.3. Results of the bioassays 
 
Activity tests of all antagonists were performed at Glycomimetics Ltd., Gaithersburg, MD, 
USA. The assay chosen is static, and cell-free [129], as described in part A.IV.1. 
 
Five triazoles (figure 44 and table 2) were synthesized and sent for testing. 
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Figure 44 : General formula of the triazoles 103. 
 
As stated in part A.III, all IC50 values are relative to the activity of sLex, (rIC50 = 1). The 
rIC50 of our reference compound, namely CGP69669, is 0.08. 
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ID Formula IC50 (µM) 
22 
 
CGP69669 
 
80 
103a 
R =  
> 1000 
103b 
R = N 
275 
103c 
R =  
90 
103d 
R =  
125 
103e 
R = 
CF3
 
350 
Table 2 : Inhibitory activity of the individual triazoles. 
 
None of the triazoles was more active than the reference compound. Therefore, the 
main conclusion of this work is that the substituents do not establish an additional 
lipophilic contact with the protein and therefore do not show improved binding. Some 
substituents (e.g. in 103a) are even deleterious for the activity. 
 
However, these results offer some insight into the binding site of E-selectin, in particular 
the part of it facing the Gal-2 position. First of all, the size of the Gal-2 substituent seems 
important. Indeed, the smaller phenyl substituent (103d) binds better than pyridinyl 
(103b), which is again better than trifluorophenyl (103e), while biphenyl (103a) 
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completely prevents binding. Secondly, flexibility seems important too, as the benzyl 
group (103c) has the best binding affinity among all, although it is sterically more 
demanding than phenyl or pyridinyl. 
 
The affinity of the benzyltriazole may also fit well with one hypothesis exposed in next 
part, namely that lipophilic interactions between the substituents in the Gal-2 and Gal-3 
positions may stabilize the acid orientation in the bioactive conformation, and thus 
enhance activity. 
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B.III. Second hypothesis : Stabilization of the bioactive 
conformation 
 
B.III.1. Introduction. 
 
The bioactive conformation of sLex (2) is known with certainty from trNOE NMR [80,81] 
and the crystal structure of Lec-EGF co-crystallized with sLex [82]. To facilitate the 
evaluation of new ligands, Kolb and Ernst [104,105] developed and validated a 2D 
internal coordinate system, allowing to visualize the spatial orientation of the 
functionnalities relevant for the pharmacophore. Two particular torsion angles were 
defined to describe the 3D-structure of sLex (see figure 45). 
The first one, called acid orientation, is defined by (Fuc-C1;Fuc-O1) ; (Acid-Cα;Acid-
C=O), while the second one, called core orientation, is defined by (Fuc-C4;Fuc-C1) ; 
(Fuc-O1;Acid-Cα). For a given ligand, molecular dynamics simulation give the probability 
of the possible conformations of the molecule (see figure 46), which are then plotted 
relatively to those angles. Based on the NMR results of Peters et al. [75,76] for the 
bioactive conformation, Kolb and Ernst [105] defined a bioactive window, visualizing an 
ensemble of conformations surrounding the bioactive one. 
 
Our hypothesis is that the conformation of a potentially active molecule in solution 
should be as close as possible to the bioactive conformation, in order to minimize 
entropic penalties upon binding. 
Different approaches to constrain the conformation of sLex mimics have been studied so 
far : (i) The introduction of bulky substituents at different positions of the molecule 
[78,127,128] ; (ii) The use of C-glycosides [198] ; (iii) The formation of macrocycles 
[107,199] (see also the existing E-selectin inhibitors, part A.III). 
 
 63 
 
OO
OH
OR
NHAc
OO
O
O
HO
HO
HOOH
OH
O
HOOC
OH
NHAcHO
HOHO
OH
OO
OH
OR
NHAc
OO
O
O
HO
HO
HOOH
OH
O
HOOC
OH
NHAcHO
HOHO
OH
 
Figure 45 : Torsion angles, as defined based on sLex. 
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Figure 46 : Probabilistic distribution of the conformation of a compound [105]. 
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In this work, we planned to study the influence of Gal-2 substituents on the pre-
organization of the bioactive conformation. We will focus on two research axes, namely 
the bulkiness of the substituent, and its possible intramolecular interactions with the 
lactic acid derivative mimicking the NeuNAc group of sLex. 
 
B.III.1.1. Relation between the α-protons at the 2-position of Gal and the 5-position of 
Fuc 
 
For antagonists with core conformation and acid orientation in the bioactive window, the 
proton in the 2-position of Gal and the 5-position of Fuc are in close spatial relationship. 
Therefore, they are also expected to influence each other, and the influence should be 
noticeable with 1H NMR experiments, particularly by using the nuclear Overhauser effect 
(nOe). In such an experiment, a 1H NMR spectrum of the molecule is first recorded 
under normal conditions, showing the chemical shifts of the protons of interest. In a 
second analysis, the spectrum is recorded while the molecule is irradiated specifically at 
the resonance frequency of one of these two protons, canceling all influences the 
chosen proton has on the rest of the molecule. If the second proton is close enough to 
the irradiated one, a substantial nOe can be observed. As close the spatial relationship, 
as large is the expected low field shift for H-5 of Fuc. 
In conclusion, if we assume that in the bioactive conformation Gal-H2 and Fuc-H5 
protons are close to each other, 1H NMR spectra with nOe should be an easy way to 
reveal how close the conformation of a given sLex mimic is relative to the bioactive one. 
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B.III.1.2. Examples 
 
The corresponding investigation already has been published [103] for a number of 
selectin antagonists (figure 47). 
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Figure 47 : Structures of some of the molecules described in [103]. 
 
Molecule 22 (CGP69669) 26 27 32 
Chem. shift Fuc-H5 
(in D2O) 4.60 ppm 4.42 ppm 4.12 ppm 4.77 ppm 
nOe between 
Gal-H2 and Fuc-H5 0.094 0.043 0.003 0.108 
rIC50 (rel. to sLex) 0.08 0.08 > 10 0.04 
Table 3 : Chemical shifts of the Fuc-H5 proton and normalized nOe values in the molecules of 
figure 47 [103], in regard to their rIC50. 
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The results clearly show that 32 is the most constrained molecule exhibiting the 
strongest nOe. The methyl group of the tetrahydropyran ring obviously forces the fucose 
in a position close to galactose, thereby stabilizing the core in the bioactive 
conformation. Consequently, the entropy cost upon binding is reduced and the binding 
affinity hence increased. 
Moreover, looking to the normal 1H NMR spectra of these molecules without irradiation, 
it appears that, even there, the chemical shift of Fuc-H5 is also correlated to the 
constraint. Indeed it changes from δ = 4.12 ppm for compound 27 to δ = 4.77 ppm for 
compound 32. We therefore have a reliable tool to evaluate new molecules in regard to 
their conformational stability. 
 
B.III.1.3. The molecules studied 
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Figure 48 : Molecules compared using the modeling tool developed by Ernst et al. [104,105]. 
Known rIC50 values are disclosed in brackets. 
 
Using the modeling tool described above, four different molecules were studied (see 
figure 48), in order to compare the effect of the presence of a benzoyl group at galactose 
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2-position, in combination with either a cyclohexyl- or phenyl-lactic acid moiety. It was 
expected that pi−pi interactions between both aromatic groups would enhance the pre-
organization of the molecules into the bioactive conformation. 
 
 
Figure 49 : 2D-plots of the molecules of figure 48. 
 
As can be seen from the plot of figure 49, the possible conformations of molecule 104 
(resp. 105) concentrate more and closer to the bioactive window (red square) than in the 
case of the reference molecule 22 (resp. 23). Compound 22 has a measured rIC50 of 
0.08 and we thus expect the one of compound 104 to be higher. The same effect is 
expected in the case of compound 105. Increased interactions due to -stacking may 
even improve more the affinity. 
 
22 23 
104 105 
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Modeling results were encouraging, and we thus tried to validate them experimentally. 
The following molecules (104 and 105, figure 50) were therefore synthesized, in order to 
confirm or at least complete in silico results. 
 
This synthesis is relatively close to the one used for compound CGP69669 [105,200]. 
The said synthesis will be extensively described in the following pages, focusing again 
on the different coupling steps. 
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Figure 50 : Target molecules 104 and 105. 
 
B.II.2. Synthesis 
 
Figure 50 shows the target molecules. We will concentrate on the synthesis of 105, 
knowing that the synthesis is the same for compound 104, provided that cyclohexyllactic 
acid (98, cf. B.II.2.1) is used instead of phenyllactic acid (97). With the exception of Gal-
2 position, the target molecules are not protected. 
 
As shown in the retrosynthesis (figure 51), 105 will be synthesized in a parallel way. 
Conditions of the final deprotection steps should be tuned in order to retain the last 
benzoyl ester. 
 
In the next pages, the synthesis will be developed step by step, focusing on the different 
coupling reactions. 
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Figure 51 : Target molecule 105 and retrosynthetic pathway to it. 
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B.III.2.1. Coupling steps 
 
The synthesis of 84 has already been described before (part B.II.2.1). Therefore, we will 
concentrate on the other steps. 
 
Preparation of the galactose building block : 
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Scheme 7 : Synthesis of the galactose building block 109 [78,104] : a) Cs2CO3, DMF, r.t., 1h ; 
BnBr, DMF, r.t., 5h (one-pot, 88% over 2 steps) ; b) Tf2O, pyridine, DCE, -20°C to -5°C, 2h (84%) 
; c) 108, Bu2SnO, MeOH, reflux, 18h ; 107, CsF, DME, r.t., 24h (36% over 2 steps). 
 
Our starting materials were 6-O-benzyl-1-ethylthio-β-D-galactose (108) and D(+)-
phenyllactic acid (97). 97 was first protected with a benzyl ester and activated by forming 
a triflate, leading to benzyl (2R)-3-phenyl-2-O-triflyl-propionate (107). It was then coupled 
with the galactose derivative via the formation of a stannylene acetal which reaction is 
still described in part B.II.2.1. 
 
In that case however, yields were dramatically lower (36% for the best one, compared to 
71% for the compound of part B.II.2.1). No real explanation has been found for the 
versatility of this stannylene acetal mediated reaction. A competitive reaction may occur, 
the fluoride ions present in solution being able to react with the lactic acid triflate. Indeed, 
benzyl 3-phenyl-2-fluoropropionate was found in a significant amount among the 
reaction’s products. 
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Moreover, the product is partly (~30%) found in the form of a lactone, essentially built 
between the carboxylic acid and the galactose 2-hydroxyl, but also in some extent with 
the galactose 4-hydroxyl (figure 52). Reaction product was therefore a mixture of three 
substances. The expected one was then separated from the lactones. 
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Figure 52 : Molecule 109 and the two possible lactones (110a and 110b). 
 
Protection and coupling of the galactose building block : 
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Scheme 8 : Synthesis of the target protected tetrasaccharide mimic 112 [78,104] : a) BzCl, 
pyridine, r.t., 16h (46%) ; b) DMTST, DCM, r.t., 19h (52%). 
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Protection is carried out with benzoyl chloride, using pyridine as a solvent. As in the 
previous step, part of the starting material 109 (about 50%) was converted into the 
derived lactones. It is obvious that lactone formation dramatically lowered the yields over 
the last two steps (coupling with lactic acid and protection with benzoyl groups). Indeed, 
up to 65% of the starting galactose derivative (108) was converted. Therefore, efforts 
have been made in order to transform the lactones into protected molecule 111. Their 
description and outcome is exposed in next part (C.IV). 
 
This coupling step was carried out with aid of dimethyl(methylthio)sulfonium triflate 
(DMTST). The mechanism of the reaction [201] is shown in figure 53. 
The group present at galactose 2-position is a benzoyl ester, thus participating to the 
coupling (cf. B.II.2.1). The glycosidation is therefore expected to be β-selective. Indeed, 
no α-anomer was produced, although yields were moderate (about 60%). 
 
O OBn
BnOOBn
O
HO
O
BzO
O
OBz
COOBn
S
OBn S S+
O
BzO
O
O
COOBn
S+
OBn
O
S
Me2S
O
BzO
O
O
COOBn
OBn
O
C+
S
S
112
 
Figure 53 : Mechanism of the DMTST promoted coupling [201]. 
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B.III.2.2 Deprotection, selective benzoyl cleavage 
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Scheme 9 : Preparation of the target molecule 105 : a) 10% Pd/C, H2 (4 bar), dioxane, r.t., 48h ; 
MeONa, 1M in MeOH, r.t., 3h (36% over 2 steps). 
 
The first step of the deprotection procedure is catalytic hydrogenation, cleaving the 
benzyl ester, and the four benzyl ethers protecting the molecule (Gal-6, Fuc-2,3,4). The 
reaction was carried out with 10% palladium on charcoal and lasted 24 h to 48 h under 4 
bar hydrogen overpressure. 
 
The second deprotection step is the cleavage of only one of the two remaining benzoyl 
groups. The standard reaction uses a solution of sodium methanolate in methanol and is 
expected to cleave all the benzoyl esters. However, it was already performed by C. 
Müller in our Institute on very similar molecules [198], where it was found by serendipity 
that the benzoyl ester at position-2 of the galactose was not cleaved, or at least, was 
retained much longer than any other benzoyl ester. Tests using model compounds then 
showed [198] that this behavior was due to the lactic acid bulky substituent (cyclohexyl 
in the cited study). 
This effect may be due to the steric hindrance of the lactic acid lipophilic substituent. It 
may even be enhanced in our case, if we consider the possible pi−pi interactions between 
the phenyllactic acid moiety and the benzoate. 
 
When applied to our molecule, sodium methanolate selectively cleaved Gal-4 benzoyl 
ester, leaving as expected the Gal-2 benzoate untouched. The obtained 105 as well as 
its cyclohexyllactic acid containing counterpart (104) were then tested in bioassays for 
their E-selectin antagonist activity, and 1H NMR spectrum compared to the ones of the 
other molecules of interest. 
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B.III.3. Results of bioassays and NMR experiments 
 
B.III.3.1 Bioassays 
 
Activity assays of the new molecule were again carried out at Glycomimetics Ltd, 
Gaithersburg, MD, USA, using the static cell-free assay. Next table (see table 4) 
compares the result to the activity of molecules 22 and 23 (B.III.1.3, figure 48). As stated 
in part A-III, all IC50 values are relative to the activity of sLex, which IC50 is by definition 
fixed at 1 mM. 
 
 Molecule ID rIC50 
22 (CGP69669) 0.08 
104 0.04 
23 0.35 
105 0.17 
Table 4 : Compared affinity of the four products (22, 23, 104, 105). 
 
As expected from in silico evaluation, affinity of the new compounds 104 and 105 was 
higher than the ones of their unprotected counterparts. In both cases the benzoyl ester 
at Gal-2 induced a 2-fold decrease of the IC50. 
 
We will now look at the 1H NMR spectra, looking for confirmation of our assumptions 
about the correlation between conformational constraints and binding affinity. 
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B.III.3.2 Chemical shifts of the Gal-2 and Fuc-5 protons in 1H NMR. 
 
ID Chemical shift 
Fuc-H5 (ppm, in D2O) 
Binding affinity 
(µM) 
triazole 103a 4.09 > 1000 
27 [103] 4.12 > 10 000 
23 [103] n.p. 350 
26 [103] 4.42 230 
triazole 103c 4.45 90 
triazole 103b 4.53 275 
105 4.54 175 
104 4.58 47 
CGP69669 22 [104] 4.60 80 
32 [103] 4.77 39 
Table 5 : Chemical shift of the Fuc-5 proton in several molecules, and their binding affinities, 
sorted through chemial shift values (n.p. : not published). 
 
A good correlation between the chemical shifts of the Fuc-H5 proton of the various 
molecules and their binding affinity is noticeable. The results confirm the predictions of 
Ernst et al. [103], namely that the binding affinity of the studied ligand is strongly 
dependent on their pre-organization into the bioactive conformation. 
 
It allows us to discriminate between the low binders (the too flexible molecule 27 or the 
bulky biphenyl triazole 103c in this case) and the good binders (lead compound 22 or 
molecule 32) with a single 1H NMR experiment. It is therefore a very valuable tool to a 
preliminary evaluation of the activity of similar molecules. 
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C. Synthetic difficulties and other considerations 
 
This part aims at describing some of the synthetic hurdles and secondary routes that 
paved the way to the results presented in the previous parts B.II and B.III. The first issue 
will be the order of the coupling steps used in both synthesis. It is followed by 
discussions about the coupling steps themselves. At the end the problem of the eventual 
formation of a lactam (first synthesis, part B.II.1) or a lactone (second synthesis, part 
B.III.1) between the carboxylic acid of the lactic acid unit and the position 2 (or 4) of the 
galactose unit is tackled. 
 
C.I. Order of the coupling steps 
 
Any chemical synthesis (of more than 3 steps) might be carried out in two different ways, 
so-called sequential or parallel. However, it is well-known that the sequential process is 
less efficient in terms of overall yield than the parallel one. If we now look at both 
syntheses described in the previous parts, in respect to the ready-to-use building blocks, 
we note that they are quite different. The second one is parallel [(Fuc<->diol)<->(Gal<-
>Lac)->103a-e], and thus already optimal, whereas the first one is fully sequential 
starting from the correctly protected fucose [(Fuc<->diol)<->Gal)<->Lac)->105]. Let us 
have a look at the possibilities for a parallel synthesis instead of the sequential one for 
103a-e. 
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C.I.1. First synthesis, parallel 
 
As already seen, there is no difficulty to fucosylate diol (83) with glycosyl donor 81 giving 
84. The problem is different with galactose and lactic acid. Because of the introduction of 
the azide, the synthesis of the galactose building block begins with peracetylated D-
galactal (89) that is transformed in a galactosyl nitrate (90) followed by the 
corresponding bromide, which is then coupled to the pseudodisaccharide 84. Galactosyl 
nitrate and bromide are however too reactive to envisage their stannylene acetal 
mediated alkylation with the lactic acid moiety. Therefore, this coupling must be done on 
the starting galactal. 
 
As stated in part B.II.2.1, the reaction is expected to be regioselective, even with a fully 
deprotected sugar. However, when tried with D-galactal, it resulted in a mixture of 3-
substituted and 6-subsituted product (see figure 54) in a 1:3 ratio. 
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Figure 54 : Products formed in the stannylene acetal mediated alkylation of 113 with 95. 
 
This result can be explained by the big difference existing between the galactal and 
galactose spatial configurations. From the mechanism (figure 41), due to the different 
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ring structures and constraints of both species, the formation of a 5-member-ring acetal 
is kinetically favored in the case of galactose, whereas the thermodynamically favored 6-
member ring formation is formed on the galactal. 
 
To avoid the formation of the 4,6-acetal, the 6-position of D-galactal is protected. From 
the many selective methods to protect a primary alcohol benzoyl protection with benzoyl 
cyanate was chosen [202] (scheme 10). 
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Scheme 10 : Monobenzoylation of D-galactal at position 6 [202] : a) BzCl, MeCN/Et3N 3:1, -45°C, 
4h (39%). 
 
The reaction worked, although not as selectively as expected : It yielded only 40% of the 
6-monobenzoylated product 115, whereas after 4h reaction, a relatively large amount of 
several polybenzoylated products could be isolated. Unfortunately, when 115 was used 
in a stannylene acetal mediated coupling, 6-O-benzoyl-D-galactal yielded no isolable 
product. 
 
C.I.2. Enzymatic fucosylation as the last synthetic step. 
 
Another coupling sequence was envisaged, with the fucose moiety added at the end of 
the synthesis. In this case, the first coupling involves 3,4,6-O-acetyl-2-azido-2-deoxy-D-
galactosyl bromide and cyclohexanediol, followed by the addition of the lactic acid 
moiety. The subsequent addition of L-fucose is carried out enzymaticallly using human 
fucosyl transferase III (FucT III) [203-205]. The major advantage of the method is the 
possibility of working with unprotected starting material. The fucosylated product would 
thus be ready for triazole library synthesis, and for subsequent bioassays, without any 
deprotection steps as originally planned (see B.II.2.3). 
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Figure 55 : Planned enzymatic fucosylation. 
 
The method also has drawbacks, the first of them being the cost of the enzyme and the 
fucosyl donor, GDP-fucose (guanosyl-diphosphate-fucose). Because of these costs, the 
reaction is limited to very small batches (< 100 mg). This, however, should be sufficient 
for a screening library (<10 mg of each product needed), but will be limiting in case a 
bigger batch has to be synthesized for extended studies. 
 
The major problem, however, was the unsolvability of the starting material under the 
conditions of the enzymatic reaction. The reaction was first tried on an analytical scale, 
using radio-labeled 14C-GDP-fucose. Various batches showed upon scintillation a 64% 
conversion. However, when run at preparative scale, the starting material (116) 
precipitated as soon as the buffer was added (sodium cacodylate and magnesium(II) 
chloride) and neither heating nor dilution led to a complete dissolution. As a 
consequence, no significant amount of the product could be isolated, even after some 
days of incubation. 
 
 80 
C.II. Supported silver silicate as a glycosylation promoter 
 
It was already discussed in part B.II that a major issue of glycosylation reactions is the 
stereoselectivity at the anomeric center. Most of the time, it is directed via neighboring 
group participation of the protecting groups. Whereas non-participating groups at 
position 2 are leading to cis-anomers (thermodynamically stable), participating groups 
are yielding trans-anomers. 
 
In the case of 2-deoxy-2-azido saccharides, glycosylation will mainly give the α-anomer, 
and specific techniques have to be chosen in order to invert the stereochemical outcome 
if the trans-isomer is desired. For that purpose, reactions in a heterogeneous medium 
using an insoluble solid glycosylation promoter are often efficient. Two different types of 
promoters are mainly used, the most recent ones being solid acids of the zeolith class 
[206]. The classical ones are insoluble silver salts [171,207]. 
 
The galactose coupling of our first synthesis (B.II.2.1) is such a case. Our building block 
was a 2-azido-2-deoxy-galactose derivative (91), the azido group being non-
participating, and we needed exclusively the β-anomer (trans) of the product. The 
aglycon coupling partner was molecule 84. Fearing that acidic promoters could drive the 
hydrolysis of the fucoside, the insoluble silver salts method was applied. 
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C.II.1. The published results 
 
Among insoluble silver salts, silver carbonate is used from time to time [208,170], but 
with variable results regarding selectivity. On the other hand, supported silver silicate 
raised a lot of interest. Most of the publications refer to the seminal work of Paulsen et 
al. [165-171] and Van Boeckel et al. [207,209,210]. Both used silver silicate (Ag2SiO3) 
supported either on silica gel, or on alumina. Interestingly, no study has been carried out 
to compare the efficacy of the respective approaches. 
 
Among all the published results, very different reaction conditions were used (reaction 
temperature, reaction time, dilution, presence of molecular sieve, etc.) and resulted in 
variable yields (from 35% to 85%) and stereoselectivities. We therefore compared 
different reaction conditions in order to find the optimal conditions. 
 
C.II.2. Finding the most relevant reaction conditions 
 
Our first trial with reactions promoted by supported silver silicate was the anomeric 
protection of our galactosyl derivative with a trimethylsilylethyl (OSE) group [211]. We 
used a silica gel supported promoter with additional molecular sieve, at room 
temperature (scheme 11). 
 
Wilstermann et al. [211] reported up to 72% yield for this reaction, whereas we only 
could reach 33%. No information, however, was given regarding the method to produce 
the silver silicate promoter, which to our knowledge is not commercially available. We 
used the method reported by Paulsen et al. [167]. 
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Scheme 11 : Protection of galactose anomeric position with an OSE group [211] : a. silica gel 
supported Ag2SiO3, DCM, r.t., 16h (33%); b. silica gel supported Ag2SiO3, DCM, r.t., 16h (33%). 
 
In subsequent trials cyclohexane-1,2-diol was used as an aglycon, towards the synthesis 
of compound 116 (C.I.2) using the same batch of promoter and leading to up to 60% 
yield. These new results suggest that the quality of the promoter was not the main cause 
of the limited success of the first reaction (that yielded 119). We therefore wanted to find 
more reliable reaction conditions. 
 
Two interesting and convergent facts were first noted : 
 - No by-products are formed during the reaction ; Almost the entire uncoupled 
aglycon could be recovered, leading to yields relatively to the consumed 
aglycon of close to 100%. 
 - TLC and MS in the course of the reaction never showed any trace of the 
galactosyl bromide. 
Both facts suggest that the glycon moiety reacts easily with the promoter, this reaction 
being hence competitive with the coupling (see figure 56). 
 
The mechanism shows, in the case of silica gel, how the competitive reaction might 
proceed. Indeed, strong interaction between silver and glycosyl bromide leads to a 
further polarization of the C-Br bond. The activated intermediate is then attacked by the 
alcohol functions present in the medium, here the aglycon (trimethylsilylethanol or 
 83 
cyclohexane-1,2-diol) or the silanol groups that could be present at the surface of the 
promoter. 
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Figure 56 : Proposed mechanism for the supported silver silicate mediated coupling. 
 
This mechanism, along with various entries of the literature [165,168,172,212-216] allow 
us to devise relevant reaction conditions. In order to avoid the competitive reaction with 
the promoter support, a high concentration of the aglycon coupling partner is needed 
close to the reaction site. This can be reached by either using a large excess of the 
aglycon 84 or by adding the donor 91 very slowly to the reaction mixture. It might also be 
useful to reduce the reaction temperature, working at 0°C, or even less. 
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C.II.3. Evaluation of both reported silver silicate supports 
 
Silver silicate was synthesized on both reported supports using the protocol published by 
Paulsen et al. [167]. Details are summarized in table 6 below. 
 
  
Silica gel supported 
silver silicate 
Alumina supported 
Silver silicate 
AgNO3 excess excess 
Na2Si3O7 4.06 mmol 4.06 mmol 
Support 0.38 g silica gel 0.38 g alox 
Starting 
materials 
Product amount 0.64 g 1.20 g 
Silver load (est.) 2.21 mmol/g 3.72 mmol/g 
 
Yield (test reaction) 44% 7% 
Table 6 : Amounts of materials used for the synthesis of both supported silver silicate promoters. 
 
The silver load is estimated based on the recovered silver nitrate, which is used in 
excess. We further assumed that the sodium trisilicate should be converted completely 
into silver silicate. More precise estimations should be possible using X-ray powder 
diffraction. Based on the estimated silver load, there is a significant difference between 
the two promoters (3.72 vs 2.21 mmol/g). 
 
For the test reaction, galactose derivative 91 is coupled to the pseudo-disaccharide 84 
(see scheme 13 below). Again, the yields are relatively low, but the difference between 
both promoters is significant. When alumina supported silver silicate was used, only 7% 
of the starting aglycon was converted (all the glycon unit was consumed however), 
whereas silica gel supported promoter gave a 44% yield. 
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Scheme 12 : Silver silicate mediated coupling of galactosyl bromide 91 to 84. 
 
Because silver cations are probably more concentrated on alumina than on silica, the 
reverse result was expected. It is likely that the competitive reaction with the support was 
more prominent in the case of alumina, consuming the galactosyl bromide before it was 
able to react with the alcohol. However, whatever the support, the competitive reaction 
could never be prevented, even by varying the reaction conditions. Therefore, it may be 
useful to explore the use of different supports. In that sense, recent publications report 
the synthesis of silica supported silver silicate in the form of nanotubes [217,218]. the 
synthesis is relatively easy, and thus accessible without specific material. However, they 
have not been tested yet as glycosidation promoters. Another possible support is 
activated charcoal, with the great advantage that it lacks reactivity. As a consequence 
the competitive reaction with the support would not take place. 
 
C.III. Lactam formation 
 
As it is already described in part B.II.2.3, hydrogenation of 96 unexpectedly lead to the 
formation of a 6-membered ring lactam by nucleophilic attack of the intermediate primary 
amine at position 2 of the galactose at the benzyl ester of the lactic acid moiety. 
The first hydrogenation was carried out using 10% palladium on activated charcoal at a 
hydrogen pressure of 4 bar in ethanol with a catalytic amount of acetic acid. The reaction 
typically took 3-5 days, until the last benzyl ethers were completely cleaved. Under these 
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conditions, the major amount of the product was in the lactam form (102b, figure 57), 
whereas the minor fraction consisted of the free acid (102a). 
 
As the lactam is difficult to cleave while keeping the integrity of the rest of the molecule, 
this result is not acceptable. Therefore, in order to prevent this side-reaction to occur, 
other methods were tried for the cleavage of the benzyl groups. 
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Figure 57 : Formation of a lactam during Pd-catalysed hydrogenation of 96. 
 
C.III.1. Optimizing the hydrogenation conditions 
 
In the course of the hydrogenation, the azide is first reduced to the amine, followed by 
the cleavage of the benzyl ester. From molecular modeling, the most probable position 
of the lactic acid residue for the molecule in solution is a gauche(-) conformation, where 
amine and ester/acid spatially separated. Hence, the reaction can only take place after a 
major conformational shift. However, both catalysts (palladium or palladium hydroxide on 
activated charcoal), with or without acetic acid, gave the same result. 
 
Due to the benzyl ester group, the electrophilicity of the carbonyl carbon is enhance, 
hence favoring the lactam formation. Since the corresponding acid has a reduced 
electrophilicity compared to the benzyl ester, we first cleaved first ester, simply using 0.1 
eq. sodium carbonate in aqueous dioxane. The free carboxylic acid was then subjected 
to hydrogenation, using dioxane as solvent. However, the lactam was still formed, in the 
same proportion as before. 
 
Independently of the catalytic system and the ester activation, other factors facilitate the 
formation of the lactam, among them the irreversibility of the reaction (especially in 
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contrary to lactone formation, see below C.IV) and the thermodynamically favored 
formation of a 6-membered ring. 
 
As a result of this investigation, it became clear that the formation of the amino group 
should be avoided by applying non-reducing conditions for the debenzylation. 
 
C.III.2. Non-reductive methods 
 
We first turned our attention toward oxidative cleavages. One of particular interest was 
performed with 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) under photoirradiation 
[219]. Two batches were set up. In the first one, the reaction was carried out under direct 
UV irradiation (100W, 365 nm). However, after 4h reaction, MS analysis showed 
complete decomposition of the starting material. In the second attempt, the reaction was 
carried out for several days under normal light. In this one the reaction worked very well 
at the beginning, and three out of four benzyl groups were readily cleaved in less than 
48h. However, the last one proved much more stable and in the mean time, oxidation of 
the primary 6-hydroxyl of the galactose moiety was detected. 
 
Another well-studied method for cleavage of the benzyl groups is the use of Lewis acids, 
e.g. Because of the acid-sensitivity of the fucoside, side reactions may occur. Three out 
of four benzyl groups were cleaved within 24h and only traces of decomposition did 
occur. Unfortunately, the fourth benzyl group again turned out to be much more stable, 
and with prolonged reaction times the competitive fucose hydrolysis became 
predominant. 
 
Because both approaches for the removal of the benzyl protection failed, we tried to 
solve the problem by modifying the protecting groups. 
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C.III.3. Other protecting groups for fucose 
 
As already stated in part B.II.2.1, ether protecting groups are the best suited because 
they are non-participating (mandatory to get α-directed coupling), Silyl ethers are 
expected to be unstable under the conditions used later in the synthesis. 
Another possible ether protecting group are p-methoxybenzyl (PMB) ethers [221-223]. 
Due to the electronic effect of the para-positionned methoxy group, those ethers should 
be more sensitive to oxidative (iode, DDQ or CAN [151,152,154]) or mild Lewis acid 
mediated cleavages [224-226]. Unfortunately, the fucose protecting PMB ethers were 
not stable enough in the glycosidation reaction of cyclohexane-1,2-diol (Br2, followed by 
the alcohol and TEAB), and was partially cleaved. 
 
A second approach is derived from the work of Buchwald et al. [227,228] on Palladium 
catalysed amination reactions. Fucose should first be protected with p-bromobenzyl 
groups (PBB), which properties (introduction, stability and cleavage) basically the same 
than for unsubstituted groups. The coupling with cyclohexane-1,2-diol would then be 
performed in standard conditions (B.II.2.1). PBB groups could now be coupled with N-
methylalanine by Pd-catalysis. The presence of an anilin nitrogen changes the 
properties of the benzyl ethers, which now have a reactivity comparable to the one of 
PMB ethers, and should thus be cleavable using mild Lewis acids. 
 
In preliminary tests the fucose building block, protected with PBB groups was coupled to 
1R,2R-cyclohexane-1,2-diol, followed by amination using Pd2(dba)3 as catalyst. 
Unfortunately, the reaction was uncomplete, leading to an unseparable mixture of mono-
, di- and tri-aminated compounds (5:30:65 resp.). Modified reaction conditions (e.g. 
different catalyst and/or ligand) could lead to better results. 
 
It would be even more comfortable if this reaction could be carried out in the last steps of 
the synthesis. Unfortunately, the phosphine ligands used in amination are incompatible 
with an azide. The reaction thus has to be carried out before the introduction of the 
azide, id est before the coupling with the galactose building block. 
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Scheme 13 : Pd-catalysed amination used as protective strategy : a) Br2, DCM, 0°C to r.t., 1h ; b) 
TEAB, DMF, r.t., 2h (59% over 2 steps) ; c) Pd2(dba)3, di-(t-butyl)-o-biphenylphosphine, t-BuONa, 
toluene, r.t., 42h (59%). 
 
C.IV. Lactone formation 
 
As it is already described in part B.III.2.1, two intramolecular lactones were 
unexpectedely formed on the galactose moiety of molecules 109 and 111. Lactones can 
be seen as suitable protecting groups. In our case, however, it is not a suitable solution. 
Indeed, when a lactone is formed between the Gal-2 hydroxyl and the lactic acid, the 
position 2 of the galactose becomes non-participating, the carbonyloxy group being 
constrained in the direction opposite to the anomeric position. Therefore, the main 
coupling product would be the α-anomer. Among the three compounds possibly formed 
after two steps (scheme 14), only 111 and 124b (50% of the total) will be able to form β-
anomers in the subsequent glycosidation. 
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Scheme 14 : Formation of the lactones over two reaction steps : a) 108, Bu2SnO, MeOH, reflux, 
18h ; 107, CsF, DME, r.t., 24h (36% over 2 steps) ; b) BzCl, pyridine, r.t., 16h (88%). 
 
C.IV.1. Chromatographic separation 
 
A first solution would be to separate the three products after benzoyl protection, via 
chromatography. Unfortunately only one lactone could be readily isolated, namely the 
one formed with the Gal-4 hydroxyl (124b), which is the minor product. The second one 
(124a) did not separate from the fully protected product 111. 
 
C.IV.2. Lactone opening and re-protection 
 
Treatment with diluted sodium hydroxide readily cleaved the lactone, as well as the other 
esters in the molecules, resulting in only one product (125, figure 58). This product then 
has to be protected again. 
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Figure 58 : Cleavage of the lactones with diluted aqueous sodium hydroxide. 
 
We expected that the lactone formation was favored by the presence of the carboxylic 
acid protecting benzyl ester. As for the lactam formation discussed in the previous 
chapter (C.III), the ester is expected to activate the carbonyl group, making it more prone 
to reacting with the free hydroxyl groups on the molecule. However, benzoyl protection 
of 125, using benzoyl chloride under esterification conditions, still yielded the lactones. 
The reasons for this reactivity were shown by MS analyses that showed the presence of 
the mixed anhydride formed between the carboxylic acid and the benzoyl chloride. The 
acid function was consequently activated again, and hence reacted towards lactone 
formation. 
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C.IV.3. Selective protection of the starting material 
 
The last solution envisaged would then be to protect the starting galactosyl derivative 
108 selectively at position 2. Indeed, position 4 should not be protected, otherwise the 
stannylene acetal mediated coupling would not be possible. 
 
The selective protection could certainly be carried out by first simultaneously protecting 
the Gal-3 and Gal-4 hydroxyl groups with a benzylidene acetal, followed by a suitable 
protection of the Gal-2 hydroxyl and subsequent cleavage of the acetal. 
 
This protection/deprotection sequence was however not tried in the course of this work, 
and we preferred the straightforward coupling of the three-product mixture with 
compound 84, despite the resulting material loss. Noteworthy is that the needed 
compound 112 was easily isolable from the mixture. 
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D. Experimental part 
 
D.I. General methods 
 
D.I.1. Optical rotation 
 
Optical rotations were measured with a Perkin-Elmer 341 polarimeter at a temperature 
of 20°C. Na-D optical rotations were extrapolated from the measured Hg values (546 
and 578 nm) with the help of Drude’s equation : 
 
α[ ]
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α[ ]


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α[ ]


α[ ]



   with  α[ ]λ = α •	
 • 
 
 
α = Measured optical rotation 
c = Concentration in g/L 
d = Recipient length in m 
λ = Wavelength in nm 
 
The solvents used for the measurements were CH3Cl p.a. (Fluka) and MeOH p.a. 
(Fluka). 
 
D.I.2. Infrared spectroscopy (IR) 
 
IR spectra were recorded on a Perkin Elmer Spectrum One FT-IR spectrometer as KBr 
pellets or films. Most characteristic absorption bands of the spectrum were given in cm-1 
and specified as vs (very strong), s (strong), m (medium), w (weak), b (broad). 
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D.I.3. Nuclear Magnetic Resonance Spectroscopy (NMR) 
 
Proton (1H NMR) and carbon-13 (13C NMR) nuclear magnetic resonance spectra were 
recorded on a Bruker UltraShieldTM Supraconducting NMR 500/70B spectrometer. 
 
1H NMR spectra were recorded at 500.1 MHz and 13C NMR spectra were recorded at 
125.8 MHz in CDCl3 or MeOD. Chemical shifts are given in δ units, parts per million 
(ppm) downfield from tetramethylsilane (TMS). 
 
Values [229] for CDCl3 :  1H NMR: 7.26 13C NMR: 77.03 
 
Values [229] for CD3OD :  1H NMR: 3.31 13C NMR: 49.00 
 
Value [229] for D2O :  1H NMR: 4.79 
 
Multiplicities were specified as follows: s (singlet), d (doublet), dd (double doublet), t 
(triplet), q (quartet), dq (double quartet), m (multiplet). Interpretation of the spectra was 
done according to 1st order. 
 
For assignment of resonance signals to the appropriate nuclei the following 
abbreviations have been used: Fuc (fucose), Gal (galactose), Lac (lactic acid), Tzl 
(triazole), Diol (cyclohexane-1,2-diol). In cases where the numbering of nuclei does not 
accord to the numbering in IUPAC nomenclature, the differences are illustrated in a 
formula scheme of the corresponding substance. 
 
D.I.4. Elementary analyses 
 
Elementary analyses were performed at the Institute of Organic Chemistry (University of 
Basel, Switzerland). 
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D.I.5. Mass spectrometry coupled with high-pressure liquid 
chromatography (MS and LC/MS) 
 
Mass spectra were recorded on a Waters Micromass ZQTM ESI spectrometer. Although 
otherwise stated, ionization parameters were the following : 60 V cone voltage and 3.50 
kV capillary voltage, and the solvent being acetonitrile / water 1:1 with 0.2% formic acid 
(10 µL/min). 
The spectrometer is coupled to an HPLC system from Waters (coupled injector/collector 
2767 Sample Manager with AutoPurificationTM system, 2996 PDA detector, SunfireTM 
columns). Analytical column is a C18, 3.5 µm, 2.1x50 mm. Preparative column is a C18 
OBDTM, 5 µm, 19x150 mm. 
Analytical (15 min, 0.5 mL/min) as well as preparative (30 min, 15 mL/min) runs were 
carried out with a gradient from acetonitrile / water 5:95 to 95:5, with 0.2% formic acid. 
 
D.I.6. Thin Layer Chromatography (TLC) 
 
Reactions were monitored by TLC using glass plates coated with silica gel 60 F254 
(Merck). The spots were detected under short wavelength UV light (254 nm) or charring 
with Mostain, a molybdate solution (a 0.02 M solution of ceric ammonium sulfate and 
ammonium molybdate tetrahydrate in aqueous 10% H2SO4. The plates were then 
heated for 2 min at 150°C. 
 
D.I.7. Filtration and chromatography 
 
Flash chromatography was performed with 200-400 mesh silica gel 60 under air 
pressure. Thin layer chromatography was used to monitor column fractions. 
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D.I.8. Hydrogenations 
 
Hydrogenations under pressure were performed in a protected mixing device from Parr 
Instrument Company, (Moline, IL, USA) in 250 mL bottles. 
 
D.I.9. Drying of the solvents 
 
Absolute solvents like dichloromethane (DCM), acetonitrile (MeCN), 1,2-dichloroethane 
(DCE), 1,2-dimethoxyethane (DME) were prepared by filtration over basic aluminium 
oxide (Fluka, type 5016 A basic).  
 
Absolute solvents like methanol, ethanol or dioxane were dried by refluxing with sodium 
and distilled immediately before use. 
 
Pyridine was freshly distilled under argon in the presence of CaH2, and stored on KOH 
platelets. 
 
N,N-Dimethylformamide (DMF) was stirred during 4 h before use on activated molecular 
sieve 4 Å beads. 
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D.II. Description of the reactions 
 
(1R,2R)-2-O-(2,3,4-Tri-O-benzyl-α-L-fucosyl)-cyclo-
hexane-1,2-diol (84) 
(1_148)  
Thioethyl 2,3,4-tri-O-benzyl-L-fucoside (81) (8.00 g, 16.7 
mmol) was dissolved in dry DCM (80 mL), and cooled to 
0°C under argon. Bromine (1.00 mL, 19.6 mmol) was added slowly at 0°C, then the 
mixture was heated slowly to r.t.. After 1 h, the remaining bromine was quenched using 
cyclohexene (2.0 mL, 30 min stirring at r.t.). 
(1R,2R)-Cyclohexane-1,2-diol (83, 2.40 g, 20.7 mmol) and tetraethylammonium bromide 
(5.30 g, 25.2 mmol) were dissolved in DMF (25 mL). Activated powdered molecular 
sieves 3 Å (1.0 g) was suspended in the solution which then was stirred for 30 min under 
argon at r.t.. Then, the fucosyl bromide solution was added dropwise to the suspension. 
After stirring for 3h, the reaction mixture was neutralized with pyridine (2 mL), diluted 
with DCM (50 mL), and washed with saturated aqueous NaHCO3 solution (30 mL) and 
water (2x30 mL). The organic layer was dried with Na2SO4 and concentrated. 
Chromatography on silica gel (petrol ether / ethyl acetate 2:1, with 0.1% Et3N) yielded 84 
(6.19 g, 70%) as a yellowish oil. 
(1_148) 
[α]D = -121.4 (c = 2.06, MeOH). 
(1_148, 21/01/05) 
1H NMR (500 MHz, CDCl3) : δ = 1.14 (d, 3H, 3J5,6 = 6.5 Hz, Fuc-H6), 1.18-1.33 (m, 4H, 
diol), 1.70 (m, 2H, diol), 2.00 (s, 2H, diol), 3.24 (m, 1H, diol-H1), 3.44 (m, 1H, diol-H2), 
3.69 (s, 1H, Fuc-H4), 3.93 (d, 1H, 3J2,3 = 10.1 Hz, Fuc-H3), 4.07 (m, 2H, fuc-H2, Fuc-
H5), 4.64-4.97 (m, 6H, CH2-Ph), 4.98 (d, 1H, Fuc-H1), 7.26-7.39 (m, 15H, 15 Ar-H). 
(1_148 2101/05) 
13C NMR (125 MHz, CDCl3) : δ = 16.7 (Fuc-C6), 24.0, 24.4, 30.1, 32.5 (4C, diol), 67.0 
(Fuc-C5), 73.2 (diol-C2), 73.3, 73.4, 74.9 (3C, 3 CH2-Ph), 76.2 (Fuc-C2), 77.5 (Fuc-C4), 
79.3 (Fuc-C3), 83.9 (diol-C1), 96.2 (Fuc-C1), 127.4, 127.5, 127.7, 128.0, 128.2, 128.4 
(15C, 15 Ar-CH), 138.5, 138.6, 138.9 (3C, 3 quat. Ar-C). 
(1_182) 
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Elemental analysis : Calculated for C33H40O6 : C, 74.41% ; H, 7.57%. Found : C, 74.31% 
; H, 7.54%. 
 
 
1,2,3,4-Tetra-O-acetyl-L-fucose (86) 
(2_004) 
L-fucose (0.60 g, 3.65 mmol, 85) was dissolved in pyridine (15 
mL), and cooled to 0°C under argon. Acetic anhydride (3.0 mL, 
31.7 mmol) was added slowly to the cold solution, which was then heated slowly to r.t. 
and stirred for 17 h. The reaction mixture was diluted with ethyl acetate (30 mL), washed 
with a saturated aqueous NaHCO3 solution (3x20 mL), and with water (2x 20 mL). The 
organic layer was dried with Na2SO4 and concentrated to yield 86 (1.20 g, quant.) as a 
yellowish solid. The compound was used in next step without further purification. 
(1_201, 01/09/05) 
α-anomer : 1H NMR (500 MHz, CDCl3) : δ = 1.15 (d, 3H, 3J5,6 = 6.5 Hz, H-6), 2.00, 2.01, 
2.14, 2.17 (4s, 12H, CH3C=O), 4.27 (q, 1H, 3J5,6 = 6.5 Hz, H-5), 5.29-5.35 (m, 3H, H-2, 
H-3, H-4), 6.33 (d, 1H, 3J1,2 = 2.9 Hz, H-1). 
(1_201, 01/09/05) 
13C NMR (125 MHz, CDCl3) : δ = 16.0 (C-6), 20.1-21.1 (4C, CH3C=O), 67.7 (C-5) 66.4, 
69.9 (C-3, C-4), 70.6 (C-2), 90.4 (C-1), 169.2, 169.5, 170.0, 170.2 (4C, CH3C=O). 
(1_201, 01/09/05) 
β-anomer : 1H NMR (500 MHz, CDCl3) : δ = 1.22 (d, 3H, 3J5,6 = 6.4 Hz, H-6), 1.99, 2.03, 
2.11, 2.18 (4s, 12H, CH3C=O), 3.96 (qd, 1H, 3J4,5 = 0.9 Hz, 3J5,6 = 6.4 Hz, H-5), 5.07 (dd, 
1H, 3J3-4 = 3.3 Hz, 3J2,3 = 10.4 Hz, H-3), 5.26 (dd, 1H, 3J4,5 = 0.9 Hz, 3J3,4 3.3 Hz H-4), 
5.32 (dd, 1H, 3J1,2 = 8.3 Hz, 3J2,3 = 10.4 Hz, H-2), 5.68 (d, 1H, 3J1,2 = 8.3 Hz, H-1). 
(1_201, 01/09/05) 
13C NMR (125 MHz, CDCl3) : δ = 15.8 (C-6), 20.1-21.1 (4C, CH3C=O), 70.0 (C-4), 70.5 
(C-2), 70.7 (C-5), 71.3 (C-3), 92.6 (C-1), 169.3, 170.0, 170.2, 170.6 (4C, CH3C=O). 
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2,3,4-Tri-O-acetyl-1-ethylthio-L-fucoside (87) 
2_005 
1,2,3,4-tri-O-acetyl-L-fucose (1.20 g, 3.61 mmol) (86) was 
dissolved in dry DCE (15 mL), and cooled to 0°C under argon. 
Ethanethiol (0.35 mL, 4.73 mmol) was added to the cold solution, followed by tin 
tetrachloride (0.65 mL, 5.53 mmol). After stirring at 0°C for 4 h, the reaction mixture was 
diluted with DCM (20 mL), washed with an aqueous KF/KH2PO4 solution (10%, 2x 20 
mL), and water (2x 20 mL). The organic layer was dried on Na2SO4 and concentrated. 
Chromatography on silica gel with petrol ether and ethyl acetate 3:1 as eluent afforded 
17 (0.94 g, 78%) as a yellowish oil 
(1_206, 09/09/05) 
α-anomer : 1H NMR (500 MHz, CDCl3) : δ = 1.15 (d, 3H, 3J5,6 = 6.5 Hz, H-6), 1.25 (t, 3H, 
3J = 7.4 Hz, S-CH2-CH3), 1.98, 2.06, 2.16 (3s, 9H, CH3C=O), 2.51 (dq, 1H, 3J = 7.4 Hz, 
2J = 12.9 Hz, S-CHH-CH3), 2.57 (dq, 1H, 3J = 7.4 Hz, 2J = 12.9 Hz, S-CHH-CH3), 4.48 (q, 
1H, 3J5,6 = 6.6 Hz, H-5), 5.21 (dd, 1H, 3J3,4 = 3.2 Hz, 3J2,3 = 10.8 Hz, H-3), 5.26 (dd, 1H, 
3J1,2 = 5.4 Hz, 3J2,3 = 10.8 Hz, H-2), 5.28 (dd, 1H, 3J4,5 = 0.8 Hz, 3J3,4 = 3.2 Hz, H-4), 5.69 
(d, 1H, 3J1,2 = 5.4 Hz, H-1). 
(1_206, 09/09/05) 
13C NMR (125 MHz, CDCl3) : δ = 14.8 (-S-CH2-CH3), 15.9 (C-6), 20.7, 20.9, (3C, 
CH3C=O), 24.2 (-S-CH2-CH3), 64.6 (C-5), 67.3 (C-2), 68.7 (C-3), 70.5 (C-4), 81.9 (C-1), 
169.7, 170.2, 170.7 (3C, CH3C=O). 
(1_206, 13/09/05) 
β-anomer : 1H NMR (500 MHz, CDCl3) : δ = 1.21 (d, 3H, 3J5,6 = 6.3 Hz, H-6), 1.27 (t, 3H, 
3J = 7.5 Hz, S-CH2-CH3), 1.98, 2.06, 2.17 (3s, 9H, CH3C=O), 2.70 (dq, 1H, 3J = 7.6 Hz, 
2J = 12.6 Hz, S-CHH-CH3), 2.75 (dq, 1H, 3J = 7.5 Hz, 2J = 12.6 Hz, S-CHH-CH3), 3.81 
(qd, 1H, 3J4,5 = 0.8 Hz,  3J5,6 = 6.3 Hz, H-5), 4.43 (d, 1H, 3J1,2 = 9.9 Hz, H-1), 5.04 (dd, 1H, 
3J3,4 = 3.4 Hz, 3J2,3 = 10.3 Hz, H-3), 5.21 (dd, 1H, 3J1,2 = 9.9 Hz, 3J2,3 = 10.3 Hz, H-2),  
5.27 (d, 1H, 3J3,4 = 3.4 Hz, H-4), 
(1_206, 13/09/05) 
13C NMR (125 MHz, CDCl3) : δ = 14.8 (-S-CH2-CH3), 16.4 (C-6), 20.7, (3C, CH3C=O), 
24.2 (-S-CH2-CH3), 73.2 (C-5), 68.0 (C-2), 72.4 (C-3), 71.0 (C-4), 83.5 (C-1), 169.9, 
170.2, 170.6 (3C, CH3C=O). 
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1-Ethylthio-L-fucoside (88) 
2_009 
2,3,4-Tri-O-acetyl-1-ethylthio-L-fucoside (1.56 g, 4.67 mmol) (87) 
was dissolved in MeOH (15 mL) and water (1 mL). Potassium 
carbonate (65 mg, 0.47 mmol) was then added. After stirring for 19 h, the reaction 
mixture was concentrated. Chromatography on silica gel with DCM and MeOH 9:1 as 
eluent afforded 88 (0.84 g, 86%) as an off-white solid. 
(2_009, 01/09/05) 
α-anomer : 1H NMR (500 MHz, MeOD) : δ = 1.22 (d, 3H, 3J5,6 = 6.6 Hz, H-6), 1.28 (t, 3H, 
3J = 7.5 Hz, S-CH2-CH3), 2.49-2.63 (m, 2H, S-CH2-CH3), 3.59 (dd, 1H, 3J3,4 = 3.1 Hz, 3J2,3 
= 10.1 Hz, H-3), 3.66 (broad s, 1H, H-4), 4.28 (q, 1H, 3J5,6 = 6.6 Hz, H-5), 5.26 (dd, 1H, 
3J1,2 = 5.6 Hz, 3J2,3 = 10.1 Hz, H-2), 5.34 (d, 1H, 3J1,2 = 5.6 Hz, H-1). 
 
13C NMR (125 MHz, MeOD) : δ = 15.5 (C-6), 16.6 (-S-CH2-CH3), 25.2 (-S-CH2-CH3), 67.9 
(C-5), 69.5 (C-2), 71.2 (C-3), 76.0 (C-4), 87.4 (C-1). 
 
β-anomer : 1H NMR (500 MHz, MeOD) : δ = 1.25 (d, 3H, 3J5,6 = 6.5 Hz, H-6), 1.28 (t, 3H, 
3J = 7.4 Hz, S-CH2-CH3), 2.64-2.78 (m, 2H, S-CH2-CH3), 3.46 (dd, 1H, 3J3,4 = 3.0 Hz, 3J2,3 
= 9.2 Hz, H-3), 3.50 (t, 1H, 3J1,2 = 3J2,3 = 9.2 Hz, H-2), 3.62-3.66 (m, 2H, H-4, H-5), 4.30 
(d, 1H, 3J1,2 = 9.2 Hz, H-1). 
 
13C NMR (125 MHz, MeOD) : δ = 15.5 (C-6), 17.1 (-S-CH2-CH3), 25.0 (-S-CH2-CH3), 72.5 
(C-2), 73.3 (C-4), 76.5 (C-3), 73.5 (C-5) 87.2 (C-1). 
 
 
2,3,4-Tri-O-benzyl-1-ethylthio-L-fucoside (81) 
1_132 
1-Ethylthio-L-fucoside (129 mg, 0.62 mmol) (88) was 
dissolved in dry DMF (5 mL) and cooled to 0°C under argon. 
De-oiled sodium hydride (90 mg, 3.75 mmol) was then added slowly. After 30 min 
stirring, benzyl bromide (300 µL, 2.53 mmol) was added dropwise. After 16 h stirring at 
r.t., the reaction mixture was quenched with MeOH (1 mL), diluted with toluene (20 mL) 
and washed with water (2x 15 mL) and brine (10 mL). The organic layer was then dried 
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on Na2SO4 and concentrated. Chromatography on silica gel with petrol ether and ethyl 
acetate 8:1 as eluent afforded 81 (237 mg, 80%) as an off-white solid. 
 
α-anomer : 1H NMR (500 MHz, CDCl3) : δ = 1.13 (d, 3H, 3J5,6 = 6.5 Hz, H-6), 1.27 (t, 3H, 
3J = 7.4 Hz, S-CH2-CH3), 2.48 (dq, 1H, 3J = 7.4 Hz, 2J = 12.9 Hz, S-CHH-CH3), 2.57 (dq, 
1H, 3J = 7.3 Hz, 2J = 12.9 Hz, S-CHH-CH3), 3.64 (d, 1H, 3J3,4 = 2.8 Hz, H-4), 3.79 (dd, 
1H, 3J3,4 = 2.8 Hz, 3J2,3 = 9.9 Hz, H-3), 4.19 (q, 1H, 3J5,6 = 6.5 Hz, H-5), 4.29 (dd, 1H, 3J1,2 
= 5.5 Hz, 3J2,3 = 9.9 Hz, H-2), 4.65 (A of AB, 1H, 2JA,B = 11.6 Hz, CH-Ph), 4.69 (A of AB, 
1H, 2JA,B = 11.8 Hz, CH-Ph), 4.71 (A of AB, 1H, 2JA,B = 11.9 Hz, CH-Ph), 4.76 (B of AB, 
1H, 2JA,B = 11.8 Hz, CH-Ph), 4.86 (B of AB, 1H, 2JA,B = 11.9 Hz, CH-Ph), 4.98 (B of AB, 
1H, 2JA,B = 11.6 Hz, CH-Ph), 5.46 (d, 1H, 3J1,2 = 5.5 Hz, H-1), 7.27-7.41 (m, 15H, Ar-H). 
 
13C NMR (125 MHz, CDCl3) : δ = 14.9 (S-CH2-CH3), 16.6 (C-6), 23.7 (S-CH2-CH3), 66.7 
(C-5), 72.4 (CH2-Ph), 73.5 (CH2-Ph), 74.9 (CH2-Ph), 76.1 (C-2), 77.7 (C-4), 79.9 (C-3), 
83.4 (C-1), 127.5, 127.6, 127.9, 128.0, 128.2, 128.3, 128.4 (15C, Ar-CH), 138.3, 138.6, 
138.9 (3C, Ar-C quat.). 
 
β-anomer : 1H NMR (500 MHz, CDCl3) : δ = 1.19 (d, 3H, 3J5,6 = 6.4 Hz, H-6), 1.29 (t, 3H, 
3J = 7.4 Hz, S-CH2-CH3), 2.66-2.80 (m, 2H, S-CH2-CH3), 3.46 (q, 1H, 3J5,6 = 6.2 Hz, H-5), 
3.55 (dd, 1H, 3J3,4 = 2.4 Hz, 3J2,3 = 9.3 Hz, H-3), 3.60 (d, 1H, 3J3,4 = 2.4 Hz, H-4), 3.81 (t, 
1H, 3J1,2 = 3J2,3 = 9.5 Hz, H-2), 4.38 (d, 1H, 3J1,2 = 9.6 Hz, H-1), 4.68 (A of AB, 1H, 2JA,B = 
11.8 Hz, CH-Ph), 4.72 (A of AB, 1H, 2JA,B = 11.9 Hz, CH-Ph), 4.76 (B of AB, 1H, 2JA,B = 
11.9 Hz, CH-Ph), 4.79 (A of AB, 1H, 2JA,B = 10.2 Hz, CH-Ph), 4.88 (B of AB, 1H, 2JA,B = 
10.2 Hz, CH-Ph), 4.98 (B of AB, 1H, 2JA,B = 11.8 Hz, CH-Ph), 7.24-7.40 (m, 15H, Ar-H). 
 
13C NMR (125 MHz, CDCl3) : δ = 15.0 (S-CH2-CH3), 17.2 (C-6), 24.6 (S-CH2-CH3), 72.8 
(CH2-Ph), 74.5 (2C, C-5, CH2-Ph) 75.7 (CH2-Ph), 76.4 (C-4), 78.3 (C-2), 84.4 (C-3), 84.9 
(C-1), 127.5, 127.6, 127.7, 128.1, 128.2, 128.3, 128.4 (15C, Ar-CH), 138.3, 138.4, 138.6 
(3C, Ar-C quat.). 
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3,4,6-Tri-O-acetyl-2-azido-2-deoxy-D-galactosyl nitrate (90). 
(1_197) 
A mixture of cerium ammonium nitrate (3.53 g, 6.44 mmol) and 
sodium azide (0.21 g, 3.23 mmol) was cooled to –20°C under 
argon. 3,4,6-Tri-O-acetyl-D-galactal (89) (585 mg, 2.15 mmol) was dissolved in dry 
MeCN (20 mL) and added to the solids. After stirring for 18 h at –20°C, cold diethyl ether 
and water (50 mL each) were added to the reaction mixture. The organic layer was 
separated, washed with water (2x30 mL), dried with Na2SO4 and concentrated. 
Chromatography on silica gel (petrol ether / ethyl acetate 5:2) yielded 90 (428 mg, 53%, 
α/β 1.5:1) as a yellow oil. 
(1_202a, 25/08/05) 
α-anomer : 1H NMR (500 MHz, CDCl3) : δ = 2.03, 2.07, 2.17 (3s, 9H, CH3C=O), 4.09-
4.13 (m, 3H, H-2, H-6, H-6’), 4.36 (td, 1H 3J4,5 = 0.9 Hz, 3J5,6 = 6.6 Hz, H-5), 5.24 (dd, 1H, 
3J3,4 = 3.2 Hz, 3J2,3 = 11.3 Hz, H-3), 5.49 (dd, 1H, 3J4,5 = 0.9 Hz, 3J3,4 = 2.5 Hz, H-4), 6.33 
(d, 1H, 3J1,2 = 4.1 Hz, H-1). 
 
13C NMR (125 MHz, CDCl3) : δ = 20.5, 20.6 (3C, 3 CH3C=O), 55.9 (C-2), 60.9 (C-6), 66.6 
(C-4), 68.6 (C-3), 69.5 (C-5), 96.9 (C-1), 169.5 (3C, 3 CH3C=O). 
 
β-anomer : 1H NMR (500 MHz, CDCl3) : δ = 2.04, 2.07, 2.17 (3s, 9H, CH3C=O), 3.82 
(dd, 1H, 3J1,2 = 8.7 Hz, 3J2,3 = 10.6 Hz, H-2), 4.05 (td, 1H 3J4,5 = 0.9 Hz, 3J5,6 = 6.6 Hz, H-
5), 4.09-4.13 (m, 2H, H-6, H-6’), 4.95 (dd, 1H, 3J3,4 = 3.3 Hz, 3J2,3 = 10.6 Hz, H-3), 5.38 
(dd, 1H, 3J4,5 = 0.9 Hz, 3J3,4 = 2.8 Hz, H-4), 5.57 (d, 1H, 3J1,2 = 8.7 Hz, H-1). 
 
13C NMR (125 MHz, CDCl3) : δ = 20.5, 20.6 (3C, 3 CH3C=O), 57.5 (C-2), 60.9 (C-6), 65.8 
(C-4), 71.7 (C-3), 71.9 (C-5), 98.1 (C-1), 169.5 (3C, 3 CH3C=O). 
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3,4,6-Tri-O-acetyl-2-azido-2-deoxy-α-D-galactosyl bromide (91). 
(1_197) 
Compound 90 (428 mg, 1.14 mmol) was dissolved in dry MeCN (20 
mL) at r.t. under argon. Dry LiBr (500 mg, 5.76 mmol) was added, 
and the reaction mixture was stirred at r.t. for 15 h. Then cold toluene 
and water (50 mL each) were added to the reaction mixture. The organic layer was 
separated, washed with water (2x 30 mL), dried with Na2SO4 and concentrated to yield 
91 (421 mg, 94%) as a light brown viscous oil. The compound was used in the next step 
without further purification. 
(1_202b, 30/08/05) 
1H NMR (500 MHz, CDCl3) : δ = 2.05, 2.06, 2.15 (3s, 9H, 3 CH3C=O), 3.98 (dd, 1H 3J1,2 
= 3.7 Hz, 3J2,3 = 10.7 Hz, H-2), 4.10 (dd, 1H, 3J5,6 = 6.6 Hz, 2J6,6’ = 11.4 Hz, H-6), 4.17 
(dd, 1H, 3J5,6’ = 6.6 Hz, 2J6,6’ = 11.4 Hz, H-6’), 4.47 (t, 1H, 3J5,6 = 6.6 Hz, H-5), 5.34 (dd, 
1H, 3J3,4 = 1.8 Hz, 3J2,3 = 10.7 Hz, H-3), 5.50 (d, 1H, 3J3,4 = 1.8 Hz, H-4), 6.47 (d, 1H, 3J1,2 
= 3.7 Hz, H-1). 
 
13C NMR (125 MHz, CDCl3) : δ = 20.5, 20.6 (3C, 3 CH3C=O), 58.6 (C-2), 60.7 (C-6), 66.6 
(C-4), 69.8 (C-3), 71.4 (C-5), 88.9 (C-1), 169.5, 169.7, 170.3 (3C, 3 CH3C=O). 
 
 
Silica gel-supported silver silicate Ag2SiO3. 
(1_189) 
Silver nitrate (430 mg, 2.53 mmol) was dissolved in water (2.5 mL), and silica gel 60 
(380 mg, Fluka) was suspended into the solution. A suspension of sodium trisilicate 
(1.23 g, 5.08 mmol) in water (2.5 mL) was added dropwise with vigorous stirring. The 
mixture was then heated to 70°C for 30 min. After decantation, the supernatant was 
removed, and the solid residue suspended again in water (5 mL) and filtered. The 
residue was again suspended in a hot (70°C) aqueous solution of silver nitrate (10%, 2 
mL) and stirred for 30 min. After cooling to r.t., acetone was added, the suspension was 
filtered, and subsequently washed with acetone and toluene. 
The resulting solid was dried, first in Rotavap, then at 70°C in high vacuum, yielding the 
promoter (640 mg, estimated silver load : 2.2 mmol/g) as a light-brown powder. 
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(1R,2R)-1-O-(3,4,6-Tri-O-acetyl-2-azido-2-deoxy-β-D-
galactosyl)-2-O-(2,3,4-tri-O-benzyl-α-L-fucosyl)-
cyclohexane-1,2-diol (92). 
(1_160) 
Compound 84 (355 mg, 0.68 mmol) was dissolved in 
dry DCM (10 mL) under argon. Silica supported silver 
silicate (0.85 g) and activated powdered molecular sieves 3 Å (0.4 g) were suspended in 
the solution, then bromide 91 (288 mg, 0.73 mmol) in dry DCM (10 mL) was added 
dropwise. After stirring for 185 h at r.t., the mixture was filtered through Celite, and the 
Celite washed with DCM. The filtrate was washed with water (2x10 mL), dried with 
Na2SO4 and concentrated. Chromatography on silica gel (toluene / ethyl acetate 6:1 to 
4:1, with 0.1% Et3N) yielded 92 (305 mg, 54%) as a yellowish, amorphous solid. 
(1_238) 
[α]D = -52.1 (c = 13.8, CHCl3). 
(1_234, 31/03/06) 
1H NMR (500 MHz, CDCl3) : δ = 1.12 (d, 3H, 3J5,6 = 6.5 Hz, Fuc-H6), 1.26-1.72 (m, 8H, 
diol-H3-H6), 1.92, 2.02, 2.04 (3s, 9H, 3 CH3C=O), 3.47 (dd, 1H, 3J1,2 = 7.9 Hz, 3J2,3 = 
10.9 Hz, Gal-H2), 3.63 (m, 1H, diol-H2), 3.65 (d, 1H, 3J3,4 = 2.4 Hz, Fuc-H4), 3.74 (m, 
1H, diol-H1), 3.78 (t, 3J5,6 = 7.3 Hz, Gal-H5) 3.96 (dd, 1H, 3J3,4 = 2.4 Hz,  3J2,3 = 10.1 Hz, 
Fuc-H3), 4.00 (dd, 1H, 3J5,6 = 5.9 Hz,  2J6,6’ = 11.0 Hz, Gal-H6), 4.04-4.08 (m, 2H, Fuc-
H2, Gal-H6’), 4.42 (d, 1H, 3J1,2 = 7.9 Hz, Gal-H1), 4.51 (q, 1H, 3J5,6 = 6.5 Hz, Fuc-H5), 
4.69-4.73 (m, 3H, Gal-H3, 2 CH-Ph), 4.78 (A of AB, 1H, 2JA,B = 11.6 Hz, CH-Ph), 4.80 (B 
of AB, 1H, 2JA,B = 11.9 Hz, CH-Ph), 4.89 (B of AB, 1H, 2JA,B = 11.6 Hz, CH-Ph), 4.91 (d, 
1H, 3J1,2 = 3.7 Hz Fuc-H1), 4.99 (B of AB, 1H, 2JA,B = 11.9 Hz, CH-Ph), 7.17-7.44 (m, 
15H, 15 Ar-H). 
 
13C NMR (125 MHz, CDCl3) : δ = 16.9 (Fuc-C6), 20.5, 20.6, 20.7 (3C, 3 CH3C=O), 23.0, 
29.0, 29.3 (4C, diol), 60.7 (Fuc-C2), 61.3 (Gal-C2), 65.9 (Fuc-C5), 66.2 (GalC-4), 70.2 
(Gal-C5), 70.8 (Gal-C3), 73.1, 73.2, 74.3 (3C, 3 CH2-Ph), 76.0 (diol-C2), 76.8 (Gal-C6), 
77.0 (Fuc-C2), 77.3 (Fuc-C4), 79.5 (diol-C1), 80.0 (Fuc-C3), 95.1 (Fuc-C1), 100.2 (Gal-
C1), 127.3-129.0 (9 peaks, 15C, 15 Ar-CH), 138.7, 139.1 (3C, 3 quat. Ar-C) 
(1_234) 
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Elemental analysis : Calculated for C45H55N3O13 : C, 63.89% ; H, 6.55% ; N, 4.97%. 
Found : C, 63.79% ; H, 6.70% ; N, 4.91%. 
 
 
(1R,2R)-1-O-(2-Azido-2-deoxy-β-D-galactosyl)-2-O-
(2,3,4-tri-O-benzyl-α-L-fucosyl)-cyclohexane-1,2-diol 
(93). 
(1_167) 
Compound 92 (300 mg, 0.35 mmol) was dissolved in 
methanol / water (1:1 10 mL), and potassium carbonate 
(5 mg, 36 µmol) was added. After stirring for 41 h at r.t., the solvents were evaporated. 
Chromatography on silica gel (dichloromethane / methanol gradient 98:2 to 90:10, with 
0.1% Et3N) yielded 93 (195 mg, 76%) as an off-white foam. 
(1_235) 
[α]D = -95.4 (c = 0.52, MeOH). 
(1_195, 09/08/05) 
1H NMR (500 MHz, CDCl3) : δ = 1.13 (d, 3H, 3J5,6 = 6.4 Hz, Fuc-H6), 1.20-1.72 (m, 8H, 
diol-H3-H6), 3.39-3.43 (m, 3H, Gal-H2, Gal-H3, Gal-H5), 3.60-3.65 (m, 1H, diol-H2), 
3.73 (s, 1H, Fuc-H3), 3.74-3.81 (m, 2H, Gal-H6, diol-H1), 3.86 (dd, 1H, 2J6,6’ = 12.3 Hz, 
3J5,6’ = 5.2 Hz, Gal-H6’), 3.94 (d, 1H, 3J3,4 = 2.9 Hz, Gal-H4), 4.02-4.08 (m, 2H, Fuc-H2, 
Fuc-H4), 4.40 (d, 1H, 3J1,2 = 7.7 Hz, Gal-H1), 4.44 (q, 1H, 3J5,6 = 6.4 Hz, Fuc-H5), 4.64 (A 
of AB, 1H, 2JA,B = 11.6 Hz, CH2-Ph), 4.65 (A of AB, 1H, 2JA,B = 11.5 Hz, CH2-Ph), 4.75 (A 
of AB, 1H, 2JA,B = 11.6 Hz, CH2-Ph), 4.76 (B of AB, 1H, 2JA,B = 11.5 Hz, CH2-Ph), 4.80 (B 
of AB, 1H, 2JA,B = 11.6 Hz, CH2-Ph), 4.97 (B of AB, 1H, 2JA,B = 11.6 Hz, CH2-Ph), 5.02 (d, 
1H, 3J1,2 = 3.2 Hz, Fuc-H1), 7.24-7.43 (m, 15H, Ar-H). 
 
13C NMR (125 MHz, CDCl3) : δ = 16.6 (Fuc-C6), 63.8 (Gal-C6), 66.1 (Fuc-C5), 69.3 (Gal-
C4), 72.0 (Gal-C3), 73.3, 72.8 (2C, 2 CH2-Ph), 74.0 (Gal-C5), 74.9 (2C, diol-C2, CH2-
Ph), 76.5 (Fuc-C2), 78.1 (2C, Fuc-C3, diol-C1), 79,6 (Fuc-C4), 93.6 (Fuc-C1), 99.4 (Gal-
C1). 
(1_235) 
Elemental analysis : Calculated for C39H49N3O10 : C, 65.08% ; H, 6.86% ; N, 5.84%. 
Found : C, 65.11% ; H, 7.02% ; N, 5.64%. 
O
N3
HO
HO
O
O
O OBn
BnO
OBn
OH
1 
2 
 106 
 
(1R,2R)-1-O-{3-O-[(Benzyl (2S)-3-cyclo-hexyl-
propionate)-2-yl]-2-azido-2-deoxy-β-D-
galactosyl}-2-O-(2,3,4-tri-O-benzyl-α-L-
fucosyl)-cyclohexane-1,2-diol (96). 
(1_200) 
Compound 93 (910 mg, 1.30 mmol), and 
dibutyltin oxide (350 mg, 1.40 mmol) were dissolved in dry methanol (50 mL) under 
argon, and activated powdered molecular sieves 3Å (1.0 g) was suspended in the 
solution. The mixture was refluxed for 18 h, cooled, filtered, and concentrated. The 
resulting solid was taken up in dry DME (20 mL) under argon, cesium fluoride (250 mg, 
1.60 mmol) was added, and the reaction mixture was stirred for 1 h. Then a solution of 
95 in DME (15 mL) was added dropwise over 3 h. After stirring for 20 h at r.t., the 
reaction was quenched with an aqueous KF/KH2PO4 solution (10%, 20 mL). The organic 
layer was separated, washed with water (2x 20 mL), dried with Na2SO4 and 
concentrated. Chromatography on silica gel (toluene / ethyl acetate 4:1 to 2:1, with 0.1% 
Et3N) yielded 96 (850 mg, 71%) as a yellowish foam. 
(1_200) 
[α]D = - 102.8 (c = 0.985, MeOH). 
(1_200, 25/08/05) 
1H NMR (500 MHz, CDCl3) : δ = 0.84-0.98 (m, 3H, cyclohexyl), 1.14 (d, 3H, 3J5,6 = 6.5 
Hz, Fuc-H6), 1.17-1.80 (m, 18H, Lac-H3, cyclohexyl, diol-H3-H6), 2.98 (dd, 1H, 3J3,4 = 
3.1 Hz, 3J2,3 = 10.0 Hz, Gal-H3), 3.28 (dd, 1H, 3J5,6’ = 3.0 Hz, 3J5,6 = 7.5 Hz, Gal-H5), 3.46 
(dd, 1H, 3J1,2 = 8.0 Hz, 3J2,3 = 10.0 Hz, Gal-H2), 3.54 (dd, 1H, 3J6,6’ = 12.3 Hz, 3J5,6 = 3.0 
Hz, Gal-H6), 3.58 (d, 1H, 3J3,4 = 3.1 Hz, Gal-H4), 3.62 (td, 1H, 3J1,2 = 4.3 Hz, 3J2,3 = 9.3 
Hz, diol-H2), 3.71 (td, 1H, 3J1,2 = 4.3 Hz, 3J1,6 = 9.4 Hz, diol-H1), 3.78 (d, 1H, 3J4,3 = 1.5 
Hz, Fuc-H4), 3.89 (dd, 1H, 2J6,6’ = 12.3 Hz, 3J5,6’ = 7.5 Hz, Gal-H6’), 4.02-4.10 (m, 3H, 
Fuc-H2, Fuc-H3, Lac-H2), 4.30 (d, 1H, 3J1,2 =8.0 Hz, Gal-H1), 4.54 (q, 1H, 3J5,6 = 6.5 Hz, 
Fuc-H5), 4.63-4.97 (m, 6H, CH2-Ph), 4.98 (s, 1H, Fuc-H1), 5.17 (A of AB, 1H, 2JA,B = 
12.0 Hz, CH2-Ph), 5.20 (B of AB, 1H, 2JA,B = 12.0 Hz, CH2-Ph), 7.26-7.43 (m, 20H, Ar-H). 
(1_200, 25/08/05) 
13C NMR (125 MHz, CDCl3) : δ = 16.6 (Fuc-C6), 23.3, 26.2, 26.3, 26.5, 29.0, 29.9, 32.2, 
33.3, 33.4, 34.0, 41.0 (11C, Lac-C3, cyclohexyl C, diol-C3-C6), 62.8 (Gal-C6), 63.3 (Gal-
C2), 66.1 (Fuc-C5), 66.7 (Gal-C4), 67.4 (CH2-Ph), 72.8 (CH2-Ph), 73.2 (CH2-Ph), 74.3 
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(Gal-C5), 75.0 (CH2-Ph), 75,1 (diol-C2), 76.4 (Fuc-C2), 77.6 (Fuc-C3), 78.1 (Fuc-C4), 
78.8 (diol-C1), 79.7 (Lac-C2), 82,2 (Gal-C3), 94.1 (Fuc-C1), 100.0 (Gal-C1), 127.7-129.2 
(20C, Ar-CH), 135.2, 138.9, 139.2, 139.6 (4C, quat. Ar-C), 148.8 (Lac-C1). 
(1_200) 
Elemental analysis : Calculated for C55H69N3O12 : C, 68.52% ; H, 7.21% ; N, 4.36%. 
Found : C, 68.38% ; H, 7.12% ; N, 4.24%. 
 
 
(2R)-3-Cyclohexyl-2-hydroxypropionic acid (98). 
(1_079) 
Phenyllactic acid (3.52 g, 21.2 mmol) (97) was dissolved 
under argon in a mixture of water (40 mL), dioxane (20 mL) 
and acetic acid (10 mL). Rhodium on alumina (5%, 0.35 g) was hydrogenated at 4 bar 
for 72 h in a Paar shaker. The reaction mixture was filtered through Celite and 
concentrated. After co-evaporation with toluene, 98 (3.41 g, 93%) was obtained as an 
off-white solid. 
(1_079) 
1H NMR (500 MHz, MeOD) : δ = 0.93-1.01 (m, 2H, H-7), 1.19-1.33 (m, 3H, cyclohexyl), 
1.56-1.73 (m, 7H, cyclohexyl, H-3), 1.87 (broad s, 1H, H-4), 4.16 (m, 1H, H-2). 
(SM) 
13C NMR (125 MHz, CDCl3) : δ = 26.0, 26.2, 26.4, 32.2, 33.9 (6C, C6H11), 41.9 (C-3), 
68.6 (C-2), 185.8 (C-1). 
 
 
Benzyl (2R)-3-cyclohexyl-2-hydroxypropionate (99). 
(1_084) 
(2R)-3-Cyclohexyl-2-hydroxypropionic acid (98) (3.40 g, 
19.8 mmol) was dissolved in methanol (20 mL), then 
cesium carbonate (7.10 g, 21.8 mmol) in water (20 mL) was added. The solution was 
stirred for 1 h at r.t.. The solvents were evaporated, and the residue co-evaporated with 
toluene (20 mL). After drying for 3 h in high vacuum, the residue was suspended in dry 
DMF (20 mL), and benzyl bromide (2.60 mL, 21.9 mmol) was added. After stirring for 20 
h, the solution was diluted with toluene (50 mL) and washed with water (3x 50 mL). The 
combined aqueous layers were washed with toluene (2x 50 mL), and combined organic 
OH
OH
O
1 
2 
3 
OH
OBn
O
1 
2 
3 
 108 
layer was washed with brine (1x 50 mL), dried with Na2SO4 and concentrated. 
Chromatography on silica gel (petrol ether / ethyl acetate 4:1) yielded 99 (3.0 g, 58%) as 
a white, amorphous solid. 
(1_084) 
1H NMR (500 MHz, CDCl3): δ = 0.85-0.96 (m, 2H, H-7), 1.09-1.27 (m, 3H, cyclohexyl), 
1.50-1.71 (m, 7H, cyclohexyl, H-3), 1.81 (m, 1H, H-4), 4.28 (dd, 1H, 3J = 3.9 Hz, 3J = 9.0 
Hz, H-2), 5.21 (s, 2H, CH2-Ph), 7.35-7.38 (m, 5H, Ar-H). 
(SM) 
13C NMR (125 MHz, CDCl3) : δ = 26.0, 26.3, 32.3, 33.7, 33.9 (6C, cyclohexyl), 42.1 (C-
3), 67.3 (CH2-Ph), 68.6 (C-2), 128.4, 128.6, 128.7 (5C, Ar-CH), 135.2 (Ar-C quat.), 175.9 
(C-1). 
 
 
Benzyl (2R)-3-cyclohexyl-2-trifluoromethylsulfonyl-oxy-
propionate (95) 
(1_168) 
Alcohol 99 (315 mg, 1.2 mmol) was dissolved in dry DCM (10 
mL) and cooled to –20°C under argon. 2,6-Di-tert-butylpyridine (350 µL, 1.6 mmol) was 
added, followed by dropwise addition of trifluoromethanesulfonic anhydride (240 µL, 1.5 
mmol). The reaction mixture was stirred for 3h while heating slowly to 0°C. Cold DCM 
and 1M aqueous KH2PO4 (10 mL each) were added to the reaction mixture. The organic 
layer was separated and washed with water (2x 10 mL), dried with Na2SO4 and 
concentrated. The crude material was filtered quickly on a short silica gel column, (petrol 
ether / ethyl acetate 20:1), yielding triflate 95 (330 mg, 70%) as a yellowish oil. 
(SM) 
1H NMR (500 MHz, CDCl3): δ = 0.85-1.94 (m, 13H, H-3, cyclohexyl), 5.17 (m, 1H, H-2), 
5.25 (s, 2H, CH2-Ph), 7.31-7.40 (m, 5H, Ar-H). 
(SM) 
13C NMR (125 MHz, CDCl3) : δ = 25.7, 26.0, 26.1, 32.0, 33.2, 33.4 (cyclohexyl), 39.2 (C-
3), 68.2 (2C, C-2, CH2-Ph), 81.9 (CF3), 128.6, 128.7, 128.9, 134.4 (5C, Ar-CH), 134.4 
(Ar-C quat.), 167.6 (C-1). 
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1,3,4,6-Tetra-O-acetyl-2-azido-2-deoxy-D-galactose (101) 
(1_166) 
Sodium azide (595 mg, 9.20 mmol) was dissolved in water 
(1.5 mL), cooled to 0°C, and DCM (2.5 mL) was added to the 
solution. Triflic anhydride (300 µL, 1.82 mmol) was then 
slowly added under vigorous stirring. After stirring 2h at 0°C, the aqueous layer was 
separated and washed with DCM (2x 1 mL). The combined organic layers, containing 
triflyl azide (TfN3) were finally washed with a saturated aqueous NaHCO3 solution and 
used in the following without further purification. 
K2CO3 (192 mg, 1.39 mmol) and CuSO4 (cat.) were added to a solution of 2-amino-2-
deoxy-galactose hydrochloride (100, 200 mg, 0.93 mmol) in water (3 mL) and MeOH (6 
mL), followed by the TfN3 in DCM solution. Some drops of MeOH were added to 
homogeneity. After stirring for 16h at r.t., the reaction was quenched with 
diisopropylamine (200 µL), and solvents were evaporated to dryness. 
The residue was taken up in pyridine and acetic anhydride was added slowly. After 16h 
stirring, the reaction mixture was diluted with ethyl acetate (30 mL), washed with a 
saturated aqueous NaHCO3 solution (3x20 mL), and with water (2x 20 mL). The organic 
layer was then dried with Na2SO4 and concentrated. Chromatography on silica gel 
(petrol ether / ethyl acetate 4:1) yielded 101 (3.0 g, 58%) as a white, crystalline solid. 
(1_004, 29/09/03) 
α-anomer : 1H NMR (500 MHz, CDCl3) : δ = 2.03, 2.08, 2.17, 2.18 (4s, 12H, 4 CH3C=O), 
3.94 (dd, 1H 3J1,2 = 3.6 Hz, 3J2,3 = 11.1 Hz, H-2), 4.06 (dd, 1H, 3J5,6 = 6.2 Hz, 2J6,6’ = 10.7 
Hz, H-6), 4.10 (dd, 1H, 3J5,6 = 6.3 Hz, 2J6,6’ = 10.7 Hz, H-6’), 4.28 (dt, 1H, 3J4,5 = 1.3 Hz, 
3J5,6 = 6.3 Hz, H-5), 5.31 (dd, 1H, 3J3,4 = 3.2 Hz, 3J2,3 = 11.1 Hz, H-3), 5.48 (dd, 1H, 3J4,5 = 
1.3 Hz, 3J3,4 = 3.2 Hz, H-4), 6.32 (d, 1H, 3J1,2 = 3.6 Hz, H-1). 
(1_017, 06/12/04) 
β-anomer : 1H NMR (500 MHz, CDCl3) : δ = 2.04, 2.07, 2.17, 2.21 (4s, 12H, 4 CH3C=O), 
3.84 (dd, 1H 3J1,2 = 8.5 Hz, 3J2,3 = 10.8 Hz, H-2), 4.00 (t, 1H, 3J5,6 = 6.6 Hz, H-5), 4.10 
(dd, 1H, 3J5,6 = 6.1 Hz, 2J6,6’ = 11.7 Hz, H-6), 4.15 (dd, 1H, 3J5,6’ = 6.9 Hz, 2J6,6’ = 11.4 Hz, 
H-6’), 4.89 (dd, 1H, 3J3,4 = 3.3 Hz, 3J2,3 = 10.8 Hz, H-3), 5.38 (dd, 1H, 3J4,5 = 0.6 Hz, 3J3,4 
= 3.2 Hz, H-4), 5.54 (d, 1H, 3J1,2 = 8.5 Hz, H-1). 
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(1R,2R)-1-O-{2-(4-biphenyl-1,2,3-triazol-1-
yl)-3-[((2S)-3-cyclohexylpropionic acid)-2-O-
yl]-2-deoxy-β-D-galactosyl]}-2-O-(α-L-
fucosyl)-cyclohexane-1,2-diol sodium salt 
(103a). 
 
Azide 96 (20 mg, 21 µmol) and 4-
ethynylbiphenyl (8 mg, 44 µmol) were 
dissolved in MeOH (2 mL). Argon was bubbled 
into the solution, in order to remove oxygen. 
An aqueous copper sulfate solution (1M, 20 
µL) was then added, followed by aqueous 
sodium ascorbate (1M, 30 µL). After stirring for 2 d at r.t., ethyl acetate (5 mL) and water 
(2 mL) were added. The organic layer was washed with water (2x5 mL), dried with 
Na2SO4 and concentrated. Chromatography on silica gel (toluene/ethyl acetate 2:1, with 
0.1% Et3N) afforded a mixture of the protected triazole and remaining 96 (7:3, 24 mg), 
which was used in the next step without further purification. 
The crude mixture was dissolved in dioxane (2 mL) under argon. 10% palladium on 
charcoal (10 mg) was added and the suspension hydrogenated at 4 bar for 2 d in a Parr 
shaker. The reaction mixture was filtered through Celite, concentrated and purified by 
preparative LC-MS. After lyophilization, 103a (10.0 mg, 60%) was obtained as a white 
powder. 
 
1H NMR (500 MHz, CD3OD) : δ = 0.56-0.80 (m, 3H, cyclohexyl), 0.82-0.96 (m, 3H, 1 diol-
H6, 2 cyclohexyl), 1.00-1.10 (m, 3H, 1 diol-H4, 1 diol-H5, 1 cyclohexyl), 1.27 (d, 3H, 3J5,6 
= 6.6 Hz, Fuc-H6), 1.24-1.39 (m, 7H, 1 diol-H3, 1 diol-H5, 5 cyclohexyl), 1.43-1.45 (m, 
2H, Lac-H3), 1.57-1.59 (m, 2H, 1 diol-H4, 1 diol-H6), 1.88-1.91 (m, 1H, 1 diol-H3), 
3.33 (td, 1H, 3J1,2 = 4.0 Hz, 3J2,3 = 8.5 Hz, diol-H2), 3.66 (td, 1H, 3J1,2 = 4.0 Hz, 3J1,6 = 8.5 
Hz, diol-H1), 3.71 (dd, 1H, 3J1,2 = 3.8 Hz, 3J2,3 = 10.1 Hz, Fuc-H2), 3.73-3.75 (m, 2H, 
Fuc-H4, Gal-H5), 3.79 (dd, 1H, 3J5,6 = 5.2 Hz, 2J6,6’ = 11.2 Hz, Gal-H6), 3.83-3.87 (m, 1H, 
Gal-H6’), 3.87 (dd, 1H, 3J3,4 = 3.4 Hz, 3J2,3 = 10.1 Hz, Fuc-H3), 3.96 (dd, 1H, 3J2,3 = 3.2 
Hz, 3J2,3’ = 9.5 Hz Lac-H2), 4.07 (d, 1H, 3J3,4 = 2.6 Hz, Gal-H4), 4.22 (dd, 1H, 3J3,4 = 2.6 
Hz, 3J2,3 = 10.6 Hz, Gal-H3), 4.55-4.61 (m, 2H, Fuc-H5, Gal-H2), 4.82 (d, 1H, 3J1,2 = 3.8 
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Hz Fuc-H1), 5.08 (d, 1H, 3J1,2 = 8.3 Hz, Gal-H1), 7.35, 7.46, 7.67, 7.72, 7.95 (m, 9H, Ar-
H), 8.48 (s, 1H, C2N3H) ; 
 
13C NMR (125 MHz, CD3OD) : δ = 16.7 (Fuc-C6), 23.7, 26.5, 26.8, 27.3, 29.3, 29.9, 32.9, 
33.9, 35.1, 41.6 (11 C, Lac-C3, cyclohexyl C, diol-C3-C6), 62.6 (Gal-C6), 64.7 (Gal-C4), 
67.4 (2C, Fuc-C5, Gal-C2), 70.0 (Fuc-C2), 71.6 (Gal-C5), 73.8 (Fuc-C3), 76.7 (Fuc-C4), 
79.0 (diol-C2), 79.5 (Lac-C2), 79.8 (diol-C1), 82.8 (Gal-C3), 97.3 (Fuc-C1), 100.3 (Gal-
C1), 125.2, 127.1, 127.9, 128.5, 128.6, 129.9 (10C, 9 Ar-CH, Tzl-CH). 
 
 
(1R,2R)-1-O-{2-[4-(pyridin-3-yl)-1,2,3-triazol-1-
yl]-3-[((2S)-3-cyclohexyl-propionic acid)-2-O-
yl]-2-deoxy-β-D-galactosyl}-2-O-(α-L-fucosyl)-
cyclohexane-1,2-diol sodium salt (103b). 
 
Azide 96 (20 mg, 21 µmol) and 3-ethynylpyridine 
(7 mg, 42 µmol) were dissolved in MeOH (2 mL). 
Argon was bubbled into the solution, in order to 
remove oxygen. An aqueous copper sulfate 
solution (1M, 20 µL) was then added, followed 
by aqueous sodium ascorbate (1M, 30 µL). After stirring for 2 d at r.t., ethyl acetate (5 
mL) and water (2 mL) were added. The organic layer was washed with water (2x5 mL), 
dried with Na2SO4 and concentrated. Chromatography on silica gel (toluene/ethyl 
acetate 2:1, with 0.1% Et3N) afforded a mixture of the protected triazole and remaining 
96 (8:2, 19 mg), which was used in the next step without further purification. 
The crude mixture was dissolved in liquid ammonia (7 mL) and kept at –75°C under 
argon. Sodium (15 mg) was added piecewise. Once the blue color persisted, the 
reaction was quenched by slowly adding solid ammonium chloride (30 mg). Liquid 
ammonia was removed by heating to r.t. and the residue was taken up in water/MeOH 
1:1 (10 mL), filtered and concentrated. Purification by LC-MS and lyophilization yielded 
103b (6.2 mg, 41%) as a white powder. 
 
1H NMR (500 MHz, CD3OD) : δ = 0.49-0.80 (m, 5H, 1 diol-H6, 4 cyclohexyl), 0.89-1.02 
(m, 2H, cyclohexyl), 1.02-1.13 (m, 2H, 1 diol-H4, 1 diol-H5), 1.27 (d, 3H, 3J5,6 = 6.6 Hz, 
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FucH-6), 1.20-1.41 (m, 8H, 1 diol-H3, 1 diol-H6, 5 cyclohexyl), 1.45-1.47 (m, 2H, Lac-
H3), 1.58-1.60 (m, 2H, 1 diol-H4, 1 diol-H6), 1.89-1.92 (m, 1H, 1 diol-H3), 3.33 (td, 1H, 
3J1,2 = 3.9 Hz, 3J2,3 = 8.6 Hz, diol-H2), 3.67 (td, 1H, 3J1,2 = 3.9 Hz, 3J1,6 = 8.6 Hz, diol-H1), 
3.71 (dd, 1H, 3J1,2 = 3.8 Hz, 3J2,3 = 10.1 Hz, Fuc-H2), 3.75 (d, 1H, 3J3,4 = 3.2 Hz, Fuc-H4), 
3.80 (dd, 1H, 3J5,6 = 4.9 Hz, 2J6,6’ = 11.3 Hz, Gal-H6), 3.85 (dd, 1H, 3J5,6’ = 7.0 Hz, 2J6,6’ = 
11.3 Hz, Gal-H6’), 3.88 (dd, 1H, 3J3,4 = 3.2 Hz, 3J2,3 10.1 Hz, Fuc-H3), 4.05 (s, 1H, Gal-
H4), 4.17 (d, 1H, 3J2,3 = 9.8 Hz, Gal-H3), 4.59 (m, 2H, Fuc-H5, Gal-H2), 4.82 (d, 1H, 3J1,2 
= 3.8 Hz, Fuc-H1), 5.10 (d, 1H, 3J1,2 = 8.2 Hz, Gal-H1), 7.69, 8.20, 8.37, 8,39, 8.63 (m, 
6H, C6H5N, C2N3H) ; 
 
13C NMR (125 MHz, MeOD) : δ = 16.7 (Fuc-C6), 23.8, 26.7, 27.0, 27.3, 29.5, 30.1, 32.9, 
34.0, 35.2, 42.9 (11C, Lac-C3, cyclohexyl C, diol-C3-C6), 62.7 (Gal-C6), 64.8 (Gal-C2), 
66.6 (Gal-C4), 67.4 (Fuc-C5), 69.9 (Fuc-C2), 71.5 (Gal-C5), 73.8 (Fuc-C3), 76.2 (Fuc-
C4), 76.6 (Diol-C2), 79.8 (diol-C1), 82.9 (Gal-C3), 97.2 (Fuc-C1), 100.1 (Gal-C1). 
 
 
(1R,2R)-1-O-{2-(4-benzyl-1,2,3-triazol-1-yl)-3-
[((2S)-3-cyclohexylpropionic acid)-2-O-yl]-2-
deoxy-β-D-galactosyl}-2-O-(α-L-fucosyl)-
cyclohexane-1,2-diol sodium salt (103c). 
 
Azide 96 (20 mg, 21 µmol) and 3-phenyl-1-
propyne (5 µL, 46 µmol) were dissolved in 
MeOH (2 mL). Argon was bubbled into the 
solution, in order to remove oxygen. An aqueous 
copper sulfate solution (1M, 20 µL) was then added, followed by aqueous sodium 
ascorbate (1M, 30 µL). After stirring for 2 d at r.t., ethyl acetate (5 mL) and water (2 mL) 
were added. The organic layer was washed with water (2x5 mL), dried with Na2SO4 and 
concentrated. Chromatography on silica gel (toluene/ethyl acetate 2:1, with 0.1% Et3N) 
afforded a mixture of the protected triazole and remaining 96 (8:2, 22 mg), which was 
used in the next step without further purification. 
Crude mixture was dissolved in dioxane (2 mL) under argon. 10% palladium on charcoal 
(10 mg) was added and the suspension hydrogenated at 4 bar for 2 d in a Parr shaker. 
The reaction mixture was filtered through Celite, concentrated and purified by 
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preparative LC-MS. After lyophilization, 103c (10.2 mg, 66%) was obtained as a white 
powder. 
 
1H NMR (500 MHz, CD3OD) : δ = 0.52-0.79 (m, 4H, 1 diol-H6, 3 cyclohexyl), 0.98-1.16 
(m, 5H, 1 diol-H4, 1 diol-H5, 3 cyclohexyl), 1.20 (d, 3H, 3J5,6 = 6.6 Hz, Fuc-H6), 1.23 1.60 
(m, 11H, Lac-H3, 4 diol-H3-H6, 5 cyclohexyl), 1.82-1.85 (m, 1H, diol-H3), 3.33 (m, 1H, 
diol-H2), 3.52 (td, 1H, 3J1,2 = 3.9 Hz, 3J1,6 = 8.5 Hz, diol-H1), 3.66 (t, 1H, 3J5,6 = 6.1 Hz, 
Gal-H5), 3.69 (m, 2H, Fuc-H2, Fuc-H4), 3.75 (dd, 1H, 3J5,6 = 5.3 Hz, 2J6,6’ = 11.2 Hz, Gal-
H6), 3.80 (dd, 1H, 3J5,6’ = 6.7 Hz, 2J6,6’ = 11.2 Hz, Gal-H6’), 3.83 (dd, 1H, 3J3,4 = 3.3 Hz, 
3J2,3 = 10.1 Hz, Fuc-H3), 3.93 (t, 1H, 3J2,3 = 6.4 Hz, Lac-H2), 4.07 (s, 2H, CH2-Ph), 4.04 
(d, 1H, 3J3,4 = 2.8 Hz, Gal-H4), 4.21 (dd, 1H, 3J3,4 = 2.8 Hz, 3J2,3 = 10.6 Hz, Gal-H3), 4.44 
(dd, 1H, 3J1,2 = 8.4 Hz, 3J2,3 = 10.6 Hz, Gal-H2), 4.51 (q, 1H, 3J5,6 = 6.6 Hz, Fuc-H5), 4.79 
(d, 1H, 3J1,2 = 3.9 Hz, Fuc-H1), 4.85 (d, 1H, 3J1,2 = 8.4 Hz, Gal-H1), 7.20, 7.27-7.28 (m, 
5H, Ar-H), 7.74 (s, 1H, C2N3H) ; 
 
13C NMR (125 MHz, MeOD) : δ = 16.4 (Fuc-C6), 23.6, 26.6, 27.0, 32.6, 33.8, 34.9, 42.3 
(11C, Lac-C3, cyclohexyl C, diol-C3-C6), 32.9 (CH2-Ph), 62.3 (Gal-C6), 64.4 (Gal-C2), 
66.6 (Gal-C4), 67.2 (Fuc-C5), 69.8 (Fuc-C2), 71.4 (2C, Fuc-C4, Fuc-C3), 73.6 (Gal-C5), 
75.8 (diol-C2), 76.4 (Lac-C2), 77.7 (diol-C1), 82.1 (Gal-C3), 97.0 (Fuc-C1), 100.2 (Gal-
C1), 125.9, 127.4, 129.5 (6C, 5 Ar-CH, Tzl-H), 140.3, 147.7 (2C, Ar-C quat., Tzl-C 
quat.). 
 
 
(1R,2R)-1-O-{2-(4-phenyl-1,2,3-triazol-1-yl)-3-
[((2S)-3-cyclohexylpropionic acid)-2-O-yl]-2-
deoxy-β-D-galactosyl}-2-O-(α-L-fucosyl)-
cyclohexane-1,2-diol sodium salt (103d). 
 
Azide 96 (20 mg, 21 µmol) and phenylacetylene 
(5 µL, 44 µmol) were dissolved in MeOH (2 mL). 
Argon was bubbled into the solution, in order to 
remove oxygen. An aqueous copper sulfate 
solution (1M, 20 µL) was then added, followed by aqueous sodium ascorbate (1M, 30 
µL). After stirring for 2 d at r.t., ethyl acetate (5 mL) and water (2 mL) were added. The 
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organic layer was washed with water (2x5 mL), dried with Na2SO4 and concentrated. 
Chromatography on silica gel (toluene/ethyl acetate 2:1, with 0.1% Et3N) afforded a 
mixture of the protected triazole and remaining 96 (7:3, 20.4 mg), which was used in the 
next step without further purification.  
The crude mixture was dissolved in dioxane (2 mL) under argon. 10% palladium on 
charcoal (10 mg) was added and the suspension hydrogenated at 4 bar for 2 d in a Parr 
shaker. The reaction mixture was filtered through Celite, concentrated and purified by 
preparative LC-MS. After lyophilization, 103d (8.2 mg, 54%) was obtained as a white 
powder. 
 
1H NMR (500 MHz, CD3OD) : δ = 0.48-0.85 (m, 4H, diol, 3 cyclohexyl), 0.87-1.12 (m, 6H, 
3 diol, 3 cyclohexyl), 1.23 (d, 3H, 3J5,6 = 6.6 Hz, Fuc-H6), 1.22-1.27 (m, 6H, diol, 5 
cyclohexyl) 1.46 (m, 2H, Lac-H3), 1.58-1.61 (m, 2H, diol), 1.85-1.88 (m, 1H, diol), 3.32 
(td, 1H, 3J1,2 = 3.9 Hz, 3J2,3 = 8.5 Hz, diol-H2), 3.65 (td, 1H, 3J1,2 = 3.9 Hz, 3J1,6 = 8.6 Hz, 
diol-H1), 3.69-3.73 (m, 3H, Fuc-H2, Fuc-H4, Gal-H5), 3.78 (dd, 1H, 3J5,6 = 5.1 Hz, 2J6,6’ = 
11.2 Hz, Gal-H6), 3.83 (dd, 1H, 3J5,6’ = 6.5 Hz, 2J6,6’ = 11.2 Hz, Gal-H6’), 3.85 (dd, 1H, 
3J3,4 = 3.1 Hz, 3J2,3 = 10.0 Hz, Fuc-H3), 3.90 (dd, 1H, 3J2,3 = 3.5 Hz, 3J2,3’ = 9.5 Hz Lac-
H2), 4.05 (d, 1H, 3J3,4 = 2.5 Hz, Gal-H4), 4.19 (dd, 1H, 3J3,4 = 2.5 Hz, 3J2,3 = 10.3 Hz, Gal-
H3), 4.55-4.60 (m, 2H, Fuc-H5, Gal-H2), 4.81 (d, 1H, 3J1,2 = 3.9 Hz Fuc-H1), 4.97 (d, 1H, 
3J1,2 = 8.2 Hz, Gal-H1), 7.34-7.42 (m, 4H, Ar-H), 7.89 (m, 2H, Tzl-H, Ar-H) ; 13C NMR 
(125 MHz, CD3OD) : δ = 16.6 (Fuc-C6), 23.8, 26.7, 26.9, 27.3, 29.3, 30.0, 32.8, 33.8, 
35.0, 42.0 (11 C, Lac-C3, cyclohexyl C, diol-C3-C6), 62.7 (Gal-C6), 65.0 (Gal-C4), 67.4 
(2C, Fuc-C5, Gal-C2), 70.1 (Fuc-C2), 71.6 (Gal-C5), 73.8 (Fuc-C3), 76.5 (Fuc-C4), 76.4 
(diol-C2), 79.6 (Lac-C2), 79.8 (diol-C1), 82.7 (Gal-C3), 97.3 (Fuc-C1), 100.3 (Gal-C1), 
125.2, 127.3, 128.5, (6C, Ar-CH, Tzl-CH), 140.2, 145.6 (2C, Ar-C-quat., Tzl-C quat.). 
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(1R,2R)-1-O-{2-[4-(4-trifluoromethylphenyl)-
1,2,3-triazol-1-yl]-3-[((2S)-3-
cyclohexylpropionic acid)-2-O-yl]-2-deoxy-β-
D-galactosyl}-2-O-(α-L-fucosyl)-cyclohexane-
1,2-diol sodium salt (103e). 
 
Azide 96 (20 mg, 21 µmol) and 4-ethynyl-α,α,α-
trifluorotoluene (7 µL, 43 µmol) were dissolved in 
MeOH (2 mL). Argon was bubbled into the 
solution, in order to remove oxygen. An aqueous 
copper sulfate solution (1M, 20 µL) was then added, followed by aqueous sodium 
ascorbate (1M, 30 µL). After stirring for 2 d at r.t., ethyl acetate (5 mL) and water (2 mL) 
were added. The organic layer was washed with water (2x5 mL), dried with Na2SO4 and 
concentrated. Chromatography on silica gel (toluene/ethyl acetate 2:1, with 0.1% Et3N) 
afforded a mixture of the protected triazole and remaining 96 (7:3, 22 mg), which was 
used in the next step without further purification. 
The crude mixture was dissolved in dioxane (2 mL) under argon. 10% palladium on 
charcoal (10 mg) was added and the suspension hydrogenated at 4 bar for 2 d in a Parr 
shaker. The reaction mixture was filtered through Celite, concentrated and purified by 
preparative LC-MS. After lyophilization, 103e (10.3 mg, 62%) was obtained as a white 
powder. 
 
1H NMR (500 MHz, CD3OD) : δ = 0.56-0.95 (m, 6H, 2 diol, 4 cyclohexyl), 0.99-1.13 (m, 
4H, 2 diol, 2 cyclohexyl), 1.26 (d, 3H, 3J5,6 = 6.5 Hz, Fuc-H6), 1.21-1.26 (m, 6H, diol, 5 
cyclohexyl) 1.44 (m, 2H, Lac-H3), 1.57-1.60 (m, 2H, diol), 1.85-1.90 (m, 1H, 1 diol), 3.33 
(m, 1H, diol-H2), 3.66 (m, 1H, diol-H1), 3.69 (dd, 1H, 3J1,2 = 3.8 Hz, 3J2,3 = 10.0 Hz, Fuc-
H2), 3.72 (t, 1H, 3J5,6 = 6.0 Hz, Gal-H5), 3.75 (d, 1H, 3J3,4 = 3.2 Hz, Fuc-H4), 3.79 (dd, 
1H, 3J5,6 = 5.1 Hz, 2J6,6’ = 11.3 Hz, Gal-H6), 3.85 (dd, 1H, 3J5,6’ = 6.8 Hz, 2J6,6’ = 11.3 Hz, 
Gal-H6’), 3.87 (dd, 1H, 3J3,4 = 3.4 Hz, 3J2,3 = 10.0 Hz, Fuc-H3), 3.96 (dd, 1H, 3J2,3 = 3.2 
Hz, 3J2,3’ = 9.4 Hz Lac-H2), 4.07 (d, 1H, 3J3,4 = 2.6 Hz, Gal-H4), 4.21 (dd, 1H, 3J3,4 = 2.6 
Hz, 3J2,3 = 10.2 Hz, Gal-H3), 4.56-4.60 (m, 2H, Fuc-H5, Gal-H2), 4.81 (d, 1H, 3J1,2 = 3.8 
Hz Fuc-H1), 5.09 (d, 1H, 3J1,2 = 8.3 Hz, Gal-H1), 7.67 (m, 2H, Ar-H), 7.89 (s, 1H, Tzl-H), 
7.94 (m, 2H, Ar-H) ; 13C NMR (125 MHz, CD3OD) : δ = 16.7 (Fuc-C6), 23.7, 26.6, 26.8, 
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27.3, 29.4, 29.9, 32.9, 33.9, 35.1, 41.8 (11 C, Lac-C3, cyclohexyl C, diol-C3-C6), 62.7 
(Gal-C6), 64.8 (Gal-C4), 67.0 (Gal-C2), 67.3 (Fuc-C5), 69.9 (Fuc-C2), 71.6 (Gal-C5), 
73.9 (Fuc-C3), 76.3 (2C, Fuc-C4, diol-C2), 79.3 (Lac-C2), 79.5 (diol-C1), 82.9 (Gal-C3), 
97.1 (Fuc-C1), 100.1 (Gal-C1), 124.9, 125.2, 127.3, 128.4, (5C, Ar-CH, Tzl-CH), 139.8, 
143.2 (3C, 2 Ar-C-quat., Tzl-C quat.). 
 
 
Benzyl (2R)-3-phenyl-2-hydroxypropionate (106) 
(2_015) 
D(+)-phenyllactic acid (97) (500 mg, 3.0 mmol) was 
dissolved in dry DMF (10 mL) containing activated 
powdered molecular sieve 3 Å (500 mg), then cesium carbonate (1.96 g, 6.0 mmol) was 
added. After the solution was stirred for 1 h at r.t., benzyl bromide (400 µL, 3.4 mmol) 
was added dropwise over 4 h. The mixture was then stirred 1 h more, filtered on Celite, 
diluted with ethyl acetate (20 mL) and washed with water (3x 20 mL). The combined 
aqueous layers were washed with ethyl acetate (2x 20 mL), and combined organic layer 
was washed with brine (1x 50 mL), dried with Na2SO4 and concentrated. 
Chromatography on silica gel (petrol ether / ethyl acetate 4:1) yielded 106 (680 mg, 
88%) as a yellowish oil. 
(2_011, 03/02/06) 
1H NMR (500 MHz, CDCl3): δ = 2.75 (d, 1H, 3J = 6.4 Hz, OH), 3.00 (dd, 1H, 3J2,3 = 6.4 
Hz, 2J = 13.9 Hz, H-3), 3.15 (dd, 1H, 3J2,3 = 4.4 Hz, 2J = 13.9, H-3’), 4.52 (m, 1H, H-2), 
5.21 (AB system, 2H, CH2-Ph), 7.16-7.41 (m, 10H, Ar-H). 
(2_011, 03/02/06) 
13C NMR (125 MHz, CDCl3) : δ = 40.5 (C-3), 67.5 (CH2-Ph), 71.2 (C-2), 126.9, 128.4, 
128.7, 129.5 (10C, Ar-CH), 135.0, 136.1 (2C, Ar-C quat.), 174.0 (C-1). 
 
 
Benzyl (2R)-3-phenyl-2-trifluoromethylsulfonyl-oxy-
propionate (107) 
(2_016) 
Alcohol 106 (682 mg, 2.7 mmol) was dissolved in dry 
DCE (30 mL) and cooled to –20°C under argon. Pyridine (280 µL, 3.5 mmol) was added, 
followed by dropwise addition of trifluoromethanesulfonic anhydride (500 µL, 3.0 mmol). 
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The reaction mixture was stirred for 2h while heating slowly to -5°C. Reaction was 
quenched using ice cold 1M aqueous KH2PO4 (20 mL). The organic layer was separated 
and washed with ice cold water (2x 20 mL), dried with Na2SO4 and concentrated. The 
crude material was filtered quickly on a short silica gel column, (petrol ether / ethyl 
acetate 20:1), yielding triflate 107 (870 mg, 84%) as a yellowish oil. 
(2_012, 07/02/06) 
1H NMR (500 MHz, CDCl3): δ = 3.18 (dd, 1H, 3J2,3 = 8.4 Hz, 2J = 14.6, H-3), 3.31 (dd, 1H, 
3J2,3 = 4.2 Hz, 2J = 14.6, H-3’), 5.21 (AB system, 2H, CH2-Ph), 5.25 (m, 1H, 3J2,3 = 4.2 
Hz, 3J2,3’ = 8.4 Hz, H-2), 7.13-7.37 (m, 10H, Ar-H). 
(2_012, 07/02/06) 
13C NMR (125 MHz, CDCl3) : δ = 38.2 (C-3), 68.4 (CH2-Ph), 83.8 (C-2), 127.9, 128.6, 
128.7, 128.8, 129.5 (10C, Ar-CH), 133.2, 134.2 (2C, Ar-C quat.), 166.5 (C-1). 
 
 
Thioethyl 6-O-benzyl-3-O-[(benzyl (2S)-3-phenyl-
propionate)-2-yl]-β-D-galactoside (109). 
(2_017) 
Thioethyl 6-O-benzyl-β-D-galactoside 108 (309 mg, 
0.99 mmol), and dibutyltin oxide (280 mg, 1.12 mmol) 
were dissolved in dry methanol (30 mL) under argon, and activated powdered molecular 
sieves 3Å (500 mg) was suspended in the solution. The mixture was refluxed for 18 h, 
cooled, filtered, and concentrated. The resulting solid was taken up in dry DME (15 mL) 
under argon, cesium fluoride (250 mg, 1.65 mmol) was added, and the reaction mixture 
was stirred for 30 min. Then a solution of 107 in DME (5 mL) was added dropwise over 3 
h. After stirring for 21 h at r.t., the reaction was quenched with an aqueous KF/KH2PO4 
solution (10%, 20 mL). The organic layer was separated, washed with water (2x 20 mL), 
dried with Na2SO4 and concentrated. Chromatography on silica gel (toluene / ethyl 
acetate 9:1 to 2:1, with 0.1% Et3N) yielded 109 (197 mg, 36%) as a yellowish oil. Product 
is mixed with its lactonized forms. It was used in the next step without further purification. 
(2_013, 16/02/06, seulement 1H et COSY) 
1H NMR (500 MHz, CDCl3): δ = 1.26 (t, 3H, 3J = 7.5 Hz, -S-CH2-CH3), 2.66-2.74 (m, 2H, -
S-CH2-CH3), 3.17-3.27 (m, 3H, Gal-H3, Lac-H3), 3.51 (t, 1H, 3J5,6 = 5.3 Hz, Gal-H5), 
3.65-3.75 (m, 2H, Gal-H6), 4.06 (broad s, 1H, Gal-H4), 4.30 (d, 1H, 3J1,2 = 9.6 Hz, Gal-
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H1), 4.45-4.57 (m, 3H, Gal-H2, 2 CH2-Ph), 4.83 (dd, 1H, 3J2,3 = 4.7 Hz, 3J2,3’ = 6.2 Hz, 
Lac-H2), 7.20-7.35 (m, 15H, Ar-H). 
 
 
Thioethyl 2,4-dibenzoyl-6-O-benzyl-3-O-[(benzyl 
(2S)-3-phenyl-propionate)-2-yl]-β-D-galactoside 
(111). 
(2_019) 
Thioethyl galactoside 109 (197 mg, 0.36 mmol) was 
dissolved in dry pyridine (5 mL) under argon. Benzoyl chloride (250 µL, 2.13 mmol) was 
added slowly to the mixture. After stirring for 16 h at r.t., the solution was diluted with 
ethyl acetate (30 mL), washed with saturated aqueous NaHCO3 (3x 20 mL) and with 
water (2x 20 mL), dried on Na2SO4 and concentrated. Chromatography on silica gel 
(petrol ether / toluene / ethyl acetate 5:5:1) yielded 111 (124 mg, 46%) and both lactone 
forms (2-Gal, 59 mg, 30%, 124a and 4-Gal, 24 mg, 12%, 124b). 
(2_019, 09/03/06) 
1H NMR (500 MHz, CDCl3): δ = 1.24 (t, 3H, 3J = 7.5 Hz, -S-CH2-CH3), 2.68-2.82 (m, 4H, 
2 Lac-H3, 2 -S-CH2-CH3), 3.54-3.62 (m, 2H, Gal-H6), 3.80 (t, 1H, 3J5,6 = 5.8 Hz, Gal-H5), 
3.86 (dd, 1H, 3J3,4 = 2.3 Hz, 3J2,3 = 9.5 Hz, Gal-H3), 4.32 (t, 1H, 3J2,3 = 6.1 Hz, Lac-H2), 
4.45 (A of AB, 1H, 2JA,B = 11.8 Hz, CH2-Ph), 4.50-4.53 (m, 2H, Gal-H1, CH2-Ph), 5.05 (A 
of AB, 1H, 2JA,B = 12.0 Hz, CH2-Ph), 5.14 (B of AB, 1H, 2JA,B = 12.0 Hz, CH2-Ph), 5.54 (t, 
1H, 3J1,2 = 3J2,3 = 9.7 Hz, Gal-H2), 5.90 (broad s, 1H, Gal-H4), 6.65 (d, 2H, J = 7.5 Hz, 
Ar-H), 6.77 (t, 2H, J = 7.6 Hz, Ar-H), 6.95 (t, 1H, J = 7.4 Hz, Ar-H), 7.22-7.32 (m, 10H, 
Ar-H), 7.44 (t, 2H, J = 7.7 Hz, Ar-H), 7.51 (t, 2H, J = 7.6 Hz, Ar-H), 7.56-7.64 (m, 2H, Ar-
H), 7.95 (d, 2H, J = 7.3 Hz, Ar-H), 8.12 (d, 2H, J = 7.3 Hz, Ar-H). 
(2_019, 09/03/06) 
13C NMR (125 MHz, CDCl3) : δ = 14.8 (-S-CH2-CH3), 24.2 (-S-CH2-CH3), 38.9 (Lac-C3), 
69.0 (2C, Gal-C6, CH2-Ph), 70.4 (Gal-C4), 70.9 (Gal-C2), 73.7 (CH2-Ph), 77.4 (Gal-C5), 
78.8 (Gal-C3), 80.8 (Lac-C2), 83.9 (Gal-C1), 126.4, 127.7, 127.9, 128.4, 128.6, 128.7, 
129.3, 129.5, 129.9, 130.1, 133.2, 135.3, 135.7, 137.9 (30C, Ar-C), 164.8, 165.5, 171.2 
(3C, Lac-C1, 2 Ph-(C=O)-O-). 
 
 
O
OBz
O
BzO
SEt
OBn
COOBn
 119 
Thioethyl 2,4-dibenzoyl-6-O-benzyl-3-O-[(benzyl (2S)-
3-phenyl-propionate)-2-yl]-β-D-galactoside (2-lactone, 
124a). 
(2_019, 09/03/06) 
1H NMR (500 MHz, CDCl3): δ = 1.33 (t, 3H, 3J = 7.5 Hz, -
S-CH2-CH3), 2.75-2.83 (m, 2H, -S-CH2-CH3), 3.15 (dd, 
1H, 3J2,3 = 4.6 Hz, 2J = 14.2 Hz, Lac-H3), 3.25 (dd, 1H, 
3J2,3 = 5.6 Hz, 2J = 14.2 Hz, Lac-H3’), 3.37 (dd, 1H, 3J3,4 = 3.0 Hz, 3J2,3 = 9.3 Hz, Gal-H3), 
3.50-3.54 (m, 2H, Gal-H6), 3.77 (t, 1H, 3J5,6 = 6.3 Hz, Gal-H5), 4.38-4.42 (m, 2H, Gal-H1, 
CH2-Ph), 4.46-4.49 (m, 2H, Gal-H2, CH2-Ph), 4.70 (t, 1H, 3J2,3 = 4.7 Hz, Lac-H2), 5.71 
(broad s, 1H, Gal-H4), 7.15-7.19 (m, 5H, Ar-H), 7.22-7.32 (m, 4H, Ar-H), 7.43-7.47 (m, 
2H, Ar-H), 7.57-7.64 (m, 2H, Ar-H), 7.98-8.01 (m, 2H, Ar-H). 
 
 
Thioethyl 2,4-dibenzoyl-6-O-benzyl-3-O-[(benzyl 
(2S)-3-phenyl-propionate)-2-yl]-β-D-galactoside (4-
lactone, 124b). 
(2_019, 09/03/06) 
1H NMR (500 MHz, CDCl3): δ = 1.23 (t, 3H, 3J = 7.5 Hz, 
-S-CH2-CH3), 2.65-2.80 (m, 2H, 2 -S-CH2-CH3), 2.95 (dd, 1H, 3J2,3 = 9.3 Hz, 2J = 14.3 
Hz, Lac-H3), 3.34 (dd, 1H, 3J2,3 = 2.4 Hz, 2J = 14.3 Hz, Lac-H3’), 3.77 (dd, 1H, 3J5,6 = 5.5 
Hz, 2J = 9.0 Hz, Gal-H6), 3.83-3.92 (m, 2H, Gal-H5, Gal-H6), 4.23 (dd, 1H, 3J3,4 = 3.8 Hz, 
3J2,3 = 9.2 Hz, Gal-H3), 4.44 (dd, 1H, 3J2,3’ = 3.0 Hz, 3J2,3 = 9.3 Hz, Lac-H2), 4.53 (d, 1H, 
3J1,2 = 10.1 Hz, Gal-H1), 4.54-4.60 (m, 2H, CH2-Ph), 4.81 (broad s, 1H, Gal-H4), 5.36 (t, 
1H, 3J1,2 = 3J2,3 = 9.7 Hz, Gal-H2), 7.04-7.19 (m, ?H, Ar-H), 7.24-7.37 (m, 4H, Ar-H), 7.48 
(t, 2H, J = 7.7 Hz, Ar-H), 7.62 (t, 1H, J = 7.4 Hz, Ar-H), 8.07 (d, 2H, J = 7.8 Hz, Ar-H). 
(2_019, 09/03/06) 
13C NMR (125 MHz, CDCl3) : δ = 14.8 (-S-CH2-CH3), 23.5 (-S-CH2-CH3), 37.3 (Lac-C3), 
66.9 (Gal-C6), 69.6 (Gal-C2), 71.7 (Lac-C2), 71.8 (Gal-C4), 73.1 (Gal-C3), 73.8 (CH2-
Ph), 75.2 (Gal-C5), 83.0 (Gal-C1), 126.6, 127.9, 128.0, 128.2, 128.5, 128.6, 129.6, 
129.9, 133.3, 136.9 (18C, Ar-C), 165.4, 169.6 (2C, Lac-C1, Ph-(C=O)-O-). 
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(1R,2R)-1-O-{2,4-dibenzoyl-3-O-[(Benzyl 
(2S)-3-phenyl-propionate)-2-yl]-β-D-
galactosyl}-2-O-(2,3,4-tri-O-benzyl-α-L-
fucosyl)-cyclohexane-1,2-diol (112). 
(2_027) 
Compound 111 (124 mg, 0.16 mmol), and 
(1R,2R)-2-O-(2,3,4-Tri-O-benzyl-α-L-
fucosyl)-cyclohexane-1,2-diol (84) (141 mg, 0.26 mmol) were dissolved in dry DCM (10 
mL) under argon and activated powdered molecular sieve 3 Å (500 mg) was added. 
After 90 min stirring, dimethyl(methylthio)sulfonium triflate (DMTST, 170 mg, 0.66 mmol) 
in dry DCM (10 mL) was added. After stirring for 19 h at r.t., the reaction mixture was 
filtered through Celite, diluted with DCM (20 mL), washed with saturated aqueous 
NaHCO3 (2x 20 mL) and water (1x 20 mL), dried on Na2SO4 and concentrated. 
Chromatography on silica gel (petrol ether / toluene / ethyl acetate 5:5:1 with 0.1% v/v 
Et3N) yielded 112 (103 mg, 52%) as a yellowish oil. 
(2_018, 03/03/06) 
1H NMR (500 MHz, CDCl3) : δ = 1.04 (m, 1H, diol-H6), 1.26 (m, 5H, Fuc-H6, 1 diol-H3, 
diol-H4), 1.42 (m, diol-H6’), 1.53-1.65 (m, 2H, diol-H3’, diol-H5), 1.80-1.90 (m, 2H, diol-
H4’, diol-H5’), 2.72 (dd, 1H, 3J2,3 = 6.5 Hz, 2J = 13.8 Hz, Lac-H3), 2.81 (dd, 1H, 3J2,3 = 5.3 
Hz, 3J2,3 = 13.8 Hz, Lac-H3’), 3.52-3.55 (m, 3H, 2 Gal-H6, diol-H2), 3.67 (m, 1H, diol-H1), 
3.71 (t, 1H, 3J5,6 = 5.9 Hz, Gal-H5), 3.81 (broad d, 1H, 3J2,3 = 9.8 Hz, Gal-H3), 3.96 (m, 
2H, Fuc-H2, Fuc-H3), 4.29 (t, 1H, 3J2,3 = 5.9 Hz, Lac-H2), 4.36 (A of AB, 1H, 2JA,B = 11.6 
Hz, CH2-Ph), 4.43-4.50 (m, 4H, Fuc-H5, 3 CH2-Ph), 4.56 (d, 1H, 3J1,2 = 8.0 Hz, Gal-H1), 
4.61 (A of AB, 1H, 2JA,B = 12.0 Hz, CH2-Ph), 4.68 (A of AB, 1H, 2JA,B = 12.7 Hz, CH2-Ph), 
4.71 (B of AB, 1H, 2JA,B = 12.3 Hz, CH2-Ph), 4.84 (B of AB, 1H, 2JA,B = 11.6 Hz, CH2-Ph), 
4.89 (s, 1H, Fuc-H1), 5.04 (AB, 2H, 2JA,B = 12.0 Hz, CH2-Ph), 5.48 (t, 1H, 3J1,2 = 3J2,3 = 
8.9 Hz, Gal-H2), 5.83 (s, 1H, Gal-H4), 6.70 (d, 2H, J = 7.5 Hz, Ar-H), 6.78 (t, 2H, J = 7.6 
Hz, Ar-H), 6.94 (t, 1H, J = 7.3 Hz, Ar-H), 7.14-7.32 (m, 25H, Ar-H), 7.44 (m, 4H, Ar-H), 
7.57 (m, 2H, Ar-H), 7.96 (d, 2H, J = 7.6 Hz, Ar-H), 8.12 (d, 2H, J = 7.6 Hz, Ar-H). 
(2_018, 03/03/06) 
13C NMR (125 MHz, CDCl3) : δ = 16.7 (Fuc-C6), 22.7 (diol-C6), 28.3, 29.7 (3C, diol-C3, 
diol-C4, diol-C5), 38.9 (Lac-C3), 66.3 (Fuc-C5), 66.8 (CH2-Ph), 68.8 (Gal-C6), 70.0 (Gal-
C4), 72.7 (CH2-Ph), 72.9 (CH2-Ph), 73.3 (Gal-C2), 73.8 (diol-C1), 74.5 (diol-C2), 74.8 
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(CH2-Ph), 76.3 (CH2-Ph), 78.1 (Fuc-C3), 78.5 (Gal-C3), 78.8 (Fuc-C4), 79.8 (Fuc-C2), 
80.7 (Lac-C2), 94.0 (Fuc-C1), 99.3 (Gal-C1), 126.4, 127.1, 127.2, 127.4, 127.6, 127.8, 
127.9, 128.0, 128.1, 128.2, 128.4, 128.5, 128.6, 129.3, 129.6, 130.0, 130.1, 133.1, 
133.2, 135.3, 135.7, 137.9, 138.8, 139.1 (48C, Ar-C), 164.5, 165.6, 171.1 (3C, Lac-C1, 2 
Ph-(C=O)-O-). 
 
 
(1R,2R)-1-O-{“lactone?”-β-D-galactosyl}-2-O-
(2,3,4-tri-O-benzyl-α-L-fucosyl)-cyclohexane-1,2-
diol (126). 
(2_027) 
Lactone 124a (59 mg, 0.11 mmol) is reacted in 
similar conditions than diester 111, to yield 126 (26 
mg, 23%). 
(2_018, 03/03/06) 
1H NMR (500 MHz, CDCl3) : δ = 1.06 (m, 1H, diol-H6), 1.17-1.31 (m, 5H, 3 Fuc-H6, diol-
H3, diol-H4), 1.65-1.71 (m, 3H, diol-H4, 2 diol-H5), 1.98 (m, 1H, diol-H3’), 2.17 (m, 1H, 
diol-H6’), 3.05 (dd, 1H, 3J2,3 = 6.9 Hz, 2J = 14.3 Hz, Lac-H3), 3.05 (dm, 1H, 2J = 14.3 Hz, 
Lac-H3’), 3.48 (m, 1H, diol-H1), 3.52-3.58 (m, 2H, Gal-H6), 3.63 (m, 1H, diol-H2), 3.93 
(dm, 1H, 3J2,3 = 10.6 Hz, Gal-H3), 4.05-4.23 (m, 6H, Gal-H2, Gal-H5, Fuc-H2, Fuc-H3, 
Fuc-H4, Fuc-H5), 4.35 (m, 1H, Lac-H2), 4.42 (A of AB, 1H, 2JA,B = 11.7 Hz, CH2-Ph), 
4.51 (B of AB, 1H, 2JA,B = 11.7 Hz, CH2-Ph), 4.73 (A of AB, 2H, 2JA,B = 11.4 Hz, 2 CH2-
Ph), 4.83-4.87 (m, 3H, CH2-Ph), 5.06 (B of AB, 1H, 2JA,B = 11.5 Hz, CH2-Ph), 5.11 (s, 1H, 
Fuc-H1), 5.24 (s, 1H, Gal-H1), 5.67 (s, 1H, Gal-H4), 7.13-7.17 (m, 3H, Ar-H), 7.18-7.21 
(m, 3H, Ar-H), 7.23-7.31 (m, 9H, Ar-H), 7.33-7.38 (m, 4H, Ar-H), 7.41-7.48 (m, 6H, Ar-H), 
7.51-7.55 (m, 2H, Ar-H), 7.66 (m, 1H, Ar-H), 8.03 (m, 2H, Ar-H). 
 
13C NMR (125 MHz, CDCl3) : δ = 16.3 (Fuc-C6), 23.4 (diol-C5), 24.3 (diol-C6), 27.7 (diol-
C4), 32.2 (diol-C3), 37.6 (Lac-C3), 66.3 (Fuc-C5), 67.4 (Gal-C3), 68.5 (Gal-C6), 68.7 
(Gal-C5), 69.0 (Gal-C4), 70.7 (CH2-Ph), 72.6 (Fuc-C4), 73.1 (CH2-Ph), 73.6 (CH2-Ph), 
74.5 (Lac-C2), 74.6 (diol-C1), 75.2 (CH2-Ph), 76.2 (Gal-C2), 77.8 (Fuc-C3), 80.2 (2C, 
Fuc-C2, diol-C2), 91.2 (Fuc-C1), 96.9 (Gal-C1), 126.8, 127.0, 127.3, 127.4, 127.5, 
127.6, 127.8, 128.0, 128.1, 128.3, 128.4, 129.4, 129.8, 133.4, 136.6, 137.7, 139.1, 
139.2, 140.0 (36C, Ar-C), 165.1, 168.7 (2C, Lac-C1, Ph-(C=O)-O-). 
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(1R,2R)-1-O-{2-benzoyl-3-O-[((2S)-3-
phenyl-propionate)-2-yl]-β-D-
galactosyl}-2-O-α-L-fucosyl)-
cyclohexane-1,2-diol (105). 
(2_028-29) 
Compound 112 (70 mg, 57 µmol) was 
dissolved in dioxane (3.0 mL) under argon. 
10% palladium on charcoal (20 mg) was added and the suspension hydrogenated at 4 
bar for 72 h in a Paar shaker. The reaction mixture was then filtered through Celite and 
concentrated. The residue was taken up in a sodium methanolate solution (1M in 
methanol, 1 mL). After 3 h stirring at r.t., it was concentrated and preparative LC-MS 
isolated 105 (14 mg, 36%) which was then freeze-dried. 
 
[α]D = - 89.7 (c = 0.685, MeOH). 
(2_029, 04/04/06) 
1H NMR (500 MHz, CD3OD) : δ = 0.97 (m, 1H, diol-H6), 1.07 (m, 2H, diol-H4, diol-H5), 
1.24 (d, 3H, 3J5,6 = 6.6 Hz, Fuc-H6), 1.25 (m, 1H, diol-H3), 1.45 (m, 1H, diol-H5’), 1.57 
(m, 1H, diol-H4’), 1.86 (m, 1H, diol-H6’), 1.93 (m, 1H, diol-H3’), 2.84 (dd, 1H, 3J2,3 = 7.7 
Hz, 2J = 14.1 Hz, Lac-H3), 2.96 (dd, 1H, 3J2,3 = 4.0 Hz, 2J = 14.1 Hz, Lac-H3’), 3.42 (dt, 
1H, 3J1,2 = 4.4 Hz, 3J2,3 = 9.2 Hz, diol-H2), 3.53 (t, 1H, 3J5,6 = 5.9 Hz, Gal-H5), 3.63 (m, 
2H, diol-H1, Gal-H3), 3.70 (dd, 1H, 3J3,4 = 3.9 Hz, 3J2,3 = 10.1 Hz, Fuc-H2), 3.72-3.74 (m, 
2H, Gal-H6, Fuc-H4), 3.79 (dd, 1H, 3J5,6 = 6.9 Hz, 2J6,6’ = 11.4 Hz, Gal-H6’), 3.87 (dd, 1H, 
3J3,4 = 3.3 Hz, 3J2,3 = 10.1 Hz, Fuc-H3), 4.01 (broad s, 1H, Gal-H4), 4.31 (dd, 1H, 3J2,3 = 
4.0 Hz, 3J2,3’ = 7.7 Hz, Lac-H2), 4.56 (q, 1H, 3J5,6 = 6.6 Hz, Fuc-H5), 4.59 (d, 1H, 3J1,2 = 
8.0 Hz, Gal-H1), 4.82 (d, 1H, 3J1,2 = 3.9 Hz, Fuc-H1), 5.34 (dd, 1H, 3J1,2 = 8.0 Hz, 3J2,3 = 
9.7 Hz, Gal-H2), 6.82-6.89 (m, 3H, benzyl Ar-H), 6.95-6.98 (m, 2H, benzyl Ar-H), 6.95-
6.98 (m, 2H, benzyl Ar-H), 7.47-7.51 (m, 2H, benzoyl Ar-H), 7.64 (m, 1H, benzoyl Ar-H), 
7.94-7.97 (m, 2H, benzoyl Ar-H). 
 
13C NMR (125 MHz, MeOD) : δ = 16.6 (Fuc-C6), 24.0, 24.1 (2C, diol-C4, diol-C5), 29.4, 
30.7 (2C, diol-C3, diol-C6), 40.5 (Lac-C3), 62.6 (Gal-C6), 67.5 (Fuc-C5), 67.9 (Gal-C4), 
70.0 (Fuc-C2), 71.5 (Fuc-C3), 73.2 (Gal-C2), 73.8 (Fuc-C4), 76.0 (Gal-C5), 76.4 (diol-
C2), 79.4 (diol-C1), 81.2 (Lac-C2), 83.1 (Gal-C3), 96.8 (Fuc-C1), 100.4 (Gal-C1), 
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127.3, 129.0, 129.5, 130.2, 130.8, 131.6, 134.2, 138.1 (12C, Ar-C), 166.8 (benzoyl 
C=O), 177.1 (Lac-C1). 
 
Elemental analysis : Calculated for C34H44O14 (+H2O): C, 58.78% ; H, 6.67%. Found : C, 
59.38% ; H, 6.70%. 
 
 
(1R,2R)-1-O-{2-benzoyl-3-O-[((2S)-3-
cyclohexyl-propionate)-2-yl]-β-D-
galactosyl}-2-O-α-L-fucosyl)-cyclohexane-
1,2-diol (105). 
(2_036) 
 
 (2_036, 17/08/06) 
1H NMR (500 MHz, CD3OD) : δ = 0.56-0.75 (m, 4H, 1 diol-H6, 3 cyclohexyl), 0.88-1.17 
(m, 5H, 1 diol-H4, 1 diol-H5, 3 cyclohexyl), 1.24 (d, 3H, 3J5,6 = 6.2 Hz, Fuc-H6), 1.23 1.60 
(m, 9H, Lac-H3, 2 diol-H3-H6, 5 cyclohexyl), 1.93-1.96 (m, 2H, diol-H3), 3.44 (dt, 1H, 
3J1,2 = 4.2 Hz, 3J1,6 = 9.2 Hz, diol-H2), 3.58 (t, 1H, 3J5,6 = 5.7 Hz, Gal-H5), 3.66 (m, 1H, 
diol-H1), 3.68-3,74 (m, 4H, Fuc-H2, Fuc-H4, Gal-H3, Gal-H6), 3.81 (dd, 1H, 3J5,6’ = 7,0 
Hz, 2J6,6’ = 11.4 Hz, Gal-H6’), 3.89 (dd, 1H, 3J3,4 = 3.2 Hz, 3J2,3 = 10.1 Hz, Fuc-H3), 3,98 
(s, 1H, Gal-H4), 4,07 (m, 1H, Lac-H2), 4.60 (q, 1H, 3J5,6 = 6.2 Hz, Fuc-H5), 4.69 (d, 1H, 
3J1,2 = 8.0 Hz, Gal-H1), 4.82 (d, 1H, 3J1,2 = 3.7 Hz, Fuc-H1), 5.38 (t, 1H, 3J1,2 = 3J2,3 = 8.9 
Hz, Gal-H2), 7.51 (t, 2H, 3JAr = 7.7 Hz, Ar-H), 7,63 (t, 1H, 3JAr = 7.4 Hz, Ar-H), 8,09 (d, 
1H, 3JAr = 7.3 Hz, Ar-H) ; 
 
13C NMR (125 MHz, MeOD) : δ = 16.6 (Fuc-C6), 24.1, 24.2, 26.6, 26.8, 27.3, 29.5, 30.9, 
33.1, 34.2, 35.1, 42.8 (11C, Lac-C3, cyclohexyl C, diol-C3-C6), 62.6 (Gal-C6), 67.5 (Fuc-
C5), 67.9 (Gal-C4), 70.0 (Fuc-C2), 71.5 (2C, Fuc-C4, Fuc-C3), 73.3 (Gal-C2), 73.9 (Fuc-
C4),76.1 (diol-C2), 76.5 (Gal-C5), 78.2 (Lac-C2), 79.4 (diol-C1), 83.3 (Gal-C3), 96.8 
(Fuc-C1), 100.4 (Gal-C1), 129.7, 130.8, 131.7, 134.4 (6C, Ar-C), 166.9 (acid). 
 
Elemental analysis : Calculated for C34H49O14Na1 (+4H2O): C, 52.53% ; H, 7.34%. Found 
: C, 52.60% ; H, 7.30%. 
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(1R,2R)-1-O-{2-(4-benzyl-1,2,3-triazol-1-yl)-3-
[((2S)-3-benzylpropionic acid)-2-O-yl]-2-
deoxy-β-D-galactosyl}-2-O-(α-L-fucosyl)-
cyclohexane-1,2-diol sodium salt (103c). 
 
 (2_038, 19/08/06) 
1H NMR (500 MHz, CD3OD) : δ = 0.47 (m, 1H, 
diol-H6), 0.89-1.00 (m, 2H, diol-H4, diol-H5), 
1.19 (d, 3H, 3J5,6 = 6.4 Hz, Fuc-H6), 1.20-1.26 
(m, 3H, diol-H3, diol-H5’, diol-H4’), 1.53 (m, 1H, diol-H6’), 1.82 (m, 1H, diol-H3’), 2.73 
(m, 2H, Lac-H3), 3.27-3.32 (m, 1H, diol-H2), 3.49 (m, 1H, diol-H1), 3.63 (t, 1H, 3J5,6 = 5.8 
Hz, Gal-H5), 3.67-3.70 (m, 2H, Fuc-H2, Fuc-H4), 3.73-3.83 (m, 3H, 2 Gal-H6, Fuc-H3), 
3.97-4.01 (m, 3H, Lac-H2, 2 Tzl-CH2), 4.13 (s, 1H, Gal-H4), 4.25 (d, 1H, 3J2,3 = 10.6 Hz, 
Gal-H3), 4.35 (t, 1H, 3J1,2 = 3J2,3 = 9.3 Hz, Gal-H2), 4.50 (q, 1H, 3J5,6 = 6.4 Hz, Fuc-H5), 
4.75-4.78 (m, 2H, Fuc-H1, Gal-H1), 6.84 (d, 2H, 3JAr = 7.0 Hz, Ar-H) 7.12-7.19 (m, 4H, 
Ar-H), 7.23-7.25 (m, 4H, Ar-H), 7.35 (s, 1H, C2N3H) ; 
 
13C NMR (125 MHz, MeOD) : δ = 16.7 (Fuc-C6), 23.7, 23.8, 29.4, 29.9 (4C, diol-C3-C6), 
32.8 (Tzl-CH2, 40.1 (Lac-C3), 62.5 (Gal-C6), 64.7 (Gal-C2), 67.2 (Gal-C4), 67.4 (Fuc-
C5), 69.9 (Fuc-C2), 71.5 (Fuc-C3), 73.8 (Fuc-C4), 76.2 (Gal-C5), 76.6 (diol-C2), 79.7 
(diol-C1), 80.9 (Lac-C2), 81.6 (Gal-C3), 97.2 (Fuc-C1), 100.3 (Gal-C1), 125.8, 127.4, 
127.5, 129.1, 129.6, 130.5 (11C, 10 Ar-CH, Tzl-CH), 138.1, 140.6 (2C, Ar-C quat.), 
147.8 (Tzl-C quat.), 164.5 (acid), 176.6 (??). 
 
Elemental analysis : Calculated for C36H46O12Na1 (+4H2O): C, 52.48% ; H, 6.69%. Found 
: C, 53.23% ; H, 6.66%. 
 
 
6-O-Benzoyl-D-galactal (115) 
(1_055) 
3,4,6-Tri-O-acetyl-D-galactal (89) (248 mg, 0.91 mol) and K2CO3 
(13 mg, 0.09 mmol) were dissolved in aqueous MeOH (10 mL). 
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After stirring for 5h at r.t., solvent was evaporated to dryness. The residue was filtered 
quickly on a short silica gel column, (DCM / MeOH 9:1), yielding the deprotected D-
galactal (113, 128 mg, 0.88 mmol) as a white solid. 
The obtained product was dissolved under argon in a dry mixture of MeCN (6 mL) and 
Et3N (2 mL), and cooled to –45°C. A solution of benzoyl cyanide (116 mg, 0.88 mmol) in 
MeCN (2 mL) was then added dropwise over 2h, and the mixture was let heat slowly to 
r.t. After 4h stirring, the reaction was quenched with MeOH (1 mL), and solvent was 
evaporated. The residue was taken up in DCM (15 mL), washed with aqueous HCl 1N 
(10 mL), aqueous saturated NaHCO3 (10 mL) and with brine (5 mL), dried on Na2SO4 
and concentrated. Chromatography on silica gel (DCM / MeOH 98:2) yielded 115 (88 
mg, 39%) as an off-white solid. 
(1_055, 15/03/04) 
1H NMR (500 MHz, CDCl3) : δ = 4.00 (s, 1H, H-4), 4.24 (t, 1H, 3J5,6 = 6.3 Hz, H-5), 4.44 
(s, 1H, H-3), 4.56 (dd, 1H, 3J5,6 = 7.1 Hz, 2J6,6’ = 11.6 Hz, H-6), 4.68 (dd, 1H, 3J5,6 = 5.8 
Hz, 2J6,6’ = 11.6 Hz, H-6), 4.76 (m, 1H, H-2), 6.33 (d, 1H, 3J1,2 = 6.1 Hz, H-1). 
 
 
3,4,6-Tri-O-acetyl-2-azido-2-deoxy-1-trimethylsilylethyl-β-
D-galactose (119). 
(1_034)  
Silica gel supported silver silicate (470 mg) and activated 
powdered molecular sieve 4 Å (300 mg) were suspended under argon in a solution of 
trimethylsilylethanol (137 µL, 0.96 mmol) in dry DCM (5 mL). After stirring for 1h at r.t., 
bromide 91 (252 mg, 0.64 mmol) in DCM (5 mL) was added dropwise. The reaction 
mixture was stirred further at r.t. over 16h and filtered through Celite. The filtered 
solution was then washed with aqueous saturated NaHCO3 (2x 10 mL) and water (2x 10 
mL), dried on Na2SO4 and concentrated. Chromatography on silica gel (petrol ether / 
EtOAc 4:1) yielded 119 (91 mg, 33%) as a yellowish oil. 
(1_034, 16/01/04) 
1H NMR (500 MHz, CDCl3) : δ = 1.00-1.12 (m, 2H, -O-CH2-CH2-SiMe3), 2.04, 2.05, 2.15 
(3s, 9H, CH3C=O), 3.63-3.69 (m, 2H, H-2, -O-CHH-CH2-SiMe3), 3.84 (td, 1H, 3J4,5 = 0.8 
Hz, 3J5,6 = 6.8 Hz, H-5), 4.02 (m, 1H, -O-CHH-CH2-SiMe3), 4.10 (dd, 1H, 3J5,6 = 7.1 Hz, 
2J6,6’ = 11.3 Hz, H-6), 4.19 (dd, 1H, 3J5,6 = 6.5 Hz, 2J6,6’ = 11.3 Hz, H-6’), 4.37 (d, 1H, 3J1,2 
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= 8.0 Hz, H-1), 4.77 (dd, 1H, 3J3,4 = 3.3 Hz, 3J2,3 = 10.9 Hz, H-3), 5.49 (dd, 1H, 3J4,5 = 0.8 
Hz, 3J3,4 = 3.3 Hz, H-4). 
 
 
2,3,4-Tri-O-(para-bromobenzyl)-1-ethylthio-β-L-fucoside 
(120). 
1_132 
1-Ethylthio-L-fucoside (129 mg, 0.62 mmol) (88) was 
dissolved in dry DMF (5 mL) and cooled to 0°C under argon. De-oiled sodium hydride 
(90 mg, 3.75 mmol) was then added slowly. After 30 min stirring, para-bromobenzyl 
bromide (696 mg, 2.78 mmol) was added dropwise. After 16 h stirring at r.t., the reaction 
mixture was quenched with MeOH (1 mL), diluted with toluene (20 mL) and washed with 
water (2x 15 mL) and brine (10 mL). The organic layer was then dried on Na2SO4 and 
concentrated. Chromatography on silica gel (petrol ether and ethyl acetate 6:1) afforded 
120 (353 mg, 80%) as an off-white solid. 
(1_132, 16/11/04) 
1H NMR (500 MHz, CDCl3) : δ = 1.23 (d, 3H, 3J5,6 = 6.0 Hz, H-6), 1.29 (t, 3H, 3J = 7.4 Hz, 
S-CH2-CH3), 2.66-2.80 (m, 2H, S-CH2-CH3), 3.49 (m, 2H, H-3, H-5), 3.58 (broad s, 1H, 
H-4), 3.74 (t, 1H, 3J1,2 = 3J2,3 = 9.3 Hz, H-2), 4.37 (d, 1H, 3J1,2 = 9.6 Hz, H-1), 4.59-4.64 
(m, 3H, CH2-Ph), 4.67 (A of AB, 1H, 2JA,B = 10.6 Hz, CH-Ph), 4.83 (B of AB, 1H, 2JA,B = 
10.6 Hz, CH-Ph), 4.85 (B of AB, 1H, 2JA,B = 12.0 Hz, CH-Ph), 7.10-7.24 (m, 6H, Ar-H), 
7.42-7.45 (m, 6H, Ar-H). 
 
 
(1R,2R)-2-O-(2,3,4-Tri-O-benzyl-α-L-fucosyl)-cyclo-
hexane-1,2-diol (122). 
(1_133)  
Thioethyl 2,3,4-tri-O-(para-bromobenzyl)-L-fucoside (120) 
(353 mg, 0.49 mmol) was dissolved in dry DCM (5 mL), and 
cooled to 0°C under argon. Bromine (50 µL, 0.98 mmol) was added slowly at 0°C, then 
the mixture was heated slowly to r.t.. After 1 h, the remaining bromine was quenched 
using cyclohexene (1.0 mL, 30 min stirring at r.t.). 
(1R,2R)-Cyclohexane-1,2-diol (83, 115 mg, 0.99 mmol) and tetraethylammonium 
bromide (208 mg, 0.99 mmol) were dissolved in DMF (2 mL). Activated powdered 
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molecular sieves 3 Å (200 mg) was suspended in the solution which then was stirred for 
30 min under argon at r.t.. Then, the fucosyl bromide (121) solution was added dropwise 
to the suspension. 
After stirring for 2h, the reaction mixture was neutralized with pyridine (0.5 mL), diluted 
with EtOAc (10 mL), and washed with saturated aqueous NaHCO3 solution (2x10 mL) 
and water (2x10 mL). The organic layer was dried with Na2SO4 and concentrated. 
Chromatography on silica gel (petrol ether / ethyl acetate 1:1, with 0.1% Et3N) yielded 
122 (222 mg, 59%) as a white solid. 
(1_133, 25/11/04) 
1H NMR (500 MHz, CDCl3) : δ = 1.18 (d, 3H, 3J5,6 = 6.5 Hz, Fuc-H6), 1.21-1.26 (m, 4H, 
diol), 1.57-1.74 (m, 2H, diol), 1.97-2.04 (m, 2H, diol), 3.26 (m, 1H, diol-H1), 3.46 (m, 1H, 
diol-H2), 3.66 (d, 1H, 3J3,4 = 2.8 Hz, Fuc-H4), 3.90 (dd, 1H, 3J3,4 = 2.8 Hz, 3J2,3 = 10.1 Hz, 
Fuc-H3), 4.00 (dd, 1H, 3J1,2 = 3.8 Hz, 3J2,3 = 10.1 Hz, Fuc-H2), 4.09 (q, 1H, 3J5,6 = 6.4 Hz, 
Fuc-H5), 4.57-4.61 (m, 2H, CH2-Ph), 4.63 (A of AB, 1H, 2JA,B = 12.0 Hz, CH-Ph), 4.67 (B 
of AB, 1H, 2JA,B = 12.1 Hz, CH-Ph), 4.73 (B of AB, 1H, 2JA,B = 12.0 Hz, CH-Ph), 4.85 (B 
of AB, 1H, 2JA,B = 11.6 Hz, CH-Ph), 5.01 (d, 1H, 3J1,2 = 3.8 Hz, Fuc-H1), 7.17-7.20 (m, 
6H, Ar-H), 7.42-7.47 (m, 6H, Ar-H). 
 (1_133 25/11/04) 
13C NMR (125 MHz, CDCl3) : δ = 16.7 (Fuc-C6), 24.0, 24.4, 30.1, 32.5 (4C, diol), 67.0 
(Fuc-C5), 72.4, 73.3, 74.4 (3C, 3 CH2-Ph), 76.2 (Fuc-C2), 78.2 (diol-C2), 79.0 (2C, Fuc-
C3, Fuc-C4), 83.9 (diol-C1), 95.8 (Fuc-C1), 128.9, 129.5, 129.8 (6C, Ar-CH), 131.4, 
131.5 (3C, Ar-CBr), 137.3, 137.4, 137.6 (3C, Ar-C quat.). 
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